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Abstract 
Enigmazole A and its congeners, isolated form the sponge Cinachyrella enigmatica, are 
the first known phosphorylated macrolides of marine origin. Their structure features an 18-
membered macrocycle which is decorated with a highly functionalized disubstituted oxazole and a 
phosphate ester, rarely found in natural polyketides. The macrolactone includes seven stereogenic 
centers and an embedded syn-2,6-disubstituted tetrahydropyran ring with an exo-methylene 
group. Enigmazole A shows cytotoxic activity against numerous cancer cell lines at significant 
concentrations. Structural siblings of it interfere selectively with mutant c-Kit signaling which is an 
important target for cancer treatment. The differentiation is found in less than 0.03% of tested 
natural products. This exceptional structure and the rare pharmacological activity make 
enigmazole A an attractive target for total synthesis. 
Scheme 1: Retrosynthetic analysis of enigmazole A. 
A concise and convergent synthesis of this natural product was envisioned featuring a 
sequence of a ring closing alkyne metathesis (RCAM) and a post-metathesis functionalization by a 
nobel metal-catalyzed rearrangement with subsequent hydroalkoxylation. 
The required fragment E was accessed in 11 steps from a commercial oxazole precursor by a 
palladium-catalyzed C–H activation and a Keck allylation reaction. Enantioselective allylation of 
aldehyde E and stannane C (5 steps) and subsequent Yamaguchi esterification with acid D (8 steps) 
afforded the metathesis precursor. Smooth RCAM created the 18-membered macrocycle in 
excellent yields. 
 
Scheme 2: Illustration of the π-acid catalyzed cascade reaction. 
A gold-catalyzed [3,3]-sigmatropic rearrangement of the propargylic acetate (F) alongside the 
alkyne followed by a transannular hydroalkoxylation (H) of allene G gave exclusively the desired 
syn-tetrahydropyran ring A in excellent yields. The use of a chiral gold catalyst was mandatory in 
this transformation to obtain a diastereomerically matched system with the substrate B. Finally, 
enigmazole A was obtained after standard manipulations. 
 
Rhizoxin D was isolated from an endosymbiotic bacterium of the genus Burkholderia 
which causes the rice seedling blight disease. Its unprecedented structure exhibits a strained 
16-membered macrocycle containing three (E)-olefins, a δ-lactone and a highly unsaturated 
sidechain which is terminated with an oxazole heterocycle. The selective cytotoxicity of rhizoxin D 
and its derivatives against cancer cell lines led to clinical trials as potential drug candidate. This 
high pharmacological potency and the strained structure drew attention to several research 
groups to pursue syntheses of this molecule. 
 
Scheme 3: Retrosynthetic analysis of rhizoxin D. 
The designed synthesis featured two key transformations: a ring-closing diyne metathesis 
(RCDM) and a substrate-directed ruthenium-catalyzed hydrostannation of a 1,3-diyne to create 
the embedded 1,3-(E,E)-diene. 
For this strategy fragment K (6 steps) was prepared by an oxidation of thermodynamically resolved 
lactols. Fragment J (11 steps) was accessible by a challenging alkenylation and an esterification. 
The 1,3-diynes in both molecules were installed by alkynylation reactions with 1,3-pentadiyne. 
Horner–Wadsworth–Emmons coupling (HWE) of fragments J and K gave the metathesis precursor, 
which underwent RCDM to obtain macrocycle I in moderate yields. Further investigations on the 
final steps of the total synthesis of rhizoxin D are ongoing. 
  
Zusammenfassung 
 Enigmazole A gehört zu einer Familie von Naturstoffen, die aus dem Schwamm 
Cinachyrella enigmatica isoliert wurden. Sie sind die ersten bekannten phosphorylierten 
Makrolaktone maritimen Ursprungs. Der 18-gliedrige Makrozyklus enthält unter anderem sieben 
Stereozentren, einen syn-2,6-disubstituierten Tetrahydropyranring mit einer exo-Methylengruppe 
und eine Seitenkette mit einem hoch funktionalisierten Oxazol Heterozyklus. Enigmazole zeigen 
bereits bei niedrigen Konzentrationen eine sehr hohe Zytotoxizität gegen eine Vielzahl von 
Krebszelllinien. Darüber hinaus zeigen strukturverwandte Verbindungen aus dieser Familie eine 
selektive Interaktion mit mutierten c-Kit Proteinen, welche ein bedeutendes Ziel bei der Therapie 
von Krebs sind. Weniger als 0,03% von fast 135 000 getesteten Naturstoffen zeigen diese 
Unterscheidung zwischen gesunden und mutierten c-Kits. 
Schema 1: Retrosynthetische Analyse von Enigmazole A. 
Eine effiziente Synthese von Enigmazole A wurde realisiert durch die Kombination aus 
Ringschlussmetathese (RCAM) und anschließender Funktionalisierung der entstandenen 
Dreifachbindung durch eine Gold-katalysierte Umlagerung gefolgt von einer Hydroalkoxylierung. 
Das Fragment E wurde u.a. durch eine Palladium-katalysierte C-H-Aktivierung und eine Keck-
Allylierung ausgehend von einem Oxazol Heterozyklus in 11 Stufen hergestellt. Mittels 
enantioselektiver Allylierung zwischen Aldehyd E und dem Stannan C (5 Stufen) und darauf 
folgender Yamaguchi-Veresterung mit D (8 Stufen) konnte der Metathesevorläufer hergestellt 
werden. Eine RCAM schloss den 18-gliedrigen Makrozyklus in sehr guten Ausbeuten. 
 
Schema 2: Vorgeschlagener Mechanismus der π-Säure-katalysierten Kaskadenreaktion. 
Eine Gold-katalysierte [3,3]-sigmatrope Umlagerung des propargylischen Acetats (F) entlang der 
Dreifachbindung, gefolgt von einer transannularen Hydroalkoxylierung (H) des Allens G lieferte 
ausschließlich den gewünschten syn-Tetrahydropyranring A in sehr guter Ausbeute. Für diese 
Reaktion war die Wahl eines chiralen Goldkatalysators unerlässlich, um ein passendes 
Diastereomerenpaar von Katalysator und Startmaterial zu erhalten. Von A ausgehend konnte 
schließlich Enigmazole A durch Standardmodifikationen hergestellt werden.  
 
 Rhizoxin D wurde aus einem endosymbiontischen Bakterium der Gattung Burkholderia 
isoliert, welches die wirtschaftlich bedeutsame Reiskeimlingsfäule auslöst. Es besteht aus einem 
spannungsreichen 16-gliedrigen Makrozyklus mit drei (E)-Olefinen, einem δ-Lakton und einer 
ungesättigten Seitenkette, die mit einem Oxazol endet. Wegen der selektiven Zytotoxizität der 
Vertreter dieser Naturstofffamilie wurden klinische Studien mit ihnen als Krebstherapeutika 
durchgeführt.  
 
SchemA 3: Retrosynthetische Analyse von Rhizoxin D. 
Die geplante Syntheseroute enthält zwei Schlüsselschritte: eine Ringschluss-Diin-
Metathese (RCDM) und eine substratgesteuerte Ruthenium-katalysierte Hydrostannylierung eines 
1,3-Diins, zur Darstellung des 1,3-(E,E)-Diens. 
Zu diesem Zwecke wurden die Fragmente J (11 Stufen) und K (6 Stufen) durch eine Horner–
Wadsworth–Emmons Kupplung (HWE) zum Metathesevorläufer kombiniert. In beiden Fragmenten 
wurden die Diin-Motive durch Alkenylierungsreaktionen mit 1,3-Pentydiin hergestellt. Durch 
RCDM konnte der geschlossene Makrozyklus I in akzeptablen Ausbeuten hergestellt werden. 
Derzeit laufen weitere Optimierungsversuche in unserer Gruppe, um die Totalsynthese von 
Rhizoxin D zeitnah abzuschließen. 
  
Table of Contents 
1. Introduction: .......................................................................................................................... 1 
1.1. Total Synthesis ............................................................................................................... 1 
1.2. Ring-Closing Alkyne Metathesis ...................................................................................... 3 
1.3. Post-Metathesis Transformations ................................................................................... 7 
2. Aim of this Thesis ................................................................................................................... 9 
3. Total Synthesis of Enigmazole A ............................................................................................10 
3.1. Introduction ..................................................................................................................10 
3.1.1. Isolation and Structure ...........................................................................................10 
3.1.2. Literature Review ...................................................................................................11 
3.1.3. Bioactivity ..............................................................................................................14 
3.2. Retrosynthetic Analysis of Enigmazole A ........................................................................16 
3.3. Model System ...............................................................................................................17 
3.4. Synthesis of Enigmazole A .............................................................................................18 
3.4.1. Synthesis of the Northern Fragment ......................................................................18 
3.4.2. Synthesis of the Southern Fragment ......................................................................19 
3.4.3. Synthesis of the Eastern Fragment .........................................................................22 
3.4.4. Combination of the Fragments and RCAM .............................................................28 
3.4.5. Key Step: The Gold-catalyzed Cascade Reaction .....................................................32 
3.4.6. Completion of the Total Synthesis ..........................................................................38 
3.4.7. Summary ...............................................................................................................40 
3.4.8. Outlook: Derivatization and SAR ............................................................................41 
4. Total Synthesis of Rhizoxin D .................................................................................................44 
4.1. Introduction ..................................................................................................................44 
4.1.1. Isolation .................................................................................................................44 
4.1.2. Bioactivity ..............................................................................................................45 
4.1.3. Literature Review .................................................................................................. 47 
4.2. Retrosynthetic Analysis and Preliminary Studies ........................................................... 49 
4.3. Synthesis of Rhizoxin D ................................................................................................. 52 
4.3.1. Synthesis of the Eastern Fragment ........................................................................ 52 
4.3.2. Synthesis of the Western Fragment....................................................................... 55 
4.3.3. Combination of the Fragments and Outlook .......................................................... 59 
5. Summary and Conclusion ..................................................................................................... 63 
6. Experimental Procedures: .................................................................................................... 70 
6.1. General Experimental Details ........................................................................................ 70 
6.2. Enigmazole A ................................................................................................................ 72 
6.2.1. The Northern Fragment ........................................................................................ 72 
6.2.2. The Southern Fragment ........................................................................................ 77 
6.2.3. The Eastern Fragment ........................................................................................... 85 
6.2.4. Combination of Fragments .................................................................................... 94 
6.2.5. NMR Data of Enigmazole A ................................................................................. 108 
6.2.6. Addenda to the Synthesis .................................................................................... 110 
6.2.7. (7S,11S)-Enigmazole A ......................................................................................... 118 
6.3. Rhizoxin D................................................................................................................... 129 
6.3.1. The Western Fragment ....................................................................................... 129 
6.3.2. The Eastern Fragment ......................................................................................... 134 
6.3.3. Combination of Fragments .................................................................................. 139 
7. Appendix ............................................................................................................................ 142 
7.1. Spectra ....................................................................................................................... 142 
7.2. List of Abbreviations ................................................................................................... 146 
8. Bibliography ....................................................................................................................... 151 
 
  
 
 
Introduction 1 
 
1. Introduction: 
1.1. Total Synthesis 
In my opinion, the beauty of total synthesis is the never ending competition of laboratory 
synthesis with Mother Nature. Nature is able to synthesize remarkable and intricate molecules 
and synthetic chemists have been trying to emulate this ever evolving process, which occurred 
over millions of years. 
The current state-of-the-art in total synthesis is the culmination of the past 200 years of 
developments in organic synthesis.[1] The first total synthesis was performed by Wöhler in 1828, 
who synthesized urea from cyanic acid and ammonia.[2] Even though one could argue that the 
preparation of urea is not a total synthesis, it proved the principle that organic molecules are 
accessible from inorganic material without the attendance of living organisms. In the ensuing 
100 years, relatively simple – but fundamentally important – chemicals like acetic acid (1845)[3], 
fructose (1886)[4] or camphor (1903)[5] were prepared in multistep syntheses. Modern targets for 
total synthesis are increasingly complex as shown by a selection of recently completed natural 
products (Figure 1.1). 
 
Figure 1.1: Examples of recently synthesized natural products: mandelalide A[6], rubriflordilactone B[7], loline[8], 
dendrobine[9] and spongistatin 1[10]. 
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Natural product chemistry should be seen as an evolving, interdisciplinary science with its 
constituent parts being, inter alia, biology, computational chemistry, pharmacology, and, in 
particular, organic synthesis. Although the target natural products have become more challenging 
and the techniques of organic synthesis have improved, the three main objectives of total 
synthesis remain unchanged:  
1) the investigation and understanding of chemical reactions,  
2) the preparation (and derivatization) of molecules which are not easily 
     accessible from natural sources, and 
3) the structural elucidation of natural products.[1]  
The complex structures of natural products, having numerous functional groups and stereocenters 
in a unique architecture, offer a tremendous challenge to chemists, especially in terms of 
selectivity. Therefore, total synthesis can serve as the ultimate setting for the testing and 
improvement of new methodologies. Furthermore, despite modern analytical methods, structural 
misassignments of natural products are still regularly published and total synthesis remains the 
ultimate tool to confirm or reassign the most complex structures.[6a, 11] In addition to these core 
aims, modern organic synthesis also strives to face up to environmental and social challenges.[12] 
Concepts such as atom economy[13] and interfacing with medicine have truly changed our 
understanding of organic synthesis.[1] 
One of the most important contributions of total synthesis to society is the development of new 
therapeutics for a range of diseases including bacterial infections, dementia and cancer.[14] Once a 
molecule with promising therapeutic properties is discovered in nature, total synthesis can be 
employed to afford usable quantities for bioactivity studies. Furthermore, by divergent synthesis, 
libraries of non-natural congeners can be created.[15] 
Macrocyclic compounds are among the most desirable to medicinal chemists due to their ring 
architecture.[16] They can exhibit a higher potency as well as a higher selectivity in drug-protein-
interactions by the structural preorganization compared to less conformationally rigid molecules. 
The synthesis of macrocyclic compounds, however, is challenging for both enthalpic (ring strain) 
and entropic (loss of conformational degrees of freedom) reasons.[17] One method for 
macrocyclization that made rapid progress over the last two decades is ring-closing alkyne 
metathesis. This methodology is the central theme of this thesis. 
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1.2. Ring-Closing Alkyne Metathesis 
Over the past 50 years, olefin metathesis (Scheme 1.1) has become one of the most powerful C–C 
bond forming reactions, owing to its high chemoselectivity, reliability and the commercial 
availability of a broad range of transition metal catalysts which show excellent stability and a high 
level of functional group tolerance.[18] The immense impact of this methodology has been 
recognized by the scientific community with the award of the Nobel Prize in Chemistry in 2005 to 
Chauvin, Grubbs and Schrock “for the development of the metathesis method in organic 
chemistry”.[19] 
 
Scheme 1.1: Illustration of olefin and alkyne metathesis. 
Olefin and alkyne metathesis (Scheme 1.1) are powerful tools in total synthesis, owing to the 
redox neutral rearrangements of unsaturated C–C bonds with the potential for further 
functionalization of the installed bonds through redox reactions, hydroelementation or π-acid 
catalysis (Chapter 1.3). Alkyne metathesis, which gained popularity by the work of Fürstner et 
al.,[20] offers great potential for building structural complexity. Alkynes allow access not only to the 
same motifs accessible by olefin metathesis, such as olefins and alkanes, but also to new and 
different structures, such as heterocycles and carbonyl derivatives. 
The first example of alkyne metathesis was reported in 1968 by Pennella et al. (Figure 1.2).[21] They 
observed that WO3 on silica catalyzes the scrambling of 2-pentyne into 2-butyne and 3-hexyne at 
200-450 °C. Six years later, Mortreux and Blanchard utilized a mixture of [Mo(CO)6] and resorcinol 
to metathesize aromatic alkynes at 160 °C in homogeneous solution. The molybdenum likely forms 
in situ some kind of alkylidyne species with phenolate ligands.[22] However, the competing 
polymerization of the starting materials with Pennella’s tungsten catalyst and the harsh reaction 
conditions (temperatures far above 150 °C) in both of these systems limited the application of 
metathesis at this time.[23]  
The generally accepted mechanism for alkyne metathesis (Scheme 1.2) was first proposed by Katz 
and McGinnis[24] in 1975, only one year after the discovery of the Mortreux[22] catalyst. Their 
proposal was analogous to the Chauvin cycle[25] for olefin metathesis. Schrock et al. subsequently 
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studied the properties of high-valent alkylidyne complexes and isolated catalytically active 
metallacyclobutadiene species (B and D), giving support to this mechanism.[26] 
 
Scheme 1.2: Generally accepted mechanism of alkyne metathesis for two methyl capped alkynes. 
According to the mechanism, a metal alkylidyne species A reacts with the alkyne substrate in a 
formal [2+2] cycloaddition forming metallacyclobutadiene B. Cycloreversion of its resonance B’ 
releases the product R1-C≡C-R2 and generates alkylidyne C. This species undergoes another [2+2] 
cycloaddition and cycloreversion with the second substrate, releasing butyne as a byproduct, and 
regenerating alkylidyne A. Since all cycloadditions and cycloreversions are in equilibrium, 
removing the butyne from the catalytic cycle, either by absorption with molecular sieves or by 
evaporation, ensures that the reaction is driven towards the desired product. High-valent 
alkylidyne complexes of molybdenum, rhenium and tungsten have all been shown to follow this 
cycle.[26c] 
In 1981, the first well-defined alkyne metathesis catalyst 6 was developed by Schrock et al.[26a, 26b] 
and this tungsten neopentylidyne still serves as a benchmark catalyst decades later.[27] The bulky 
alkoxide ligands impede dimerization of the complex via oxygen bridges and subsequent 
decomposition. The scope is however limited because of the high Lewis acidity of the tungsten 
center, which does not tolerate coordinating groups like amines or carboxylates.[20] In contrast to 
the high metathetic activity of 6, the molybdenum analogue [(tBuO)3Mo ≡ CCMe3] showed 
essentially no catalytic activity.[28] 
The trisamido molybdenum complex 7, originally designed by Cummins for the stoichiometric 
cleavage of nitrogen,[29] finally ended the “tungsten age” of metathesis catalysts. Complex 7 reacts 
with dichloromethane to form in situ a catalytically active complex which, due to its lower Lewis 
acidity, tolerates a much broader variety of functional/coordinating groups. Therefore this 
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catalytic system was the catalyst of choice in the Fürstner group for over ten years. Nevertheless, 
the broad applicability of this catalyst still suffered from its high sensitivity toward oxygen, 
nitrogen and moisture. 
 
Figure 1.2: The historic timeline of the development of alkyne metathesis catalysts. 
In 2010, Fürstner et al. developed a silanolate ligated molybdenum catalyst 8, which extended the 
scope of alkyne metathesis to highly functionalized, sensitive and elaborate substrates under mild 
conditions.[30] The combination of the high-valent molybdenum center and three arylsilanolates 
ensures a balance of stability and activity. Furthermore, catalyst 8 could be rendered air stable by 
complexation with heterocycles like 1,10-phenanthroline (9) or pyridine. This development made 
metathesis user-friendly and the catalysts commercially distributable.[31] The bench-stable 
precatalysts are converted in situ into active species 8 by treatment with manganese(II) or zinc(II) 
chloride. Only in the cases of extremely sterically demanding alkynes or of molecules with several 
protic functionalities do the silanolate catalysts 8-9 show poor catalytic activity or lead to 
polymerization in the case of small substrates.[32] 
With such challenging substrates, better results can be achieved with multidentate ligated 
molybdenum catalysts, which take advantage of the chelate effect. Zhang et al.[33] as well as 
Fürstner et al.[34] developed ligand systems allowing transformations beyond the scope of 
catalyst 8. In these cases, the active species is formed in situ upon addition of precatalyst 12 to 
one of the ligands 13-15 (Figure 1.3). However, despite significant experimentation, the exact 
structure of the catalytically relevant alkylidyne remains unknown.  
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Figure 1.3: Structure of multidentate RCAM catalysts designed by our group. 
Although, the potential of alkyne metathesis was explored by numerous groups since the 
development of Schrock’s catalyst in 1981, it was only in 1998 that Fürstner et al. showed the 
power of intramolecular alkyne metathesis to create macrocycles.[35] The ability to form 
macrocycles containing triple bonds sparked a resurgence of interest in alkyne metathesis. 
Furthermore, the substrate scope was recently extended to enynes and 1,3-diynes, leading to 
multiple sites for functionalization in the products formed.[36] The value of RCAM has already been 
shown in the syntheses of a variety of natural products,[20, 37] and is always closely related to the 
post-metathesis functionalization of the triple bond. 
  
Introduction 7 
 
1.3. Post-Metathesis Transformations 
To realize the full potential of ring closing alkyne metathesis in the synthesis of natural products, 
further transformation of the created triple bond is of primary importance. In the Fürstner group, 
a broad repertoire of possible transformations has been developed for this purpose. Among the 
most successful ones are, inter alia, trans-selective hydrogenation[38], π-acid catalysis[39], and 
selective hydrostannation[40], the latter two having special significance for this thesis.  
π-Acid catalysis describes any transformation in which a Lewis-acid[41] (LA) activates an 
unsaturated C–C bond which then reacts with a nucleophile either in an intra- or intermolecular 
fashion, giving access to various motifs. According to the theory of hard and soft acids and bases 
(HSAB) by Pearson,[42] LAs and Lewis bases (LB) can be categorized by their polarizability. For 
example, hard LAs are less polarizable (higher electronegativity) than soft ones. This categorization 
allows general predictions on the affinity and reactivity of LA/LB to be made (hard LAs form 
stronger interactions with hard LBs). In order to activate a soft LB, such as an alkyne, a soft LA is 
required. Platinum(II) and gold(I) are especially suited to this task, and their applications have 
made π-acid catalysis to one of the most rapidly growing disciplines of catalysis.[39] 
The high nuclear charge of these noble metals causes a contraction of the s-orbitals which strongly 
shield the outer 5d and 4f-orbitals.[43] These orbitals are therefore diffuse in nature and give these 
metal cations their soft LA properties. Interaction of these soft LAs with alkynes results in the 
formation of π-complexes (A, Scheme 1.3). Activation of the π-system (as described by the Dewar-
Chatt-Duncanson model[44]) enables a nucleophile to attack with anti-selectivity (B) under mild 
conditions. Slippage of the gold along the π-system affords intermediate C which, after proton 
transfer and proto-deauration, releases the product E and regenerates the catalytic species. 
 
Scheme 1.3: Illustration of π-acid catalysis for alkyne and gold(I). 
π-Acid catalysis with gold (or other metals) provides the possibility to use alkynes in a broad 
variety of transformations, such as nucleophile additions, (cyclo-) isomerizations and 
cycloadditions. Of particular importance is the ability to form new (hetero-) cycles or extend 
existing ones, making π-acid catalysis a very powerful method in total synthesis. 
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Another method for the functionalization of alkynes is hydroelementation which refers to the 
addition of H–ERn (E = Sn, B, Si etc.) across double or triple bonds. Classical hydroelementation 
reactions, such as hydroborations,[45] traditionally occur in a syn-fashion, limiting their versatility. 
In 2001, Trost et al. reported the ruthenium-catalyzed trans-hydrosilylation of alkynes, which 
extended the synthetic scope immensely.[46] Due to the high interest of our group in alkyne 
functionalizations, we have investigated such trans-selective hydroelementations. Recent results 
include the development of the trans-selective ruthenium-catalyzed hydroelementation of alkynes 
with boranes[47] or stannanes.[40] Catalyzed hydrostannation reactions, in particular, render (E)-
olefins accessible by a hydrostannation and subsequent destannation sequences, tolerating a 
broad scope of functional groups including motifs which would not survive established “non-
catalyzed” hydrostannation protocols (relying on Lewis acids or free-radicals). Furthermore, 
hydroelementation reactions provide a handle for additional functionalizations of the resulting 
alkenyl metal species. For example, the combination of hydroelementation (F → G, Scheme 1.4) 
with cross coupling (G → H) allows for the synthesis of tri-substituted olefins. 
In addition, a cooperative effect between the Ru-catalyst and a protic functionality in an 
unsymmetric alkyne ensures region-control of the hydrostannation (Scheme 1.4). The presence of 
a hydroxy directing group (I), for example, results in very high α–regioselectivity in favor of 
product J. In this work, we will rely on this remarkable selectivity and will showcase its usefulness 
in the late stages of the synthesis of a natural product. 
 
Scheme 1.4: Illustration of hydroelementation reactions on alkynes. 
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2. Aim of this Thesis 
After developing the latest generation of alkyne metathesis catalysts and demonstrating their 
utility in several total syntheses, post-metathesis functionalization became a major interest in the 
Fürstner group. Novel and reliable methodologies for alkyne functionalization would allow access 
to additional chemical motifs and enhance the importance of RCAM in organic synthesis. This 
thesis is focused on the investigation of new strategies for the functionalization of alkynes and 
their applications in two natural product syntheses (Figure 2.1).  
First, an unprecedented metal-catalyzed [3,3]-sigmatropic rearrangement/transannular 
hydroalkoxylation cascade is described, giving access to a syn-tetrahydropyran from a propargylic 
acetate in a single step. This new methodology is applied, as the post-metathesis transformation, 
in the total synthesis of enigmazole A (16). 
Second, the combination of two recently reported methodologies from the Fürstner group, ring 
closing diyne metathesis and α-selective trans-hydrostannation, enabled access to macrocyclic, 
trisubstituted 1,3-(E,E)-dienes in an elegant and concise manner. Rhizoxin D (17) was identified as 
a suitable target for this sequence of reactions.  
 
Figure 2.1: Structures of the targeted natural products. The functionalized alkynes are highlighted in red. 
Furthermore, the applied methodologies would grant divergence to efficiently synthesize 
unnatural, structural derivatives of 16 and 17. These derivatives could contribute to 
pharmacological studies and, as a consequence, help to discover new lead structures for anti-
cancer therapeutics. 
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3. Total Synthesis of Enigmazole A 
3.1. Introduction 
3.1.1. Isolation and Structure  
Enigmazole A (16) and its congeners, 15-O-methylenigmazole A (18) and 13-hydroxy-O-
methylenigmazole A (19), have been isolated from the marine sponge Cinachyrella enigmatica in 
2010 (Figure 3.1) and represent the first phosphorylated macrolides of marine origin.[48] 
C. enigmatica was collected in 1998 in Papua New Guinea as part of the marine collection program 
of the U.S. National Cancer Institute. In addition to the aforementioned natural products, another 
member of the family, i.e. enigmazole B (20), was reported in two dissertations, which however 
disagree on the saturation between carbon C7 and C8 (Scheme 3.1).[49]  
 
Figure 3.1: Structures of the enigmazole family. 
Alongside the 18-membered macrocyclic ring, 16–18 feature an embedded 2,6-disubstituted 4-
methylenetetrahydropyran ring and a densely functionalized 2,4-disubstituted oxazole sidechain 
attached at C17. In addition, 16–18 present a phosphate ester at C5, a rare feature found in only a 
few polyketide natural products.[50] The structure of enigmazole A (16) was elucidated by 
derivatization, degradation experiments and intensive 1D and 2D NMR analyses which revealed 
the absolute configuration of the eight stereogenic centers. Molecular modeling studies were in 
agreement with the stereochemistry assignments. The first total synthesis by Molinski et al. [51] 
published back-to-back with the isolation paper confirmed the absolute stereochemistry. 
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3.1.2. Literature Review 
Total Synthesis by the Molinski group 2010 
The first total synthesis of enigmazole A (16) was reported by Molinski et al. in 2010.[51] As shown 
in the retrosynthetic analysis (Scheme 3.1), a macrolactonization of 21 was envisioned as the ring 
closing event. The key intermediate 21 was prepared by a hetero Diels-Alder reaction between 22 
and 23, constructing the syn-tetrahydropyran ring, followed by Wittig olefination with 24. 
Fragment 24 was accessed by two-directional heterocycle extension by (i) Negishi cross coupling 
of oxazole 26 with iodide 25 and (ii) subsequent asymmetric allylation. The hetero Diels-Alder 
reaction and the macrolactonization proved to be particularly challenging and required detailed 
investigations. 
 
Scheme 3.1: Retrosynthetic analysis of Molinski's synthesis of enigmazole (16). 
To achieve stereocontrol of the hetero Diels-Alder reaction between 22 and 23, a range of chiral 
Lewis acids was screened. However all attempts at reagent-controlled stereoselectivity proved to 
be unsuccessful and did not afford the desired diastereomer 27a (Scheme 3.2). Instead, achiral 
Lewis acid catalysis afforded 27 in good yield (81%) but as a mixture of three diastereomers. 
Gratifyingly, this substrate-control afforded 27a as the major product (d.r. >3:1) which could be 
separated from the minor isomers.  
 
Scheme 3.2: Hetero Diels-Alder reaction of fragments 22 and 23: Conditions: a) BF3·OEt2, (cat.), DCM, −78 °C, then 
CH(OMe)3, MeOH, CSA, −78 °C → rt, 81%. 
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After deprotection and oxidation of 27a, the Wittig olefination of the corresponding aldehyde and 
24 gave fragment 28 (Scheme 3.3). A sequence of protecting group manipulations and 
hydrogenation of the (Z)-olefin gave access to compound 21. Attempts at regioselective 
macrolactonization of 21 to obtain 30 using various conditions were low yielding and gave the 
undesired 16-memebered macrocycle 29 as the major product (best conditions: 29:30 = 3:1 and 
only 31% yield). Molinski et al. suspected that 29 was kinetically and thermodynamically favored 
over 30.  
 
Scheme 3.3: Molinski's optimization of the Keck macrolactonization. Conditions: a) (PPh3)3RhCl (cat.), H2, THF/t-BuOH 
(1:1), 50 °C, 83% (21), 70% (31); b) LiOH, MeOH/H2O, 80 °C; c) CSA (cat.), MeOH, rt, quant. over 2 steps (21); d) (i) DCC, 
DMAP, DMAP·HCl, CHCl3, reflux, then (ii) AcOH, MeOH, 35% over 3 steps (33). 
To overcome this regioselectivity issue, the order of hydrogenation–macrocyclization was 
reversed. Precursor 32, still bearing the (Z)-olefin, allowed for selective macrocyclization under 
Keck conditions to form the 18-membered ring 33, which was acetylated in situ to prevent further 
ring contraction. Hydrogenation of 33 afforded the desired macrocycle 31, containing all of the 
stereocenters of enigmazole A (16). Standard transformations and protecting group manipulations 
ultimately gave access to the natural product 16 in 24 steps (LLS) with an overall yield of 0.16%. 
 
Total Synthesis by the Smith group 2015 
Independent from the work described in this thesis, Smith et al. reported a total synthesis of 
enigmazole A (16) featuring a distinct strategy.[52] As shown in the retrosynthetic analysis 
(Scheme 3.4), macrolactonization, similar to that in Molinski’s synthesis, was employed to 
generate the 18-membered macrolactone in excellent yield (89%). The choice of orthogonal 
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protecting groups at the C15 and C17 hydroxy groups prevented the formation of the undesired 
16-membered macrolactone in this step. The key motif, the syn-tetrahydropyran, was formed in a 
three-stage sequence including Petasis-Ferrier rearrangement, employing fragments 34 and 35. 
The main fragment 35 was accessible from dithiane 36 and epoxide 38. Dithiane 36 was prepared 
by Negishi coupling, and 38 arose from a multicomponent Type I Anion Relay Chemistry, 
previously developed by the Smith group.[53] 
 
Scheme 3.4: Retrosynthetic analysis of Smith’s synthesis of enigmazole A (16). 
The approach by Smith to construct the syn-tetrahydropyran is particular convergent, as seven of 
the eight stereocenters were already installed in the two fragments 34 and 35. Acetalization 
connected these two building blocks forming dioxanone 42 (Scheme 3.5). After microwave 
accelerated Petasis olefination, 43 was used in the Ferrier carbocyclization affording a 
tetrahydropyranone, which was directly transformed to the exo-methylene-tetrahydropyran to 
prevent the retro-Michael fragmentation. The stereochemical configuration at C7 was retained, 
giving exclusively 44. Straightforward transformations of 44 finally afforded enigmazole A (16) in 
22 steps (LLS) with an overall yield of 4.4%. 
 
Scheme 3.5: The Petasis olefination/Ferrier carbocyclization sequence. Conditions: a) (i) 35, HMDS, THF, 40–45 °C, then 
(ii) 34, TMSOTf, H2O (cat.), DCM, −78 °C, 95%, d.r. >20:1; b) Cp2TiMe2, 2,6-lutidine (cat.), toluene/THF, MW 100 °C, 87%; 
c) Me2AlCl, DCM, −78 °C, 30 sec., then Ph3P=CH2, 84%, d.r. >20:1.  
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3.1.3. Bioactivity 
Enigmazole A (16) was found to be the most cytotoxic component of the Cinachyrella enigmatica 
extracts, and therefore it was tested in the NCI 60-cell antitumor assay.[48] It showed significant 
cytotoxic activity against 60 human tumor cell lines (IG50 value of 1.7 µM), but no specificity among 
the cell lines. Therefore, further analysis to identify the molecular target or certain cytotoxic 
pathways for its activity could not be performed.[54] Because of structural similarity to calyculin A, 
which is known to be a potent serine/threonine protein phosphatase inhibitor,[55] enigmazole A 
(16) was also tested against a panel of 16 different protein phosphatase enzymes including PPT1 
and PPT2A.[56] It showed no activity at concentrations ≤40 µg/mL, thereby indicating that its 
cytotoxic effect is not related to the inhibition of phosphatases. Furthermore, enigmazole A (16) 
was screened in an assay with 70 different protein kinases to rule the possibility out that it 
interferes in the cellular phosphorylation dynamics by blocking the addition of phosphate groups 
to proteins. Once again the molecule was inactive at concentrations ≤40 µg/mL. Proteins 
controlling the function of cellular signal transduction pathways are often regulated by their 
phosphorylation state and disruption of these functions can result in inhibited growth or cell 
death. The phosphate group present in 16 could potentially interfere with those pathways. 
However, despite extensive tests Gustafson et al. could not find any evidence to support this 
hypothesis.[48] 
The most important observation was made in an assay for the inhibition of the receptor tyrosine 
kinase protein (c-Kit).[57] This receptor is an evolutionary highly conserved transmembrane 
glycoprotein with tyrosine kinase activity. The receptor shares structural homology with platelet-
derived growth factor receptor (PDGFR) and macrophage colony-stimulating-factor receptor 
(CSF-1). c-Kit signaling plays a very important role in the regulation of the red blood cell 
production, lymphocyte proliferation, mast cell development and function, melanin and gamete 
formation.[57] It subsequently regulates gene expression and the proliferation, differentiation, 
growth and survival of hematopoietic cells.[57] Mutations of c-Kit have been associated with several 
cancers, for example systemic mastocytosis, acute myelogenous leukemia and gastrointestinal 
stromal cell tumors.[58] The relevance of this target is confirmed by established kinase inhibitors 
like imatinib (Gleevec/Glivec©), which targets the c-Kit receptor, among others.[59] While the 
enigmazoles 16, 18 and 19 showed no differentiation between wild-type and mutant c-Kit, several 
advanced chromatographic fractions also isolated from C. enigmatica selectively inhibited cells 
expressing the mutant c-Kit.[48] This phenotypic effect is rarely observed. Only 32 out of 134631 
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tested natural product extracts produced the desired differentiation.[48, 60] Analysis of the tested 
fractions referred the activity to structural siblings of enigmazole A (16). Gustafson et al. planned 
to communicate the structural and biological characterization of these compounds in subsequent 
work,[48] but these results already showed the importance of the enigmazole scaffold as a potential 
lead-structure for anti-cancer drugs. 
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3.2. Retrosynthetic Analysis of Enigmazole A 
Our group envisioned a concise and flexible route for the total synthesis of enigmazole A (16) by 
applying in-house developed RCAM and π-acid catalysis (Scheme 3.6). Our idea was to approach 
the tetrahydropyran ring and the C5/C7 oxygen pattern via a noble metal-catalyzed [3,3]-
sigmatropic rearrangement of the acetate group present in the key intermediate 47. The formed 
allene 46 could be engaged in a transannular hydroalkoxylation with the same catalyst, thereby 
forming compound 45. This cascade could place all atoms in position and deliver the enol acetate 
at C5 as a handle for the installation of the phosphate ester. The chemo- and stereoselectivity of 
this cascade is crucial to the success of this route. A synthetical equivalent could be obtained by a 
stepwise approach via enone formation followed by an oxa-Michael addition.[61] 
Macrocycle 47 could be derived from diyne 48 by RCAM. The open macrocycle 48 could be 
accessed by allylation of the southern fragment 50 with the eastern fragment 51 and subsequent 
esterification with the northern fragment 49. The eastern fragment 51 could be prepared by an 
allylation reaction performed on literature known oxazole 52. 
 
Scheme 3.6: Retrosynthetic analysis of enigmazole A (16). 
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3.3.  Model System 
Prior to the total synthesis, our group studied the key steps on the simplified model substrate 53. 
This compound was prepared by Dr. de Haro in 2013.[62]  
The key intermediate 54 was obtained by an esterification of 55 and 56 (Scheme 3.7). The main 
fragment 56 was prepared by the combination of fragments 57-59 via two Grignard additions. 
 
Scheme 3.7: Retrosynthesis of model substrate 53. 
RCAM of 54 afforded 53 in very good yields using molybdenum alkylidyne complex 8 under 
standard in-house conditions (Scheme 3.8). Both the propargylic acetate and the PMB protecting 
group were tolerated in the metathesis reaction. Upon oxidative cleavage of the PMB protecting 
group, compound 60 was obtained. As initially envisioned, treatment of 60 with catalytic amount 
of Ph3PAuNTf2 triggered a [3,3]-sigmatropic rearrangement; subsequent transannular 
hydroalkoxylation afforded the embedded 2,6-disubstituted tetrahydropyran 61 in excellent yield 
as a single diastereoisomer. Saponification of the acetate group gave the model substrate 53.  
 
Scheme 3.8: RCAM and gold catalyzed cascade for the model substrate. Conditions: a) complex 8 (cat.), 5Å MS, toluene, 
80 °C, 95%; b) DDQ, DCM/phosphate buffer pH 7 1:1, rt, 98%; c) Ph3PAuNTf2 (cat.), DCM, rt, 95%; d) in situ addition to c: 
K2CO3, MeOH, rt, 78% (over two steps). 
The NMR analysis and X-ray diffraction confirmed the diequatorial substitution of the 
tetrahydropyran moiety of 53 ensuring the validity of this model for the total synthesis of 
enigmazole A (16). Encouraged by this model study we proceeded towards the forward synthesis 
of 16. 
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3.4.  Synthesis of Enigmazole A 
Preceding experiments and results performed by Dr. Teresa de Haro made it possible to directly 
start into this project with the synthesis of advanced intermediates. Detailed and comprehensive 
analysis of already established steps allowed access to bigger scales and ensured more material for 
the investigation of the key steps. The forward synthesis started with the preparation of fragments 
49, 50 and 63. The eastern fragment 63 was part of the longest linear sequence. 
 
Scheme 3.9: Retrosynthesis of Enigmazole A (16) showing key fragments 49, 50 and 63. 
 
3.4.1. Synthesis of the Northern Fragment  
Access to northern fragment 49 was achieved in a straightforward synthesis (Scheme 3.10), 
starting with a selective asymmetric alkylation of the pseudo-ephedrine derived propionamide 68 
with iodide 65, mediated by lithium diisopropylamide in presence of lithium chloride. Product 69 
was obtained in excellent yield and in very high diastereoselectivity (d.r. = 96:4; determined at the 
stage of aldehyde 70). The well-established methodology of Myers[63] guaranteed reliable access to 
this route on a multigram scale. Reductive cleavage of the auxiliary gave an primary alcohol as 
already described before by Panek[64] and subsequent mild ruthenium-catalyzed Ley-Griffith 
oxidation[65] afforded the literature known aldehyde 70.[66] This aldehyde was transferred in an 
alkylative Corey-Fuchs reaction[67] to the end-capped alkyne 72. The desired product was only 
isolated when zinc powder was added to the reaction mixture. In the absence of zinc powder the 
in situ generated triphenylphosphine dibromide substituted the silylated alcohol by a bromide.[68] 
Desilylation and subsequent oxidation afforded the northern fragment 49.[69] In this oxidation, 4-
methylmorpholine N-oxide was beneficial by (i) stabilizing the aldehyde hydrate intermediate, and 
(ii) recycling the active ruthenium(VIII) catalyst as co-oxidant. Under these conditions, 49 was 
obtained in excellent yield (92%) without epimerization in the α-position. Alternative oxidative 
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conditions[70] were not met with success. In summary, 49 was obtained in 8 steps with an overall 
yield of 37% from commercially available materials. 
 
Scheme 3.10: Synthesis of northern fragment 49. Conditions: a) (i)NaI, acetone, reflux; (ii) TBS-Cl, imidazole, DCM, 0 °C, 
85% (over two steps); b) Et3N, DCM, rt, 75%; c) LDA, LiCl, THF, −78°C →rt, 98%; d.r. = 96:4; d) LDA, then BH3·NH3, THF, 
0 °C → rt, 89%; e) TPAP (cat.), NMO, 4 Å MS., DCM, 88%; f) CBr4, PPh3, Zn, DCM, 74%; g) n-BuLi, then MeI, −78 °C → rt, 
97%; h) TBAF, THF, 96%; i) TPAP (cat.), NMO·H2O, ACN, 92%. 
 
 
3.4.2. Synthesis of the Southern Fragment  
Racemic synthesis: 
Synthesis of the southern fragment 50 was originally planned in a racemic fashion. Due to the 
formation of allene 46 after the [3,3]-sigmatropic rearrangement, the stereochemistry of the 
migrating acetate group should not influence the stereochemical outcome (discussed in 
Section 3.4.5). This hypothesis was further confirmed by studies on the model substrate 
(Chapter 3.3). 
The synthesis of 50 started from commercially available 2-butynol, which was oxidized to 2-
butynal (75) (Scheme 3.11). Several oxidation agents were screened, but the best results 
(67% yield) were obtained by conducting a TEMPO catalyzed biphasic oxidation, employing N-
chlorosuccinimide as oxidant and tetrabutylammonium chloride as phase transfer agent.[71] The 
main problems were the purification and handling of 75 due to the volatility and instability. Freshly 
distilled fractions changed their color from colorless to pink within a few minutes which we 
associated with decomposition. Despite the color change, 75 could be used in the next step 
without significant decrease in yield. The lifetime of aldehyde 75 could be extended to several 
months if stored under argon at −80 °C. Boron trifluoride diethyl etherate promoted allylation of 
2-butynal (75) with (2-chloromethyl)allyl trimethylsilane (76), and subsequent acetylation of the 
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racemic secondary alcohol gave access to chloride 77. Halogen exchange under Finkelstein 
conditions[72] gave 78, which could be converted into allyltin building block 50 by a Pd2(dba)3 
catalyzed coupling with bis(tributyltin).[73] Attempts to introduce the tributyltin fragment by 
nucleophilic substitution of the allyl halogens using tributylstannyllithium resulted in 
decomposition of the starting material. In conclusion, the racemic southern fragment 50 was 
successfully synthetized in 5 steps and 30% overall yield from 2-butynol. Other approaches for the 
synthesis of 50, which were investigated by Dr. de Haro, were unsuccessful.[74] 
 
Scheme 3.11: Racemic synthesis of southern fragment 50. Conditions: a) BF3·OEt2,then 76, DCM, −60°C, 60%; b) Ac2O, 
Et3N, DMAP (cat.), DCM, rt, quant.; c) NaI, acetone, 70 °C, 95%; d) (SnBu3)2, Pd2(dba)3·CHCl3 (cat.), degassed THF, 55°C, 
78%; e) n-BuLi, HSnBu3, THF, −78°C, 60%. 
The pivalic ester analogue of 50 was prepared following the route outlined above to provide a 
migrating group other than the acetate in the [3,3]-sigmatropic rearrangements. The different 
steric and electronic properties of the pivalate might have an influence on the rearrangement and 
its stereoselectivity.  
 
Enantioselective synthesis: 
The absolute configuration of the acetate group in molecule 50 turned out to be essential in the 
key-step cascade (see Chapter 3.4.5). Therefore, access to the enantiopure building blocks (R) and 
(S)-50 was needed. Due to prior knowledge in our group concerning alkynylation reactions, (R)/(S)-
50 should be accessed by this methodology (Scheme 3.12). Aldehyde 80 was prepared in a 
straightforward route starting from dimethyl itaconate (79). Diisobutylaluminum hydride 
reduction[75] afforded the corresponding diol. Subsequent mono-TBS protection[76] and oxidation 
gave desired aldehyde 80, setting the stage for the asymmetric alkynylation reaction. Carreira 
conditions, which are known to give poor yields and enantioselectivities with unsaturated 
substrates,[77] led to an isomerization of 80 to the α,β-unsaturated aldehyde, which did not 
undergo further reaction. A more positive outcome was obtained by using the Pu conditions.[78] 
This method includes pre-formation of the alkynyl-zinc species by refluxing diethyl zinc and 
propyne, followed by the titanium-catalyzed addition to aldehyde 80 in presence of 1,1'-bi-2-
naphthol (BINOL) as chiral ligand. However, under the standard conditions, the yields were not 
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reproducible probably due to the volatility of propyne which caused inconsistent formation of the 
propynyl-zinc species. Operating under various propyne pressures did not improve the outcome. 
While (R)-81 could be obtained in 60% yield and e.e. ≥88%, (S)-81 was obtained in only 28% yield 
and an unsatisfactory e.e. of ≤22%. The absolute configuration was determined by Mosher ester 
analysis[79] of 81. A racemic reference was prepared by the addition of propynyl lithium to 
aldehyde 80. Overall, the stereoselective alkynylation of 80 proved to be unsuccessful. 
 
Scheme 3.12: Enantioselective approach using alkynylation. Conditions: a) Dibal-H, THF, 0°C → rt, 98%; b) NaH, THF, 
−78°C, then TBS-Cl, −30 °C, 38%; c) DMP, DCM, rt, 86%. 
In parallel, another approach was examined to access the enantiopure southern fragment 50 
starting from the symmetric 3-chloro-2-(chloromethyl)prop-1-ene (82) (Scheme 3.13). Selective 
monostannylation afforded 83,[80] which was subjected to a Keck allylation[81] with 2-butynal (75) 
to undergo clean conversion to secondary alcohol (S)-77 in good yield (84%) and enantiomeric 
selectivity (e.e. ≥95%). The absolute configuration was determined by Mosher ester analysis[79] 
showing that (S)-BINOL afforded (S)-77 and (R)-BINOL the (R)-enantiomer. It is noteworthy to 
mention that good results were only obtained with freshly distilled titanium isopropoxide and 
molecular sieves, which were oven dried over several days at 120 °C.[82] Molecular sieves which 
were activated over 24 h at 200 °C and 10−3 mbar (standard procedure for the RCAM) completely 
inactivated the allylation reaction. Interactions with the titanium catalyst, the isopropoxide-ligands 
and the molecular sieves might be the reason for this observation. Transformations alike to the 
racemic route afforded desired (R) and (S)-enantiomer of 50 over 5 steps and 25% overall yield on 
a multigram scale. 
 
Scheme 3.13: Enantioselective approach using Keck allylation. Conditions: a) LDA, Bu3SnH, THF, −78°C, 49%; b) (iPrO)4Ti 
(cat.), (S)-BINAP (cat.), 4 Å MS, DCM, reflux, then 75, rt, then 83, −78°C, 84%, e.e. ≥95%; c) Ac2O, Et3N, DMAP (cat.), DCM, 
rt, 93%; c) NaI, acetone, 70 °C, 88%; d) (SnBu3)2, Pd2(dba)3·CHCl3 (cat.), degassed THF, 55°C, 73%. 
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3.4.3. Synthesis of the Eastern Fragment 
The eastern fragment 51 represents the first part of the longest linear sequence and two possible 
pathways, A and B, were envisioned for the synthesis of this fragment in our group (Scheme 3.14). 
Initial studies on these possible routes were performed by Dr. de Haro and the reported results on 
pathway A are based on her work. 
 
Scheme 3.14: Retrosynthetic analysis of the eastern fragment 51. 
Pathway A focused on an olefin cross-metathesis to form intermediate 84, which would afford the 
1,3-syn-diol motif of 51 via an intramolecular hydrosilylation reaction. The challenge of this 
pathway would be the stereoselectivity of this hydrosilylation and the selective, orthogonal 
protection of the two resulting secondary alcohols. In pathway B, the 1,3-diols would be obtained 
by an addition Grignard reagent 85 to epoxide 86. Both pathways converge in substrate 87, which 
could derive from aldehyde 52, already reported in the total synthesis by Molinski.[51] We 
envisioned a shortcut to the previous reported route including a disassembly of 52 into ethyl 4-
oxazole carboxylate (88) and alkenyl iodide 25. 
The first milestone of the route was the access to key intermediate 52 in an efficient and elegant 
manner. Extension of Ma’s methodology on Cu(I)-catalyzed regioselective anti-
carbometallations[83] to methylmagnesium reagents followed by an iodine quench gave in one step 
the literature known allylic alcohol 90.[51] Optimization reactions, involving screening of several 
Grignard reagents and solvents gave high regioselectivities (Table 3.1). Allylic alcohol 90 was 
obtained in good yield only by employing methylmagnesium bromide in a mixture of THF/toluene 
3:1 (Entry 1-3). Toluene showed slightly better regioselectivities compared to benzene (Entry 3+4). 
Nevertheless, the biggest drawback in this reaction was the high excess of reagent (7 equiv of 
Grignard reagent and iodine) which was necessary to reach full conversion and good selectivity 
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(Entry 4-6). Ultimately, this approach afforded 90 from commercially available (R)-(+)-3-butyn-2-ol 
(89) on multigram scale in only one step and 74% yield. So far 90 was accessible in three steps with 
an overall yield of 19 %.[51] 
Table 3.1: Optimization of the carbomagnesiation of butyn-2-ol terminated by an iodine quench. 
 
Subsequent O-methylation of 90 using methyl iodide and sodium hydride[51] gave alkenyl iodide 
25, which was coupled in a palladium-catalyzed C–H activation reaction with the commercially 
available ethyl 4-oxazole carboxylate (88) (Scheme 3.15).[84] To the best of our knowledge, this is 
the first time that a C–H activation of an oxazole has been applied in total synthesis. 
Diisobutylaluminium hydride reduction of the ethyl ester at low temperatures gave key 
intermediate 52 in good yield (80%).[51] 
 
Scheme 3.15: Synthesis of key intermediate 52. Conditions: a) (i) MeMgBr, CuI, toluene, −78 °C → rt; (ii) I2, THF, −40 °C → 
rt, 74%; b) MeI, NaH, imidazole (cat.), THF, −40 °C → rt, 64%; c) Pd(OAc)2 (cat.), 2-(dicyclohexylphosphino)-biphenyl (cat.), 
Cs2CO3, 1,4-dioxane, 110 °C, 74%; d) Dibal-H, DCM, −90 °C, 80%. 
Despite literature precedence on asymmetric allylation reactions in total synthesis[85] and 
particularly involving oxazoles,[86] we faced difficulties in obtaining good yield and selectivity for 
the allylation reaction of aldehyde 52. Several allylation conditions such as Maruoka[87] and 
Leighton[88] (Entry 1+2) were screened (Table 3.2), but gave either poor yield and almost no 
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stereoselectivity. Applying Krische[89] conditions to either the aldehyde 52 or the corresponding 
alcohol gave the desired product 87 in good enantioselectivity, but only low yield (Entry 3). The 
Brown[90] and Keck[81, 91] protocols finally showed very good yield and selectivity (Entry 4+5). Due to 
the slightly higher d.r. the Keck allylation was chosen in the final route. Again, it is noteworthy to 
mention, that the allylation only proceeded with freshly distilled titanium isopropoxide and 
molecular sieves, which were oven dried over several days at 120 °C.[82] The enantiomeric ratio of 
the obtained allylic alcohol 87 was determined by subsequent Mosher ester analysis.[79] 
Table 3.2: Screening of different allylation conditions. 
entry reaction conditions yield (%) d.r.
1 Maruoka allylation: bidentate-Ti(IV)-(S)-BINOL (10 mol %),
allyl tributyltin, DCM, -15 ºC to 0 ºC, 18 h
2 Leighton allylation: A (100 mol%), DCM, -10 ºC, 20 h
3 Krische allylation: Allyl acetate (10 equiv), Ir(Cod)Cl2
(2.5 mol %), (S)-BINAP (5 mol %), Cs2CO3 (20 mol%),
m-nitrobenzoic acid (10 mol %), iPrOH (200 mol %), THF,
100 ºC, 20 h
4 Brown allylation: (-)-(Ipc)2BOMe, allylmagnesium bromide,
Et2O, -100 ºC, 1.5 h
5 Keck allylation: Ti(OiPr)4 (10 mol%), (S)-BINOL 
(10 mol %), allyl tributyltin, 4Å MS, DCM, -20 ºC, 96 h
42
(84 brsm)
53:47
0 0
40 95:5
96 93:7
95-99 >95:5
 
With the common intermediate 87 in hand, pathway A was first investigated (Scheme 3.16). The 
two building blocks 94 and 87 were coupled via a cross metathesis using Hoveyda-Grubbs 2nd 
generation catalyst.[92] Inspired by a report by Roush,[93] who synthesized syn,syn- and syn-anti-
1,3,5-triols by intramolecular hydrosilylation of pent-3-en-1,5-diols catalyzed by Karstedt’s 
catalyst,[94] alcohol 95 was transformed into dimethylsilyl ether 96, which gave siloxanes 98a and 
98b under the described conditions. The best diastereomeric ratio was 71:29. 
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Scheme 3.16: Forward synthesis of pathway A. Conditions: a) TBS-Cl, imidazole, DMAP (cat.), DCM, rt, quant.; b) 87, 
Hoveyda-Grubbs 2nd (cat.), DCM, rt, 59%; c) (HMe2Si)2NH, neat, rt, quant.; d) 97 (cat.), toluene, −78°C → 0°C, yield n.d.. 
To assign the absolute stereochemistry, acetonides 100a and 100b were prepared from the 
silylethers 98 via the corresponding diols 99a and 99b (Scheme 3.17). However, 13C NMR analysis 
following Rychnovsky´s protocol[93, 95] revealed 1,3-anti configuration for the major diastereomer 
100b. These results implied that the silylation of compound 96 is not directed intramolecularly by 
the hydroxy-silyl-ether as suggested by Roush[93], but rather by the oxazole moiety coordinating 
the palladium(0) species to favor the anti-1,3-diol. For detailed information on this pathway, see 
Dr. de Haro’s research summary.[74] 
 
Scheme 3.17: Analysis of the absolute configuration of 98. Conditions: a) KHCO3, H2O2, THF/MeOH 1:1, rt, 76% (over 3 
steps); b) 2,2-dimethoxypropane, PPTS (cat.), DCM, rt, yield n.d.. 
 
Because of the unsatisfying stereoselectivity in pathway A (29:71 for desired 98a), the alternative 
route B was investigated to get access to the eastern fragment 51 (Scheme 3.14). Route B used the 
same allylic alcohol 87 as a starting point, however, instead of chain extension as described above, 
the syn-diol should be installed first. A regio- and stereoselective iodo-cyclization reaction turned 
out to be an efficient way to rearrange Boc-protected compound 101 to carbonate 102 
(Scheme 3.18). 
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Scheme 3.18: Forward synthesis of eastern fragment 63 following pathway B. Conditions: a) (Boc)2O, DMAP (cat.), ACN, 
rt, 92%; b) IBr, toluene, −78 °C, 54–73%; c) K2CO3, MeOH, rt, 79% (d.r. >95:5); d) TBS-Cl, imidazole, DMAP (cat.), DCM, rt, 
98%; e) 105, CuI (cat.), THF, −78 °C → −40 °C, 92%; f) TBDPS-OTf, 2,6-lutidine, DCM, 0 °C, 88%; g) TMS-OTf, 2,4,6-
trimethylpyridine, DCM, rt, 97%. 
Different electrophilic iodine sources, such as N-iodosuccinimide (NIS)[96], iodine[97] and iodine 
monobromide[98], were screened (Table 3.3, Entry 1-3) and best results were obtained by 
employing a 1 M solution of iodine monobromide in dichloromethane at −90 °C. These conditions 
afforded 102 in good yield (≥70%) and excellent diastereoselectivity (≥95:5). The reaction times 
were kept short and the temperatures below −78 °C in order to prevent product decomposition. 
Lower temperatures had no positive influence on the outcome (Entry 3 vs 5). The yield was 
however not reproducible on multigram scales for unknown reasons (Entry 5). While regio- and 
stereoselectivity remained constant, the yield dropped from 70% to 54% on scales employing 
>300 mg (101). Iodine monobromide concentrations below 1 M resulted in incomplete 
consumption of starting material 101 which could be reisolated, giving moderate yield (59%) but 
no decomposition of 101 or 102 (99% brsm) (Entry 4).  
Table 3.3: Optimization of the iodo-lactonization reaction.  
 
[a] determined by NMR; [b] 54% on 4 g scale, 73% on 200 mg. 
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The resulting iodide 102 was treated with potassium carbonate in methanol to cleave the cyclic 
carbonate and immediately close the terminal oxirane ring (103, Scheme 3.18). The iodo-
cyclization and methanolysis could also be performed in one-pot but with much lower yield 
(<40%). 
Inspired by a report of Berkessel, we saw a potential shortcut by applying the methodology of 
stereoselective epoxidation of olefins.[99] The direct syn-epoxidation of homoallylic alcohol 87 was 
tried employing vanadium and titanium catalyst systems (Scheme 3.19).[100] Initial attempts 
already showed that the starting material 87 was too sensitive, resulting in complete degradation. 
 
Scheme 3.19: Direct syn-epoxication of homoallylic alcohol 87 using vanadium or titanium catalyst systems. 
After TBS protection of secondary alcohol 103, 104 was prepared for the final carbon chain 
elongation (Scheme 3.18). Therefore, epoxide 104 was opened in a copper-catalyzed addition of 
functionalized Grignard reagent 105, giving the desired product 106 regioselectively in very good 
yield (92%).[101] Grignard reagent 105 was prepared from the commercially available bromide 
precursor via a modified procedure described by Forbes.[102] At this stage the stereoselectivity of 
the 1,3-syn-diol motif was determined by acetonide formation, as described before, after 
desilylation of 106. The 1H NMR shifts of the methyl signals of the acetonide (19 and 30 ppm) 
confirmed the syn-stereochemistry of the 1,3-diol motif. Standard TBDPS-protection and cleavage 
of the acetal afforded eastern fragment 63. Aware of the problems which might occur on using 
such a stable TBDPS-protecting group, the TES/TBS-analogue 109 was synthesized following the 
same route (Scheme 3.20). 
 
Scheme 3.20: Synthesis of eastern fragment 109 with alternative silyl protecting groups. Conditions: a) TES-Cl, imidazole, 
DMAP (cat.), DCM, rt, 93%; b) 105, CuI (cat.), THF, −78 °C → −40 °C, 77%; c) TBS-Cl, imidazole, DMAP (cat.), DCM, rt, 74%; 
d) TMSOTf, 2,4,6-trimethylpyridine, DCM, rt, 93%. 
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Overall, we were able to prepare the eastern fragment 63 (and its sibling 109) from commercially 
available (R)-(+)-3-butyn-2-ol (89) in 12 steps with an overall yield of 11.2% (and 7.2% respectively) 
(Scheme 3.21). In the case of the TBS/TBDPS-fragment 63, all reactions were performed on a 
multigram scale (≥5 mmol). Due to this robust and scalable route, investigations on the 
combination of the three fragments and the key steps could be performed as described in the next 
chapter. 
 
Scheme 3.21: Synthesis of eastern fragment 63. Conditions: a) (i) MeMgBr, CuI, toluene, −78 °C → rt; (ii) I2, THF, −40 °C → 
rt, 74%; b) MeI, NaH, imidazole (cat.), THF, −40 °C → rt, 64%; c) Pd(OAc)2 (cat.), 2-(dicyclohexylphosphino)-biphenyl (cat.), 
Cs2CO3, 1,4-dioxane, 110 °C, 74%; d) Dibal-H, DCM, −90 °C, 80%; e) Ti(OiPr)4 (cat.), (S)-BINOL (cat.), allyl tributyltin, 4 Å 
MS, DCM, −20 °C, 98%; f) (Boc)2O, DMAP (cat.), ACN, rt, 92%; g) IBr, toluene, −78 °C, 54–73%; h) K2CO3, MeOH, rt, 79% 
(d.r.>95:5); i) TBS-Cl, imidazole, DMAP (cat.), DCM, rt, 98%; j) 105, CuI (cat.), THF, −78 °C → −40 °C, 92%; k) TBDPSOTf, 
2,6-lutidine, DCM, 0 °C, 88%; l) TMSOTf, 2,4,6-trimethylpyridine, DCM, rt, 97%. 
 
3.4.4. Combination of the Fragments and RCAM 
With access to the three fragments, 49, 50 and 63, on reliable and multigram scale syntheses, their 
assembly was investigated. Coupling of aldehyde 63 and stannane 50 was envisioned via an 
asymmetric allylation reaction. The best results were obtained by applying the conditions 
described by Corey et al. using chiral diaminoborane 110 (Scheme 3.22).[103] The reaction proceeds 
via the in situ formation of the boron species 110, followed by a boron-stannane exchange prior to 
stereoselective allylation of aldehyde 63. Very good yield (95%) and selectivity (≥10:1) of the 
desired (11R)-epimer 111 was achieved in spite of the fragile characteristics of the propargyl 
acetate motif in 50 that could easily eliminate to give a conjugated π-system. For derivatization 
purposes and mechanistic insight into the [3,3]-sigmatropic rearrangement, the corresponding 
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(11S)-epimer of 111 was prepared following the same conditions and (R,R)-110 in comparable 
yield. The stereochemical outcome of each isomer was confirmed by Mosher ester analysis[79] and 
was in full agreement with Corey’s observations. One advantage of this methodology was the 
commercial availability of the (R,R) or (S,S)-1,2-diamino-1,2-diphenylethane ligands, which could 
be fully recovered after the workup. 
 
Scheme 3.22: Coupling of eastern 63 and southern fragment 50 by enantioselective allylation. Conditions: a) (S)-110, 
DCM, −78°C, 95% (d.r. > 10:1); b) TrocCl, DMAP (cat), pyridine, DCM, 0 °C → rt, quant.; c) camphorsulfonic acid (cat.), 
DCM/MeOH (3:1), 0 °C → rt, 61% (98% brsm). 
Standard PMB-protection of secondary alcohol 111 was unsuccessful, despite intensive 
attempts.[74] Much better results were obtained by 2,2,2-trichlorethoxycarbonyl (Troc) protection 
which was equally orthogonal to the silyl esters in 111. Selective TBS deprotection of 112 afforded 
113. To suppress the cleavage of the acetate ester in 112 during the reaction, the progress was 
monitored by TLC and the reaction was stopped as soon as the undesired cleavage was observed. 
Starting material 112 and the desired product 113 were isolated without major loss of material via 
secondary side reactions (61%, 98% brsm). Subsequent Yamaguchi esterification with the northern 
fragment 49,[104] as already elaborated in our group before,[105] gave the metathesis precursor 62 
in quantitative yield (Scheme 3.23). The corresponding TES-analogue of 62 was also prepared by 
following the same route, but not used further due to the success employing the TBDPS-protected 
substrate 62. 
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Scheme 3.23: Combination of the last fragment and closing of the macrocycle by RCAM. Conditions: a) 2,4,6-
trichlorobenzoyl chloride, Et3N, then 113, DMAP, toluene, 0 °C, quant.; b) 8 (cat.), 4Å + 5Å MS, toluene, 79%; c) Zn, HOAc, 
ultrasonication, 93%. 
With 62 in hand, we started the screening of conditions for RCAM (Table 3.4), which would already 
set the complete carbon framework of enigmazole A (16). Initial attempts were similar to those 
described in the model system (Chapter 3.3) using the neutral catalyst 8 at elevated temperatures 
giving only moderate yield (40-60%) (Entry 1-2).[62] Due to the complete consumption of 62 after 
2 h, the temperature was lowered, resulting in an increase of yield (>70%) (Entry 3). Decreasing of 
catalyst loading from initial 50 mol% to 10 mol% resulted in incomplete conversion. In these cases 
more catalyst had to be added to achieve complete consumption of starting material, leading to 
longer reaction times, but to comparable yield (70-80%) (Entry 4). In all experiments a quite fast 
decomposition of catalyst 8 was observed indicated by color change of the reaction mixture and 
loss of activity. Initially, experiments employing the more stable ate-complex 116 showed 
complete conversion of diyne 62, but gave only moderate yield (57%) (Entry 5). The actual break 
through was achieved by decreasing the reaction time to less than 60 min (Entry 6). Under these 
conditions, catalyst loadings between 16-18 mol% showed complete consumption of 62 and very 
good yield (85-90%). The reliability of this step allowed a metathesis on 1.7 g scale with 79% 
isolated yield of 116 (Entry 7). 
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Table 3.4: Screening of ring closing alkyne metathesis conditions. 
 
 
[a] after every 24 h additional 10 mol% of catalyst 8 were added; [b] 51 mg scale; [c] 1.7 g scale. 
In summary, the RCAM of this specific molecule (62) worked in a reliable and reproducible manner 
with catalyst loadings between 25-30 mol% at room temperature and reaction times of less than 
1 h. Complete conversions were also obtained with lower catalyst loadings of 16-18 mol%, but the 
low catalyst loading made the reaction very sensitive to moisture or impurities in the starting 
material. The addition of catalyst in several portions over time, e.g. 3 × 10 mol%, adding up to 
30 mol%, gave worse results than the addition of only one batch. This effect and the short reaction 
times could be explained by the inhibition of the catalytic cycle by free silanol ligands due to 
catalyst decomposition. During these experiments, we never observed noteworthy amounts of 
dimer formed by metathesis of 62 with itself (head/head or head/tail). Nevertheless, the lower 
yield at extended reaction times might indicate that 114 underwent decomposition or 
polymerization under metathesis conditions. 
To set the stage for the gold-catalyzed cascade, the Troc-ester 114 had to be cleaved to allow the 
hydroxy group to participate in the transannular attack. This standard deprotection, however, 
proved to be unexpectedly challenging. Literature known procedures applying zinc in acetic acid 
always led to incomplete conversions and disappointing yield (<40%).[106] Intensive screenings on 
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reaction parameters, such as the mesh sizes of zinc dust and additives, finally provided an 
extremely efficient ultra-sound accelerated method giving ≥95% yield (Scheme 3.23). To this end, 
114 was treated with high excess of zinc dust (10 mesh, Sigma Aldrich) and sonicated for 
30-45 min. The inorganic salts were filtered off and the crude mixture was concentrated. Aqueous 
workup, as originally reported in the literature, led to partial decomposition. Other conditions, e.g. 
saponification with potassium carbonate in methanol, led to transesterification (methoxy carbonyl 
ester instead of trichloroethoxy) or to decomposition. It is noteworthy that this was the first 
reaction of the entire route which was not performed on a gram scale (510 mg largest scale). 
 
 
3.4.5. Key Step: The Gold-catalyzed Cascade Reaction 
With the carbon framework of enigmazole A (16) all set in key intermediate 115, we proceeded to 
investigate the cascade reaction featuring a [3,3]-sigmatropic rearrangement followed by 
transannular hydroalkoxylation, generating the tetrahydropyran motif present in 117 (Table 3.5). 
Due to the preliminary studies on the model substrate, initial reaction conditions were already 
established.[62] Nevertheless, the exact same reaction conditions gave exclusively decomposition 
of the starting material 115 (Entry 1), forcing intensive investigations on different catalyst systems.  
Substrate 115 was exposed to several gold catalysts, with varying ligands and counter ions, as well 
as to other metals known to trigger [3,3]-rearrangements, such as platinum (Entry 2-8).[107] Only in 
a few cases the experiments showed traces of the desired product 117, which could only be 
detected by MS analysis (Entry 2-3). Driven by these first indications, further attempts of using 
gold(I)-species with hexafluoroantimonate(V) or tosylate counter ions led to the isolation of two 
byproducts referred by NMR analysis as structure 117c and 118 (Entry 9). Unfortunately, the 
tetrahydropyran rings showed an anti-configuration for both products. The first promising results 
were obtained with the NHC-ligand IPr 120 giving the desired product 117a and its isomer 117b 
albeit in low yield (38%) and selectivity (d.r. = 2:3).  
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Table 3.5: Brief summary of the catalysts screening for the reaction cascade giving the tetrahydropyran ring.  
 
[a] MS analysis revealing traces of 117 in a complex mixture of starting material 115 and undefined byproducts. 
With reference compounds 117a-c in hand, this transformation could be followed by HPLC-MS. 
Interestingly, a clear difference in the consumption of the two epimers of 115 (undefined 
stereocenter at C7) was observed in all experiments. These observations led to the hypothesis, 
that exclusively one of the two possible π-complexes A and A’ (Scheme 3.24) is formed (here A) 
which does not undergo the [3,3]-sigmatropic rearrangement due to steric and/or electronic 
reasons. Therefore, we could not expect the desired intermediate B’ to be formed. This might be a 
result of the complex and rigid macrocyclic structure of 115. 
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Scheme 3.24: Models of the π-complexes of the gold catalyst and substrate 115 affecting the reaction outcome. 
In addition, allene 46, which would be formed by the [3,3]-sigmatropic rearrangement, was never 
observed, supporting the hypothesis that already the early stage of coordination might be 
interfered. Side product 118, obtained by SN2-type elimination of the acetate group by the C11-
OH, suggested close proximity of these two groups. Consequently, the cascade might be initiated 
by this hydroxy group, but only if the correct stereochemical configuration of the π-complex (B’) 
would allow that. 
To underline our hypothesis, chiral gold catalysts were screened to find a matching 
substrate/catalyst pair, which could introduce the right stereochemical environment in 115 (and 
46) for the reaction cascade to occur (Table 3.6). Indeed, conditions using binuclear 
precatalyst 121 (DTBM-MeO-Biphep-(AuCl)2) developed by the Toste group,[108] showed moderate 
yield and enhanced selectivity in favor of 117a (Entry 3-4). Especially gratifying was the beneficial 
influence of the ligand chirality on the diastereomeric ratio of 117a and 117b. Other similar chiral 
catalysts only gave traces of 117 or complex mixtures (Entry 1-2). To confirm that the chirality of 
the ligand and not the different electronics influenced the outcome, several similar substituted 
triphenyl phosphines were tested (Entry 5-7). None of them showed similar stereoselectivity or 
reactivity compared to precatalyst 121; yet, it must be considered, that these catalysts did not 
feature the binuclear gold-center. Optimizations on the solvent and counter ion finally gave the 
desired syn-tetrahydropyran 117a in 55% yield and a diastereomeric ratio of 4:1 (117a/b) (Entry 8-
9). Despite the improved results in these experiments, HPLC-MS still indicated, that only one of the 
two diastereomers of 115 afforded the desired product 117a, while the other diastereomer mainly 
reacted to a variety of unidentified byproducts. 
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Table 3.6: Optimization of the gold-catalyzed reaction cascade using chiral catalysts. 
 
[a] in case of bad d.r. the products were not isolated. sm = starting material 115. 
To further improve the reaction outcome, the two diastereomers of 115 were separated by 
preparative LC giving two enantiopure compounds 115a and 115b with unknown absolute 
configuration at C7 (Scheme 3.25). To determine the absolute stereochemistry, the 
tetrahydropyran ring was closed by an intramolecular SN2 substitution of the prior mesylated C11-
hydroxy group with C7-OH. NMR analysis of the two six membered rings 122a and 122b revealed 
their configuration and allowed the conclusion to be drawn regarding the configuration of 115a/b. 
Comparison of the HPLC retention times, obtained in the previous experiments, confirmed the (S)-
isomer 115a as the diastereomer reacting selectively to 117a. Aware of the absolute configuration, 
the desired diastereomer 115a was prepared by the previously described route employing the (S)-
southern fragment 50 (described in Section 3.4.2). 
 
Scheme 3.25: Determination of the absolute configuration of 115 by chemical transformation. Conditions: a) TEA, MsCl, 
DCM, 21 °C; b) K2CO3, MeOH/DCM 1:1, rt, yields not determined. 
The matching pair of catalyst (R)-121 and enantiopure starting material 115a ultimately afforded 
selectively the desired product 117a in excellent yield (91%) and subsequent basic saponification 
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afforded ketone 123 (Scheme 3.26). The configuration of 117a can be explained by the attack 
occurring exclusively from the site distal to the acetate at the allene (transition state B, 
Scheme 3.27). Considering a pseudo-chair-like transition state C, the six-membered ring should be 
favored over an eight-membered ring setting the syn-configuration at the tetrahydropyran.  
 
Scheme 3.26: Gold cascade with the optimized conditions. Conditions: a) (R)-121 (cat.), AgSbF6 (cat.), DCM, rt, 91%; b) 
K2CO3, MeOH, 95%. 
The hypothesis of a mismatch of catalyst and substrate, as suspected from HPLC-MS analysis, had 
still to be confirmed. Indeed, the mismatch pair, (S)-catalyst 121 and (S)-substrate 115b, afforded 
the desired product 117a in only 50-70% yield, but gave in addition the unexpected tricycle 124 
which was unmistakably assigned by NMR analysis (Scheme 3.27). The stereochemistry at the 
cyclopropane ring could not be elucidated. Apparently, upon activation of the alkyne by the gold 
catalyst, the C10 exo-methylene group reacts as a nucleophile and forms intermediate D, which 
undergoes cyclopropanation to E. Cycloisomerization involving the gold species, well known in π-
acid catalysis,[109] gives finally 124.  
 
Scheme 3.27: Intermediates of the gold cascade with the (S)-diastereomer 115a. Conditions: a) (R)-catalyst 121 (cat.), 
AgSbF6 (cat.), DCM, rt, 91%; b) (S)-catalyst 121 (cat.), AgSbF6 (cat.), DCM, rt, 50-70% (117a) + 20-30% (124).  
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An even stronger example of mismatch between the substrate and the catalyst was shown in the 
case of the (R)-isomer 115b. The combination of 115b and precatalyst (S)-121 resulted in complete 
degradation of the starting material (Scheme 3.28). The other enantiomer of the catalyst, (R)-121, 
gave only traces of desired product 117a (10-20%) and a second, aromatic side product 125 in 
acceptable yield (approx. 50%). A possible reaction mechanism initiated by the [3,3]-sigmatropic 
rearrangement could first proceed via allene B’ (C5-epimer to B). In this environment, the attack of 
the exo-methylene is favored over the attack of C11-OH giving transition state F and after 
aromatization compound 125. Indeed, similar reactions were reported in the literature before.[110] 
 
Scheme 3.28: Intermediate of the gold cascade with (R)-diastereomer 115b. Conditions: a) (R)-catalyst 121 (cat.), AgSbF6 
(cat.), DCM, rt, 50% (125) + 10-20% (117a); b) (S)-catalyst 121 (cat.), AgSbF6 (cat.), DCM, rt, decomposition only. 
Collectively, those results demonstrate the important role of stereochemical matching between 
catalyst and substrate. The big difference in the reactivity of the two diastereomers B and B’ of 46 
has to be seen in the context of literature showing that [3,3]-sigmatropic rearrangements of 
propargylic esters are reversible and the corresponding allenes prone to racemization.[108] While 
methodological studies and the model substrate had shown the desired results, the real substrate 
is the perfect example for the influence of intricate details in total synthesis. The combination of 
strain, bulk and electronics makes each reaction unique – especially with such elaborated 
intermediates. 
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3.4.6. Completion of the Total Synthesis 
To complete the total synthesis, last adjustments were missing including the installation of the 
phosphate ester and global deprotection. In order to install the phosphate ester at C5, ketone 123 
had to be stereo-selectively reduced. Initial screenings on several reagent-controlled methods, 
including CBS-catalysts [111] or BINAP/BINOL derived catalysts[112], did not afford any desired 
product 126 (Table 3.7, Entry 1-3). Substrate-control by L- or K-selectride provided first amounts of 
126 but also lactol 127 as major byproduct (Entry 4). Better selectivities for the desired epimer 
126a were achieved with sodium borohydride (Entry 5). Variations of boron salt, temperature, 
solvent or additives did not improve the selectivity (d.r. ≤2:1) (Entry 6-8). In contrast, the 
undesired epimer 126b could be prepared with a selectivity of 95:5 using lithium tri-tert-
butoxyaluminum hydride (Entry 9). The two diastereomers 126 were easily separable by flash 
chromatography and could be isolated in 60% and 30% yield; the undesired epimer 126b already 
representing a potential candidate for library synthesis. 
Table 3.7: Optimization of the stereoselective reduction of ketone 123. 
 
[a] Corey-Bakshi-Shibata reductions performed with different boranes. sm = 123; sp = unidentified side products. 
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Phosphorylation of 126a gave access to protected enigmazole 128a,[51] but the global deprotection 
step posed some unexpected challenges. Under basic or acidic conditions the 18-membered 
macrocycle tended to undergo ring contraction by trans-esterification with the deprotected C15-
OH. Furthermore, most fluoride sources, such as caesium fluoride, ammonium fluoride, selectfluor 
or TASF, left the silyl ether untouched. Only tetra-n-butylammonium fluoride (TBAF) gave, beside 
the described transesterification, traces of 16. Ultimately, the best yields were obtained by using a 
high excess of TBAF (50 equiv), which had to be buffered by acidic acid (75 equiv) to prevent ring 
contraction. Other reagent/buffer ratios resulted in either transesterification to the undesired 16-
membered ring or recovered starting material. Slight heating to 40 °C was essential to accelerate 
the cleavage, which still needed 12-14 days under the described conditions. Ultimately, 
enigmazole A (16) was isolated in 82% yield. The counter ion of the phosphate ester could be 
adjusted by ion exchange with the help of HPLC chromatography or an ion exchange resin, 
furnishing the free acid, the triethylammonium, or the tetrabutylammonium salt of 16. 
 
Scheme 3.29: Phosphorylation and global deprotection in the total synthesis of Enigmazole A. Conditions: a) (i) 
(FmO)2PNiPr2, tetrazole, ACN; (ii) aq. H2O2, 0 °C, quant.; b) TBAF/HOAc 1:1.5, THF, 40 °C, 14d, 82%. 
All analytical data were in full agreement with those reported in the literature[48, 51]. Acquired NMR 
data of the different salts are compared in Table 6.1 and 6.2.  
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3.4.7. Summary 
Overall, the total synthesis of enigmazole A (16) presented herein is robust, scalable and concise 
allowing access to the natural product in 23 steps (LLS) with an overall yield of 3.3% 
(Scheme 3.30). The two key steps of this total synthesis are (i) the RCAM of the highly 
functionalized substrate 62 giving the desired macrocycle 115 on a multigram scale in excellent 
yield and (ii) a new and unprecedented post-metathesis functionalization to access the syn-
tetrahydropyran ring 123. This gold-catalyzed rearrangement/transannular hydroalkoxylation 
cascade is a noteworthy example of a complex catalyst/substrate chirality interaction. 
Experiments on the substrate/catalyst combinations revealed several reaction mechanisms 
leading to different cyclic byproducts 115a/b, 124, and 125. Further structural derivatization of 16 
(as described in the next chapter) by exloring the possibilitis of the reported methodologies could 
contribute to insights on the biological activity of enigmazole A (16). 
 
Scheme 3.30: Fragment combination and final synthesis of enigmazole A (16). Conditions: a) (S)-50, (S)-110, DCM, −78°C, 
95% (d.r. > 10:1); b) TrocCl, DMAP (cat), pyridine, DCM, 0 °C → rt, quant.; c) camphorsulfonic acid (cat.), DCM/MeOH 
(3:1), 0 °C → rt, 61% (98% brsm); d) 2,4,6-trichlorobenzoyl chloride, Et3N, then 112a, DMAP, toluene, 0 °C, quant.; e) 116 
(cat.), 4Å + 5Å MS, toluene, 79%; f) Zn, HOAc, ultrasonication, 93%; g) (R)-121 (cat.), AgSbF6 (cat.), DCM, rt, 91%; h) 
K2CO3, MeOH, 95%; i) NaBH4, MeOH, −40°C, 62%; j) (i) (FmO)2PNiPr2, tetrazole, ACN; (ii) aq. H2O2, 0 °C, quant.; k) 
TBAF/HOAc 1:1.5, THF, 40 °C, 14d, 82%. 
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3.4.8. Outlook: Derivatization and SAR 
The limited availability of the enigmazoles (16, 17-20) from natural sources and their potent 
bioactivity make them attractive synthetic targets for structural derivatization. The syntheses of 
structural siblings could give valuable insight into their structure-activity-relationship, and 
therefore contribute to the development of new lead structures for anti-cancer drugs. Taking the 
performed synthetic route of enigmazole A (16) into account, we envisioned modifications on the 
four structural motifs highlighted in Figure 3.2. These motifs are interesting targets for two 
reasons, (i) they cover most of the functional groups of 16 and (ii) they are readily accessible by 
the previously described route. 
 
Figure 3.2: Targets for the derivatization of enigmazole A (16). 
(I) We embarked on the synthesis of a carbamate at C5 in place of the phosphate ester as they 
have similar electronic character. In analogy to the previously reported route, carbamate 130a was 
prepared from the corresponding alcohol 126a as a first synthetic congener of 16 
(Scheme 3.31).[113]  
 
Scheme 3.31: Synthesis of C5-carbamate 130. Conditions: a) (i) trichloroacetyl isocyanate, DCM, 0 °C; (ii) rinsed over 
neutral Al2O3; b) TBAF, AcOH, THF, 40 °C, 14 d, 70% (over two steps). 
(II) Epimers at C5 and C7 were already formed along the way to the completion of 16, and C7/11 
diastereomer was accessible through a minor variation. The C11-epimer of 111, for example, was 
prepared via enantioselective allylation of aldehyde 63 with 50 in the presence of (R)-110 
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(Scheme 3.22). With compound 111c in hand, we moved on to prepare (7S,11S)-
enigmazole A (132). All steps were performed under similar conditions as described in the total 
synthesis of enigmazole A (16) and gave comparable yields. The [3,3]-sigmatropic rearrangement 
showed the same catalyst/substrate chirality match/mismatch. Use of achiral gold catalysts gave 
poor yields (<10%) and mainly the anti-tetrahydropyran. Under the same catalyst system with 
(S)-121, 115c converted to the desired product 117d in 75% yield and a d.r. ≥95%. In contrast, 
diastereomer 115d gave undfined mixtures with the screened catalyst. Interestingly, the reduction 
of 131 with sodium borohydride gave exclusively a single diastereomer in excellent yield. The 
stereochemistry at C5 could not be assigned unambiguously due to the small amounts of isolated 
material. Standard transformations finally afforded the streochemical-sibling 132. 
 
Scheme 3.32: Synthesis (7S,11S)-enigmazole A (132). Conditions: a) (R)-110, DCM, −78°C, 95% (d.r. >10:1). 
(III) Future derivatives would consider the C15 hydroxy group. For example, methylation of this 
group could give the naturally occurring sibling 18. Further investigations are ongoing in our group. 
(IV) The modification of the oxazole side chain remains a challenge. Since this heterocycle is 
carried along the entire route, its modification should be made at a late stage. One possibility 
could be the oxidative cleavage of the olefins in the oxazole side chain, which would give access to 
substrates such as 134 and 135 (Scheme 3.33). Similar substrates featuring exo-methylene groups 
and/or oxazoles are known to react selectively under different oxidative conditions.[51, 114] 
Unfortunately, initial attempts on this transformation resulted in the decomposition of the starting 
material 126. Particularly, oxidative cleavage of the exo-methylene[115] could give the crucial 
precursor 133 for the synthesis of enigmazole B (20). 
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Scheme 3.33: Possible modifications of enigmazole A (16) creating a unique compound library. 
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4. Total Synthesis of Rhizoxin D 
4.1. Introduction 
4.1.1. Isolation 
Rhizoxin (140), the first representative of a large family of polyketide macrolides (17 and 141-148, 
Figure 4.1 and 4.2), was isolated from the plant pathogenic fungi of Rhizopus sp. by Iwasaki and 
co-workers in 1984.[116] The Iwasaki group investigated the origin of the rice seedling blight disease 
and found that swelling was caused not by pathogens inside the seedling root, but by the 
metabolites of Rhizopus, such as 140, which were absorbed into the bed soil. In particular, the 
fungus Rhizopus chinensis was found to cause the major loss of seedlings and was therefore used 
as the source for isolating 140. 
Structurally, rhizoxin (140) exhibits eleven stereogenic centers, two epoxides, a δ-lactone 
annulated to a 16-membered macrocyclic lactone and a triene side-chain, which is terminated 
with an oxazole heterocycle. The di-desepoxy congener, rhizoxin D (17), which is the putative 
biosynthetic precursor of rhizoxin (140), was isolated shortly afterwards from the same fungus.[117] 
The structures were determined by extensive NMR analysis, X-ray diffraction and degradation 
studies.[118] 
 
Figure 4.1: Structures of the rhizoxin (140) and rhizoxin D (17). 
In 2005, Partida-Martinez and Hertweck showed that rhizoxin (140) is biosynthesized not by the 
fungi of Rhizopus themselves, but by endosymbiotic bacteria of the genus Burkholderia.[119] The 
proof of principle was based on the three “Koch postulates” in classical microbiology. Upon 
antibiotic treatment of Rhizopus, a symbiont-free Rhizopus strain could be isolated, which did not 
show any rhizoxin (140) production. On the other hand, the isolated and incubated Burkholderia 
strain produced 140 and its congeners in pure culture. Interestingly, the isolated symbiont lost its 
ability to synthesize rhizoxin (140) over time, hinting at a more complex chemical signaling in the 
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fungal–bacterial symbiosis to trigger and/or maintain rhizoxin (140) biosynthesis. After re-
introduction of the bacteria to the fungus, the reestablished endosymbiotic relationship enabled 
the production of rhizoxin (140) again. With this work, Partida-Martinez and Hertweck showed a 
remarkably complex relationship that extends the pathogenic fungus–plantae interaction to a 
third player, a bacterium, which holds major implications in crop protection.  
 
4.1.2. Bioactivity 
At concentrations lower than 10 ng/mL, rhizoxin (140) induces an abnormal swelling of rice 
seedlings known as rice blight, which is an economically costly agricultural disease.[116a] Biological 
studies showed that rhizoxin (140) has a potent activity (≥0.1 µg/mL) against a variety of 
phytopathogenic fungi, but shows only little activity against bacteria. Further investigations 
revealed the remarkable in vitro and in vivo potency against human and murine tumor cells 
(L1210, K562 or P388 leukemia and B16 melanoma) including vincristine- and Adriamycin-resistant 
sublines (Table 4.1).[120] 140 was found to be less toxic and more potent than vincristine (Oncovin), 
a top-of-the-line chemotherapy agent, rendering rhizoxin (140) an effective antitumor drug 
candidate for clinical trials.[121] 
Table 4.1: Cytotoxicity of rhizoxin (140) and vincristine in mouse and tumor cell lines sensitive and resistant to vincristine 
and Adriamycin.[120a] 
 
Due to the physical characteristics of the swelling of rice seedlings, it was already assumed in a 
very early stage of research that rhizoxin inhibits the cell division. Indeed, rhizoxin binds at the β-
tubulin of many eukaryotic cells causing inhibition of tubulin polymerization.[122] This disruption of 
microtubule formation prevents the formation of the mitotic spindle and inhibits cell division 
leading to cell death.[123] Binding studies revealed that rhizoxins have their own distinct binding 
site, which may overlap with the binding site of the vinca alkaloids, also affecting their binding to 
proteins.[122] 
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Figure 4.2 Structures of rhizoxin (140) and its analogues. 
The promising biological activities of rhizoxin (140) prompted detailed investigations of structure-
activity relationship (SAR).[116b, 124] Biologically essential parts of the rhizoxin structure are the free 
hydroxy group at C13, the δ-lactone spanning C5-7, and the methyl group at C8.[125] Acetylation of 
the hydroxy group (142) or removal of the carbonyl of the δ-lactone (143) resulted in loss of 
activity (Table 4.2). It was found that these oxygen functionalities (plus the carbonyl at C1) form 
hydrogen bonds to the active site of β-tubulin.[126] The epoxide functionalities at C2-3 and C11-12 
could be replaced by double bonds (17 and 141) without significant influence on the activity. In 
contrast, hydrolytic opening of the epoxides had detrimental effects (144), presumably due to 
conformational changes in the 16-membered macrocycle.[123] Compared to the macrocyclic core 
modifications at the oxazole side-chain were better tolerated and had less effect on the activity. 
Thereby, derivatizations at the end of the chain C22-26 (146-148) had the smallest influence. 
Table 4.2: Activity of rhizoxin (140) and derivatives on cytotoxicity (P388) and tubulin polymerization.[123, 125] n.a. = no 
activity. 
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Phase I and II clinical trials of rhizoxin (140) and its derivatives were carried out in the USA, Japan 
and Europe. However, 140 did not show sufficient in vivo results or major therapeutic advantages 
compared to other chemotherapeutic agents.[127] Therefore, the trials led to no further approvals.  
 
4.1.3. Literature Review 
The rhizoxin family attracted several groups to pursue syntheses of these natural products due to 
their bioactivity and structure. Detailed reviews of previous syntheses can be found in the 
literature;[116b, 128] only the most recent synthesis by Altmann et al. in 2013 is discussed briefly 
because the ring closing event featured a RCAM.[129] 
Originally, the synthesis relied on olefin metathesis to close the macrocycle. This strategy proved 
unsuccessful in spite of extensive efforts. Ultimately, the retrosynthetic analysis focused on a 
modified approach employing a RCAM (Scheme 4.1). The desired product 149 could be obtained 
by the hydroxy-directed epoxidation of rhizoxin D (17), its desepoxy congener, after RCAM of 150 
and subsequent Stille coupling to install the sidechain. Key intermediate 150 would be obtained by 
a HWE olefination between the two fragments 151 and 152, which would be accessed by a 
Paterson aldol reaction between 153 and 154, asymmetric allylation reaction and ring closing 
olefin metathesis (RCM) of 155 and 156. 
 
Scheme 4.1: Retrosynthetic analysis of WF-1360F (149) by the Altmann group. 
The two fragments 151 (8 steps) and 152 (16 steps) were prepared following straightforward 
routes and joined by HWE olefination (Scheme 4.2). The subsequent RCAM of 150 required high 
temperatures and long reaction times to afford the desired macrocycle 157 in good yield (69%). 
However, the reduction of enyne 157 to the desired 1,3-(E,E)-diene motif 159 proved to be 
challenging. trans-Selective hydrogenation or hydroelementation attempts were unsuccessful or 
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gave poor yields and E/Z-selectivities. The conjugated diene 159 was accessed in a step wise 
procedure through conversion of 157 into (Z)-olefin 158 and subsequent isomerization of the 
olefin in good yield (65% over two steps) and in excellent E/Z ratio (20:1). The coupling of 159 and 
the sidechain followed by global deprotection afforded rhizoxin D (17); a hydroxy-directed 
epoxidation of 17 gave WF-1360F (149). 
 
Scheme 4.2: RCAM applied by the group of Altmann to synthesize WF-1360F (149). Conditions: a) LiCl, DBU, THF/ACN 
3:1, 0 °C → rt, 81%; b) 9 (cat.), MnCl2, toluene, 5 Å MS, 125 °C, 69%; c) (i) [Co2(CO)8], DCM, rt; (ii) 1-ethylpiperidine 
hypophosphite, benzene, reflux, 74% over 3 cycles; d) AIBN, PhSH, benzene, reflux, 88%, E/Z = 20:1. 
In conclusion, Altmann et al. showed a convergent synthesis of two members of the rhizoxin 
family. It is worth noting the unsuccessful attempts in employing olefin metathesis for ring 
macrocyclization event and the problems with the 1,3-(E,E)-diene motif, showing the challenge of 
constructing the strained 16-membered macrocycle. 
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4.2. Retrosynthetic Analysis and Preliminary Studies 
Our group envisioned a retrosynthetic analysis of rhizoxin D (17) via RCDM, which would construct 
a versatile diyne motif (Scheme 4.3). This motif would allow downstream modifications between 
C9 to C12 which may give access to a broad variety of family members and their analogues. The 
synthesis should not only extend the understanding and application of our own methodology, but 
further provide new insights in the structure-activity relationship of the rhizoxin core.  
 
Scheme 4.3: Retrosynthesis of Rhizoxin D (17) showing the two key fragments 164 and 165. PG = protecting group, R = 
aryl or alkoxy. 
Retrosynthetically, we envisioned that 17 could be prepared by previously reported olefination 
between sidechain 160 and key intermediate 161.[130] The (E,E)-diene in 161 would be installed in 
four steps: first, a sequence of regioselective hydrostannation and methyl-Stille coupling to 
provide the trisubstituted olefin, followed by a second sequence of 
hydrostannation/destannylation completing the desired diene. This sequence was already verified 
on a simple test substrate described later in this section. Macrolactone 162 would be obtained by 
a RCDM of tetrayne precursor 163. This compound could be prepared via an olefination reaction 
between phosphonate 164 and aldehyde 165. 
 
Scheme 4.4: Retrosynthetic analysis of the eastern fragment 165. 
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The eastern fragment 165 could be prepared by an oxidation of the thermodynamically favored 
hemiacetal derived from an oxidative cleavage of cyclopentene 166. Cyclopentene 168 was 
planned to undergo regioselective alkylation of epoxide 167. 167 could be accessed via an 
intramolecular condensation reaction of the diol obtained by nucleophilic addition of 1,3-
pentadiyne (170) to known epoxide 169.[131] 
 
Scheme 4.5: Retrosynthetic analysis of the western fragment 164. 
The western fragment 164 could be made by methylation of the alcohol, derived from a directed 
anti-selective reduction of ketone 180 (Scheme 4.5). This ketone could be obtained via 
alkenylation of β-lactone 182 or any pre-activated derivative (e.g. an ester or Weinreb amide) with 
alkenyl halide 181. Lactone 182 would be prepared by trans-selective and asymmetric [2+2] 
cyclocondensation[132] of aldehyde 183 with propionyl bromide or by a tandem Mukaiyama aldol-
lactonization[133] with a thiopyridylsilylketene acetal. Aldehyde 183 could be accessed by an 
enantioselective alkynylation of aldehyde 184 with 1,3-pentadiyne (170), followed by protection 
and oxidation state adjustments.  
Preliminary studies on the transformation of the 1,3-diyne motif into a (E,E)-diene were conducted 
by Felix Ungeheuer, who demonstrated that the scope of classical RCAM could be extended to 1,3-
diynes.[36, 128] To verify the regioselectivity of trans-hydrostannations on 1,3-diynes, the very much 
simplified test system 185 was used (Scheme 4.6). In this system, the hydrostannation[40] was 
highly regioselective for the α-position yielding product 186 in 74% yield. Unfortunately, bis-
stannation was also observed leading to side product 187 in 20% yield.  
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Scheme 4.6: Trans-selective hydrostannation of 1,3-diynes. Conditions: a) [Cp*RuCl4]n (cat.), Bu3SnH, deg. DCM, rt, 74% 
186 and 20% 187. 
Subsequent methyl-Stille coupling of stannane 186 afforded the desired trisubstituted olefin 189 
in very good yield (92%) (Scheme 4.7). A second hydrostannation reaction on enyne 189, using the 
same conditions as before, afforded a mixture of diastereomers 190/191 (10:1) which could be 
transferred into the desired product 192 by destannylation. In the light of these positive results 
combined with the concise retrosynthetic analysis, we embarked in the forward synthesis of 
rhizoxin D (17). 
 
Scheme 4.7: Final transformation of the 1,3-diyne motif into (E,E)-1,3-diene. Conditions: a) [Pd(PPh3)4] (cat.), 
[Ph2PO2][NBu4], CuTc, MeI, DMF, 92%; b) [Cp*RuCl4]n (cat.), Bu3SnH, deg. DCM, rt, 89%; c) destannylation (not 
performed).[128] 
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4.3. Synthesis of Rhizoxin D 
The studies towards the total synthesis of rhizoxin D (17) performed by Felix Ungeheuer promised 
a feasible approach to this molecule.[128] Remaining tasks were reproducing the explored reactions 
on larger scale, the optimization of several challenging transformations, and the investigation on 
the final key steps to complete the total synthesis of rhizoxin D (17). The key milestone of the 
project was to obtain intermediate 161, an analogue of a former total synthesis,[134] which could 
be accessed via RCDM and hydrostannation reactions developed in our group (Scheme 4.8). The 
corresponding tetrayne precursor 193 could be disconnected into the two main fragments, 194 
and 165. 
The main focus of this chapter is to discuss the synthesis of the eastern fragment 165 along with 
optimization on the synthesis of 194 and the combination of the two fragments. The western 
fragment 194 was previously reported by Felix Ungeheuer and details can be found in his 
thesis.[128]  
 
Scheme 4.8 Retrosynthesis of rhizoxin D (17) showing key fragments 194 and 165. 
 
4.3.1. Synthesis of the Eastern Fragment 
A previous route to the eastern fragment 165 pursued by our group is shown in Scheme 4.9.[128] 
However, due to subsequent experience gained on the preparation and handling of 1,3-
pentadiyne (170), which is part of the synthesis of western fragment 194 (Section 4.3.2), we 
envisioned a shortcut and optimization of the route. 
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Scheme 4.9: Original synthesis of the eastern fragment 165.[128] Conditions: a) (-)-DIPT, Ti(OiPr)4, TBHP, 3 Å MS, DCM, −20 
°C to rt, 78%; b) TMS-acetylene, n-BuLi, toluene, −78 °C then Et2AlCl, 0 °C then 169, 95%; c) Tos-Cl, Bu2SnO, Et3N, DCM, rt, 
75%; d) DBU, DCM, rt, 85%; e) Mg, Et2O, then CuI, THF, −40 °C, 68%; f) NBS, AgNO3 (cat.), acetone, rt; g) propyne, CuCl, 
NH2OH·HCl, aq. BuNH2 (30% in water), 60% (over two steps); h) OsO4 (cat), NMO, acetone/H2O (2:1), 70% (d.r. = 7.7:1); i) 
NaIO4 (10% on SiO2), DCM, rt; j) PIDA, TEMPO (cat.), Yb(OTf)3 (cat.), DCM, rt, 76% (over two steps). 
The second generation synthesis started with the same epoxide 169 which was obtained by an 
asymmetric Sharpless epoxidation[135] of trans-crotyl alcohol (195) as previously described in the 
literature.[131] As the preparation of TMS-alkyne 196 required the installation of the diyne 
functionality at a later stage, we planned to add diyne 170 directly to epoxide 169. Diyne 170 was 
prepared from 1,4-dichloro-2-butyne by a base-induced elimination reaction quenched with 
methyl iodine.[136] Unfortunately, the previously described conditions to make TMS-alkyne 196 
(>95% yield, one isomer)[137] gave very poor selectivities when 170 was used as pre-nucleophile to 
afford desired diyne 204a (Table 4.3, Entry 1). In addition to the poor selectivity we observed 
several side products, which were the corresponding diastereomer 204b and the 1,3-diol 205. 
Variations of the conditions did not improve the yields (Entry 2).[138] Also, prior deprotonation of 
the alcohol using n-butyllithium gave the same ratio of product and side products (Entry 3). A 
positive influence on the selectivity was observed after increasing the reaction time of the diynyl-
lithium species and diethyl aluminum chloride, probably allowing for complete transmetalation 
(Entry 4). The best yields and selectivities were obtained by using dichloromethane as solvent, 
giving 204a in 95% isolated yield on a multi gram scale with very good regio- and 
diastereoselectivity (Entry 5). This observation was in agreement with the findings in a publication 
by Oshima,[139] showing that use of less polar solvents, such as hexane or dichloromethane, 
increases the regioselectivity for the desired β-addition. However, literature suggests that this 
effect is highly substrate dependent.[140] 
54 Rhizoxin D 
 
Table 4.3: Optimization of the alkynylation reaction. 
 
[a] mixture of isomers; [b] the epoxide was deprotonated with n-BuLi (1 equiv) before adding it to the reaction mixture; 
[c] epoxide 169 was added after 2 h. pd = product 204a, sp = side products 204b and 205. 
General experimental procedure: n-BuLi was added to a solution of diyne 170 in toluene at −78°C. AYer 30 min the 
reaction mixture was warmed up to 0 °C, before Et2AlCl was added. After 30 min, a solution of the epoxide 169 in toluene 
was added still at 0 °C. Stirring of the reaction mixture was continued over night at ambient temperature. 
A separation of regioisomers 204 and 205 was not possible at this stage, but the mixture could be 
directly used in the next reactions in which only the desired regioisomer 204 could form epoxide 
206 after chemoselective tosylation and treatment with DBU (Scheme 4.10). Copper-catalyzed 
epoxide opening at the primary position using the Grignard reagent derived from 
4-bromocyclopent-1-en (199) gave compound 201 as well as trace amounts of the corresponding 
hydrolysis product 204. The 4-bromocyclopent-1-en (199) was accessible from commercially 
available cyclopent-3-en-1-ol in one step on large scale and excellent yield.[141] The critical step in 
this reaction was the formation of the Grignard reagent derived from 199. Only magnesium 
turnings which were activated by the addition of catalytic amounts of 1,2-dibromo-ethane reacted 
with bromide 199. A reaction set at 1 M concentration gave the best results. Curiously, no reaction 
was observed between the corresponding iodide and magnesium. Attempted lithium/halogen 
exchange with t-butyllithium resulted in complex mixtures. 
 
Scheme 4.10: Synthesis of cyclopentene 201. Conditions: a) i) Tos-Cl, Bu2SnO (cat.), Et3N, DCM; ii) DBU, 72% (stepwise 
97% and 86%); b) Mg, 199, Et2O, rt, then CuI, −40 °C, then 206, 86%.  
The δ-lactone was installed by an oxidative cleavage of cyclopentene 201 (Scheme 4.11). Direct 
ozonolysis of 201 and subsequent ytterbium-catalyzed oxidation[142] of 207 afforded 165 in only 
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two steps and excellent yield (81% over two steps). Other oxidizing agents, like TPAP[65] or PCC[143], 
showed similar results; however it was always necessary to purify and oxidize dialdehyde 207 
immediately to obtain reasonable yields above 30%. 
 
Scheme 4.11: Synthesis of the eastern fragment 165. Conditions: a) O3, DCM, −78 °C, then PPh3, 88%; b) PIDA, TEMPO 
(cat.), Yb(OTf)3 (cat.), DCM, 92%. 
Both aldehydes 207 and 165 were very unstable, probably due to polymerization (even at −25°C), 
explaining the broad range of yield (30-90%) in the oxidations of 207. Consequently, the storage 
times were kept short and these aldehydes were directly used in the next reactions. 
In summary, the eastern fragment 165 was accessed in 6 steps from the commercially available 
(2E)-but-2-en-1-ol (195) with an overall yield of up to 43% (Scheme 4.12). All steps were scalable 
and reliable. 
 
Scheme 4.12: Final synthesis of the eastern fragment 165. Conditions: a) n-BuLi, Et2AlCl, then 169, DCM, −78°C → 0 °C, 
95%; b) i) Tos-Cl, Bu2SnO (cat.), Et3N, DCM; ii) DBU, 72% (stepwise: 97% and 86%); c) Mg, 199, Et2O, rt, then CuI, −40 °C, 
then 206, 86%; d) O3, DCM, −78 °C, then PPh3, 88%; e) PIDA, TEMPO (cat.), Yb(OTf)3 (cat.), DCM, 92%. 
 
4.3.2. Synthesis of the Western Fragment 
The western fragment 194 displayed the longest linear sequence in the proposed total synthesis of 
rhizoxin D (17). Felix Ungeheuer proposed a synthetic route to this fragment and provided 
preliminary results (Scheme 4.13).[128] 
However, the red-highlighted steps remain challenging. In particular, the coupling of the alkenyl 
sidechain 215 with β-lactone 213 required further investigations which will be discussed below. 
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This β-lactone was used as a mixture of inseparable diastereomers (S,S)-213a and (R,R)-213b (d.r. 
= 5:1). 
 
Scheme 4.13: Original synthesis of the western fragment 219 by Felix Ungeheuer.[128] Conditions: a) TES-Cl, Et3N, DMAP 
(cat.), DCM, 87%; b) SO3·Py, Et3N, DMSO/DCM (1:1), 0 °C to rt, 85%; c) 170, Me2Zn, (R,R)-ProPhenol, Ph3P=O, toluene, 
0 °C, 84%; d) TBS-Cl, imidazole, DCM, 87%; e) (ClCO)2, DMSO, , −78 °C to −30 °C, 1 h then −78 °C, Et3N, 76%; f) 212, ZnCl2, 
DCM, 62% (d.r. = 5:1); g) MeNH(OMe), AlMe3, DCM, 0 °C, 78%; h) 215, t-BuLi, THF, −78 °C, 15 min, then CeCl3·2LiCl, 
30 min, then 214, −78 °C, THF, 45 min, 38% (96% brsm); i) SmI2, p-nitrobenzaldehyde, THF, −10 °C, 70%; j) (CH3)3OBF4, 
1,8-bis-(dimethylamino)naphthalin, DCM, 69% (77% brsm.); k) K2CO3, MeOH/THF 1:1, 71%. 
Initial efforts in our group on the direct alkenylation of β-lactone 213 using the alkenyl-lithium 
species formed by a lithium-iodine exchange with t-butyl lithium and alkenyl iodine 215 gave very 
poor yields and resulted in epimerization at the α-stereocenter next to the lactone (Scheme 4.14). 
Epimerization for similar additions were already reported in the literature and did not come 
unexpected.[144] Transmetalation of the lithium species to a less Brønsted basic organocerium 
analogue prevented this epimerization. Treatment of the lithium species with anhydrous 
cerium(III) chloride gave a deep orange solution of an organocerium species, which was only stable 
at low temperatures (≤−60 °C). Addijon of this solujon to lactone 213 gave the desired product 
216 in yields around 20% along with recovered starting material 213, as well as the double 
addition product 220. Further experiments varying concentration, temperature, reaction time and 
equivalents of reagents could not increase the yield above 30%. It is noteworthy that the best 
results were obtained when the lithium-cerium exchange was performed over several hours (≥2 h) 
at −78 °C with an excess amount of cerium(III) chloride. Shorter reaction times resulted in 
epimerization of the α-stereogenic center, suggesting that the transmetalation was not 
completed. Using a solution of CeCl3·2LiCl in tetrahydrofuran as described by Knochel[145] improved 
the yield and reproducibility due to the increased solubility of cerium chloride in the reaction 
medium. Under those conditions we never observed byproduct 220. To further explore the 
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reactivity of substrate 213, we tested it in simple reactions, utilizing vinylmagnesium bromide as 
nucleophile (with and without copper(I) iodide). Although these transformations were very well 
described in the literature,[146] low conversion was observed even at elevated temperatures, and 
starting material 213 could be re-isolated. This indicates very low reactivity of this substrate 
towards nucleophilic additions in general. 
 
Scheme 4.14: Initial attempts for the preparation of unsaturated ketone 216. Conditions: a) 215, t-BuLi, Et2O/pentane, 
−90 °C, then 213, −78 °C, 20 min, 24%; b) 215, t-BuLi, Et2O/pentane, −78 °C, then CeCl3, 1 h, then 213, −78 , 1 h, 20%; c) 
CH3NH(OCH3), AlMe3, DCM, 0 °C, 78% (213, 11%); d) 215, t-BuLi, THF, −78 °C, 15 min, then CeCl3·2LiCl, 30 min, then 214a, 
−78 °C, THF, 45 min, 38% (96% brsm). 
To achieve better reactivity, we planned to transfer β-lactone 213 into another carbonyl 
derivative. Alkenylation reactions of similar Weinreb amides, for example, were very well 
described in the literature.[147] The transformation of 213 into Weinreb amide 214 proceeded with 
good yields (70-90%) on up to 2.4 g scale.[148] At this stage, diastereomers 214a and 214b could be 
separated by flash chromatography and we proceeded with 214a.  
Initial attempts on the alkenylation of Weinreb amide 214a with alkenyl iodide 215 in our group 
are shown in Table 4.4 (Entry 1-4).[128] Best results (Entry 4) were obtained using similar conditions 
as described for the direct alkenylation of β-lactone 213 (see above). The reaction yields were 
between 30% and 40% in favor of the desired product 216 (50-60% brsm 214). Full conversion was 
not observed even when 5 equivalents of the alkenyl-cerium species were employed. When we 
applied the improved conditions taken from the direct alkenylation procedure, ensuring complete 
transmetalation by stirring the organolithium species and the CeCl3·2LiCl solution for 3 h, yields 
decreased dramatically and complex reaction mixtures were observed. Taking these results into 
account, we modified the procedure by direct addition of the organolithium species of 215 to a 
solution of Weinreb amide 214a and CeCl3·2LiCl at −78 °C without initial metal exchange. This 
modification afforded 216 in better yield up to 60% (Entry 5). The results might indicate that both 
reactions proceeded via different pathways. While the alkenylation of β-lactone 213 proceeded by 
addition of an organocerium species to the lactone, the alkenylation of Weinreb amide 214 is only 
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promoted by cerium(III), allowing the lithium species to attack the carbon center. This would also 
explain why 214 did not react with Grignard reagents, such as methylmagnesium bromide or 
vinylmagnesium bromide, without further activation, even though similar Weinreb amides are 
very well known to react under these conditions.[149]  
Table 4.4: Screening of conditions for the synthesis of ketone 216. Entry 1-4 show results of Felix Ungeheuer.[128] 
Conditions: a) TMS-Cl, TEA, DMAP (cat.), 0 °C → rt, DCM, quant. 
 
[a] Li/I exchange was conducted in Et2O for 20 min at −78 °C, (then transmetalaZon,) Weinreb amide was added as a 
solution in THF to the alkenyl reagent dropwise; [b] alcohol 214a was prior deprotonated with 0.6 eq. of n-BuLi at −78 °C 
and stirred for 15 min; [c] Li/I exchange was conducted in Et2O for 30 min at −78 °C, Li-alkenyl was added to a solution of 
Weinreb amide and CeCl3 dropwise at −78 °C; [d] two steps: yield of alkenylaZon 91%, TES deprotecZon 50%; [e] Li/I 
exchange was conducted in THF for 30 min at −78 °C, Li-alkenyl was added to a solution of Weinreb amide and CeCl3 
dropwise at −78 °C; crude product dissolved in DCM/MeOH 5:1 and treated with CSA. 
Ultimately, the best results for this transformation were obtained when the hydroxyl group in 
Weinreb amide 214 was protected as TES or TMS silyl ethers (Entry 6 and 7) which were obtained 
in excellent yields (91% and quant). To ensure substrate stability under reaction conditions, we 
first used the more stable TES-ether of 214a in the alkenylation reaction which afforded excellent 
yields of the TES-protected-216 (>90%) (Entry 6). The deprotection of the TES-ether under acidic 
conditions was unselective, due to the primary TBS ether in substrate 214, affording only 50% of 
the desired product 216. To overcome this problem the more labile TMS-ether 221 was used for 
the alkenylation reaction with similar success. Subsequent TMS-deprotection (without loss of the 
TBS group) afforded 216 in 83% yield over three steps (protection, alkenylation, and 
deprotection). The reaction was also performed in one-pot, which afforded lower yields. In this 
case, the Weinreb amide 214 was protected in situ by using n-butyllithium and trimethylsilyl 
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chloride (1 equivalent each), followed by the alkenylation and final deprotection during the 
aqueous workup (1 N hydrochloric acid).  
After the alkenylation reaction, a methylated hydroxy group at position C17 had to be installed in 
216. An intramolecular Evans–Tishchenko reaction[150] set the desired absolute configuration and 
protected the directing hydroxy group at C15 in one step (Scheme 4.15). The best results were 
obtained by using catalytic amounts of freshly prepared samarium(II) iodide and 3 equivalents of 
p-nitrobenzaldehyde in degassed solvent (freeze-pump-thaw method). Interestingly, use of more 
than 3 equivalents of benzaldehyde led to an unprecedented protection of both hydroxy groups 
(C15/17) probably due to a disproportionation of the aldehyde by a Cannizzaro-type mechanism. 
 
Scheme 4.15: Final steps of the synthesis of the eastern fragment 219. Conditions: a) SmI2 (cat.), p-nitrobenzaldehyde, 
deg. THF, −25 °C, 85%; b) (CH3)3OBF4, 1,8-bis-(dimethylamino)naphthalin, DCM, 78% (83% brsm); c) K2CO3, MeOH/THF 
1:1, 78%. 
Subsequent methylation of desired product 217 and PNB deprotection[128] afforded the western 
fragment 219 in 11-13 steps and an overall yield of 3.3-4.1%. The longer route including the TMS-
protection-deprotection sequence gave the better overall yield. 
 
4.3.3. Combination of the Fragments and Outlook 
With the two building blocks in hand, we proposed two different routes for the combination of 
fragment 219 and 165 (Scheme 4.16). The first route was based on the transformation of western 
fragment 219 to Horner-Wadsworth-Emmons (HWE) precursor 194 used in the previous synthesis 
of rhizoxin.[129] Reaction of this phosphonate with aldehyde 165 gave desired product 193 in good 
yield (77%). The second route included esterification of acid 222 and western fragment 219. The 
acid was obtained in one step from eastern fragment 165 by a HWE reaction. First attempts to 
couple both building blocks via an esterification failed.[128] Further investigations will be performed 
at a later stage to differentiate this total synthesis from previously reported ones and to make use 
of the more stable acid 222 rather than aldehyde 165. 
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Scheme 4.16: Strategies for the combination of fragment 219 and 165. Conditions: a) EDC·HCl, diethylphosphonoacetic 
acid, 3 Å MS, DMAP (cat.), DCM, rt, 85%; b) 165, LiCl, DBU, ACN, rt, 77% (91% brsm); c) Zn(OTf)2, DBU, TMEDA, 
diethylphosphonoacetic acid, THF, rt, 73% (E:Z = 10:1); d) 219, esterification conditions. 
Up to this step, the optimized route made tetrayne 193 available in reliable yields and provided 
considerable amounts to investigate the key steps: ring closing diyne metathesis and 
functionalization of the diyne motif. The RCDM of 193 has already been demonstrated by Felix 
Ungeheuer, albeit in moderate yield and on very small scale (Scheme 4.17).[128] 
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Scheme 4.17: RCDM of tetra-yne 193 giving desired product 223 and a unknown side product. Conditions: a) 8 (cat.), 4 Å 
and 5 Å MS, toluene, <50%. 
Since there is room for further improvement, we moved on to monitor the reaction by HPLC-MS. 
To our surprise, we observed, in parallel to the consumption of 193, the formation of two products 
(Figure 4.3). HPLC-MS analysis indicated that the two newly formed products are the desired 
monomer 223 and a second unknown byproduct. In addition, the poor combined yield of the two 
products (<50%) suggested formation of polymer or decomposition of the substrate/products 
under the reaction conditions. Preparative LC allowed separation of the two compounds and the 
structure of 223 was confirmed by NMR and MS analysis. The structure of the second product 
could not be assigned unambiguously, but NMR analysis revealed its close structural relationship 
to 223. Surprisingly, MS analysis suggested either a monomeric or dimeric triyne-containing 
macrocycle, which was so far never observed in RCDM.  
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HPLC-MS analysis showed the consumption of the unknown byproduct after the addition of more 
catalyst 8 to yield either polymerization or decomposition products with no traces of 223 
observed. Ultimately, the best yield of 223 (30-50%) was obtained by RCDM at ambient 
temperature with 4 Å and 5 Å molecular sieves and portion wise addition of catalyst 8 
(2 × 15 mol%). These conditions gave exclusively the desired product 223. 
 
Figure 4.3: HPLC trace of the RCDM. Black starting material, purple reaction mixture after 1 h. 
Further experiments on the optimization of the RCDM are currently in progress in our group. From 
previous studies, we know that varying the reaction temperature and concentration can have 
profound impact on the overall outcome.[32] In addition, our group has recently developed a 
variety of new ring closing alkyne metathesis catalysts 12-15[34] which will be investigated in this 
specific transformation. 
An alternative route would involve modifying the starting material 193 by removing the TBS 
protecting groups prior to metathesis to give unprotected propargylic alcohol 225 (Scheme 4.18). 
The removal of the sterically demanding TBS groups could change the conformation of the starting 
material and of the macrocyle and therefore lead to improved yields. We are expecting to be able 
to overcome the selectivity issues and continue the total synthesis of rhizoxin D (17). 
 
Scheme 4.18: Final steps to the total synthesis of rhizoxin D (17). Conditions: a) TBS deprotection; b) RCDM; c) 
hydrostannation; d) methyl-Stille coupling; e) hydrostannation; f) destannylation. 
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In conclusion, we were able to access the open tetrayne 193 in only 13-15 steps and 4.1-5.6% 
overall yield. All reactions up to this important key intermediate gave high yields and were carried 
out on workable scales (>100 mg). The last missing transformations for completion of the total 
synthesis of rhizoxin D (17) would include hydroxy-directed hydrostannation reactions to install 
the methylated-(E,E)-diene and the attachment of the literature known sidechain 160. 
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5. Summary and Conclusion 
Almost 20 years after the first ring closing alkyne metathesis (RCAM) was performed in the 
Fürstner group, it has established its important role for organic synthesis.[20] Improvements over 
the years in catalyst structure and reaction protocols have expanded the scope of RCAM, including 
employment in several complex total syntheses.[6b, 105] In combination with post-metathesis alkyne 
functionalizations, RCAM has become an important tool to construct macrocyclic frameworks. 
This thesis explored the scope of RCAM and applications of state-of-the-art alkyne 
functionalization methods in the context of synthesizing two natural products, enigmazole A (16) 
and rhizoxin D (17) (Figure 5.1). Both natural products belong to families with rare structural 
motifs and selective anti-cancer activities. 
 
Figure 5.1: Enigmazole and rhizoxin natural product families. 
In 2010, enigmazole A (16) and its congeners were isolated from the marine sponge 
Cinachyrella enigmatica, which was collected in Papua New Guinea as part of a marine collection 
program of the U.S. National Cancer Institute. These polyketide natural products represent the 
first phosphorylated macrolides of marine origin and show interesting structural features.[48] The 
18-membered macrocyclic ring contains seven stereogenic centers, a phosphate ester, an 
embedded syn-tetrahydropyran ring, and a functionalized oxazole sidechain. Enigmazole A (16), in 
particular, showed significant cytotoxic activity in the NCI 60-cell antitumor assay (IG50 = 1.7 µM). 
Noteworthy is the selective differentiation of wild-type and mutant receptor tyrosine kinase c-Kit 
with structural analogues of enigmazole A (16), which is an important target in cancer therapy. 
This differentiation is found in less than 0.03% of 135.000 tested natural products.[48] The 
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intriguing biological activity and the challenging structure prompted us to pursue the synthesis of 
enigmazole A (16). 
The envisioned retrosynthetic analysis contained two key transformations, (i) a noble metal 
catalyzed [3,3]-sigmatropic rearrangement with subsequent hydroalkoxylation and (ii) a RCAM 
(Scheme 5.1). The sigmatropic rearrangement could form the syn-tetrahydropyran ring in key 
intermediate 45 via intramolecular hydroalkoxylation of allene 46, which would be derived from 
macrocycle 47. 47 could be formed by an asymmetric allylation, an esterification, and a RCAM of 
three fragments 49-51. 
 
Scheme 5.1: Retrosynthetic analysis of enigmazole A (16). 
Synthesis of northern fragment 49 began with Myers asymmetric alkylation[63] between 65 and 68 
giving amide 69 in excellent yield (98%) and selectivity (d.r. = 96:4) (Scheme 5.2). Reductive 
cleavage of the auxiliary and Ley-Griffith oxidation[64-65] afforded aldehyde 71. Corey-Fuchs 
reaction[67] installed the methyl-capped alkyne, and subsequent desilylation and TPAP-catalyzed 
oxidation[69] afforded acid 49 in 8 steps and 37% overall yield. 
 
Scheme 5.2: Synthesis of the northern fragment 49. 
The synthesis of southern fragment 50 involved Keck allylation[81] of but-2-ynal (75) with stannane 
83 to form (S)-77 after acetylation in excellent stereoselectivity (e.e. ≥95%) (Scheme 5.3). 
Finkelstein reaction and palladium-catalyzed stannation[73] of the allyl iodide afforded the desired 
fragment (S)-50 in 5 steps and 25% overall yield. 
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Scheme 5.3: Synthesis of the southern fragment (S)-50. 
The eastern fragment 63 represents beginning of the longest linear sequence and was prepared 
starting from commercially available (R)-(+)-3-butyn-2-ol (89) (Scheme 5.4). A trans-
carbomagnesiation of 89 and iodine quench gave access to an alkenyl iodide,[83] which was 
coupled to ethyl 4-oxazole carboxylate (88) via palladium-catalyzed C–H activation reaction to 
afford aldehyde 52.[84] The four steps sequence including inter alia a highly stereoselective Keck 
allylation[81] (d.r. >95:5) of 52, followed by a regio- and stereoselective iodo-cyclization (d.r. >95:5) 
afforded 103. Regioselective, copper-catalyzed epoxide opening at 103 with Grignard reagent 105 
and standard protecting group manipulations gave building block 63 in 12 steps and overall yield 
of 11.2%. The route allowed preparation of 63 in multigram quantities. 
 
Scheme 5.4: Synthesis of the eastern fragment 63. 
With robust and scalable routes for all fragments, their assembly was investigated (Scheme 5.5). 
Enantioselective Corey allylation[103] between aldehyde 63 and stannane 50 gave 112 in good 
stereoselectivity (d.r. >10:1) and excellent yield (95%). Standard protecting group manipulations 
and Yamaguchi esterification[104] with acid 49 afforded metathesis precursor 62. Due to the high 
density of coordinating functionalities in 62, RCAM required unusually high catalyst loading 
(30 mol%) to achieve complete conversion.[30] Nevertheless, the metathesis reaction was 
successfully performed on 1.7 g scale with 79% yield. [3,3]-Sigmatropic rearrangement of 115 with 
subsequent transannular attack of the hydroxy group afforded product 117a in 91% yield. The 
rearrangement, which is a noteworthy example of a complex catalyst/substrate chirality 
interaction, required the use of a chiral binuclear gold(I)-catalyst (for details see Section 3.4.5). 
Saponification of 117a and substrate-controlled reduction of the ketone afforded 126a in 62% 
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yield (and C5-epimer 126b in 33%). Phosphorylation[51] and global deprotection gave enigmazole A 
(16) in 23 steps (LLS) with an overall yield of up to 3.3%. 
 
Scheme 5.5: Fragment coupling and completion of the total synthesis of enigmazole A (16). 
 
In 1984, rhizoxin (140) was first isolated by Iwasaki et al. during the investigations on the 
rice seedling blight disease.[116a] Several congeners were also isolated, including rhizoxin D (17), the 
biosynthetic di-desepoxy precursor of rhizoxin (140).[117] 17 features an unprecedented 16-
membered macrocyclic ring containing three (E)-olefins, a δ-lactone, and a highly unsaturated, 
oxazole terminated sidechain. The high potency of the rhizoxins against human and murine tumor 
cells led to high interest in the synthetic community. Several members of the rhizoxin family were 
synthesized but the 1,3-diene motif was rarely modified, which makes it an interesting target for 
further SAR studies. The recently reported metathesis of 1,3-diynes could give access to 
derivatives at this particular position in the molecule.[36] 
Our group[128] envisioned a convergent synthetic route towards rhizoxin D (17), which would allow 
late stage modifications of the 1,3-diyne motif via combinations of hydrostannation and cross-
coupling or destannylation reactions. The key intermediate towards the synthesis of 
rhizoxin D (17) could be 161. A sequence of hydroelementation reactions would provide 1,3-(E,E)-
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diene motif of 161 from 1,3-diyne 162 (Scheme 5.6). 162 could be prepared by olefination of two 
building blocks 164 and 165 and subsequent ring closing diyne metathesis (RCDM). 
 
Scheme 5.6: Retrosynthetic analysis of rhizoxin D (17). 
The synthesis of the eastern fragment 165 started with a regio- and stereoselective alkynylation of 
epoxide 169 (95%, single isomer) (Scheme 5.7). The obtained diol 204a was turned into an 
epoxide, which was then opened by the Grignard reagent 226 to afford 201. Ozonolysis of 
cyclopentene 201 and oxidation of the lactol gave 165 in 6 steps and overall yield of 43%. 
 
Scheme 5.7: Synthesis of the eastern fragment 165. 
The route to the western fragment 194 started from aldehyde 209 and 1,3-alkyne 170. 
Asymmetric alkynylation under Trost conditions[151] and modified Swern oxidation[152] afforded 
211. β-Lactone 213a was prepared by a tandem Mukayama aldol-lactonization reaction.[133a] 
Alkenylation of 213a with alkenyl iodide 215 was achieved after first transforming 213a into the 
corresponding Weinreb amide. An Evans-Tishenko reaction[150] set the missing stereocenter and 
ultimately afforded fragment 194 in 13 steps and overall yield of 7.1%. 
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Scheme 5.8: Synthesis of the western fragment 194. 
The coupling of fragment 165 and 194 was achieved by HWE olefination (Scheme 5.9). So far, 
RCDM of tetrayne 193 afforded the desired macrocycle 223 in less than 50% yield. We were able 
to observe byproduct formation and (probably) polymerization, which could be overcome in the 
future by optimizations on the reaction parameters, such as temperature, concentration, and 
catalyst. 
Nevertheless, we were able to access precursor 193 in only 13-15 steps and up to 2.7% overall 
yield. All reactions gave high yields and could be performed on at least >100 mg scales. Further 
optimization of the RCDM is currently ongoing. Once macrocylce 223 can be accessed, the 
subsequent α-selective hydrostannation/methyl-Stille sequence would give access to the 1,3-(E,E)-
diene motif. Further progress on this synthesis will be reported in due course. 
 
Scheme 5.9: Key steps of the synthesis towards rhizoxin D (17). 
 
In this thesis, the successful total synthesis of enigmazole A (16) was achieved and the key 
intermediate 193 towards rhizoxin D (17) was prepared. The benefit of ring closing alkyne 
metathesis was demonstrated on a highly functionalized substrate in a late stage during the 
synthesis of enigmazole A (16). This metathesis was reliable on a multigram scale unprecedented 
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for such a complex substrate. The densely functionalized macrocycle and the oxazole heterocyclic 
sidechain had no major impact on the stability of the Fürstner metathesis catalysts. Post-
metathesis functionalization of the obtained alkyne by π-acid catalysis afforded a syn-
tetrahydropyran ring and revealed an interesting catalyst/substrate chirality match/mismatch 
case. Furthermore, the recently reported ring-closing diyne metathesis was applied in the 
synthesis towards rhizoxin D (17) and gave promising preliminary results. Further investigations 
are necessary to optimize the yield and finish the total synthesis of rhizoxin D (17). Due to the 
concise syntheses presented in this thesis, new derivatives of enigmazole A (16) and rhizoxin D 
(17) could be obtained in the future, which may provide pharmacological insights on new cancer 
therapeutics. 
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6. Experimental Procedures: 
6.1.  General Experimental Details 
All reactions were carried out under Argon in flame-dried glassware using anhydrous solvents, 
unless water was used as solvent or it is otherwise noted. The solvents were purified by distillation 
over the drying agents indicated and were transferred under argon: tetrahydrofuran, diethyl ether 
(Mg/anthracene), dichloromethane, hexane, pentane, toluene (Na/K), methanol (Mg, stored over 
3 Å MS), ethanol (3 Å MS), ethyl acetate (P2O5, filtered through dry Al2O3, stored over 4 Å MS); 
dioxane, DMF, acetonitrile, triethyl amine and pyridine were dried by an adsorbtion solvent 
purification system based on molecular sieves. Titanium(IV) isopropoxide, 1,8-diazabicycloundec-
7-ene, TMS-Cl (CaH2) and iPr2NEt (CaH2) were distilled over the drying agents indicated under 
argon prior to use. p-Nitrobenzaldehyde was freshly recrystallized from ethanol prior to use. 
Unless stated otherwise, all commercially available compounds (ABCR, Acros, Aldrich, Alfa Aesar, 
Fluka, Oakwood, STREM, TCI) were used as received. Conditions for the synthesis of each 
compound are described in the experimental below. The gold catalysts were prepared following 
the procedure reported herein for the example of 121. The samarium(II) iodide solution was 
prepared from a reaction of samarium metal and iodine by modifying Imamoto’s procedure.[153] 
The complexes 8 and 116 were prepared according to cited protocol within the department of 
Prof. Fürstner.[31] 
Thin layer chromatography (TLC): Macherey-Nagel precoated plates (POLYGRAM® SIL/UV254); 
Flash chromatography: Merck silica gel 60 (40–63 µm) with predistilled or HPLC grade solvents. 
TLC plates were visualized by exposure to an aqueous solution of potassium permanganate or 
ethanolic solution of vanillin followed by heating with a heat gun. 
NMR: Spectra were recorded on Bruker DPX 300, AV 400, AV 500 or AVIII 600 spectrometers in the 
solvents indicated; chemical shifts (δ) are given in ppm relative to TMS, coupling constants (J) in 
Hz. The solvent signals were used as references and the chemical shifts converted to the TMS scale 
(CDCl3: δC ≡ 77.2 ppm; residual CHCl3 in CDCl3: δH ≡ 7.26 ppm; CD3OD: δC ≡ 49.0 ppm; residual 
CHD2OD: δH ≡ 3.31 ppm). Important key fragments or complex byproducts were analyzed by the 
NMR department of our institute, especially by Frau Gabor. 
IR: Spectrum One (Perkin-Elmer) spectrometer, wavenumbers (ν) in cm−1. MS (EI): Finnigan MAT 
8200 (70 eV), ESI-MS: ESQ3000 (Bruker), accurate mass determinations: Bruker APEX III FT-MS (7 T 
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magnet) or Mat 95 (Finnigan). Optical rotations ([α]
) were measured with a Perkin-Elmer Model 
343 or an A-KRÜSS Optronic Model P8000-t polarimeter. 
LC-MS analyses were conducted with a LC-MS2020 instrument from Shimadzu (pumps LC-20 AD, 
autosampler SIL-20AC, column oven CTO-20AC, diode array detector SPD-M20A, controller CBM-
20A, ESI detector and software LCMS-solution) with an ZORBAX Eclipse Plus C18 1.8 µm, 3.0 or 
4.6 mm ID × 50 mm (Agilent). A binary gradient of acetonitrile or methanol in water or aq. 
triethylammonium acetate (TEAA) buffer (10 mmol. pH 8) was used at a flow rates of 0.5 
(3.0 mm ID) or 0.8 (4.6 mm ID) mL/min. The oven temperature was kept at 35 °C and a detection 
wave length of 254 nm was used. Preparative LC was conducted on a LC-20A prominence system 
(pumps LC-20AP, column oven CTO-20AC, diode array detector SPD-M20A, fraction collector FRC-
10A, controller CBM-20A and software LC-solution) from Shimadzu.  
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6.2.  Enigmazole A 
6.2.1. The Northern Fragment 
(R)-tert-Butyl(3-iodo-2-methylpropoxy)dimethylsilane (65)[154] 
Sodium iodide (20.0 g, 133 mmol, 4.00 equiv) was added to a solution of the (R)-3-bromo-2-
methylpropan-1-ol (5.00 g, 32.6 mmol, 1 equiv) in anh. acetone (60 mL). The 
mixture was refluxed for 18 h at 70 °C. Water (20 mL) was added and acetone was 
removed under reduced pressure. The resulting mixture was extracted with dichloromethane (2 x 
30 mL) and washed with aq. sat. ammonium thiosulfate solution (2 x 30 mL). The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated. The 
crude material was directly used in the next step. 
Imidazole (2.40 g, 35.8 mmol, 1.10 equiv) and TBS-Cl (5.40 g, 35.8 mmol, 1.10 equiv) were added 
at 0 °C to a solution of (R)-3-iodo-2-methylpropan-1-ol (6.30 g, 32.6 mmol, 1.00 equiv) in anh. 
dichloromethane (100 mL). The reaction mixture was stirred for 3 h at 0 °C, before it was filtered 
through a plug of celite, which was rinsed with pentane (50 mL). The filtrate was concentrated 
under reduced pressure and the residue was suspended in pentane (10 mL) and filtered again. The 
concentrated filtrate was purified by flash chromatography (pure hexane) to give the desired 
product 65 (8.54 g, 27.2 mmol, 85%). 
[]
	
 = −10.5 (c = 4.14, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 3.52 (dd, J = 10.1, 4.9 Hz, 1H), 3.39 
(dd, J = 10.1, 6.7 Hz, 1H), 3.30 (dd, J = 9.6, 5.2 Hz, 1H), 3.24 (dd, J = 9.6, 5.4 Hz, 1H), 1.67–1.59 (m, 
1H), 0.95 (d, J = 6.6 Hz, 3H), 0.89 (s, 9H), 0.060 (s, 3H), 0.059 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 
66.9, 37.6, 26.1, 18.5, 17.5, 13.9, -5.1 (2C); IR (film): ν = 2955, 2929, 2894, 2857, 1470, 1475, 1419, 
1386, 1361, 1329, 1251, 1197, 1181, 1136, 1098, 1065, 1035, 1006, 937, 835, 773 cm−1; MS (EI) 
m/z (%): 257 (100); HRMS (CI): m/z: calcd. for C10H24OISi [M++H]: 315.0641, found: 315.0642. 
 
(2S,4S)-5-((tert-Butyldimethylsilyl)oxy)-N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N-2,4-
trimethylpentanamide (69)[64] 
n-BuLi (1.6 M in hexanes, 48.8 mL, 78.1 mmol, 1.70 equiv) was added dropwise at −78 oC to a 
stirred suspension of flame-dried lithium chloride (12.8 g, 308 mmol, 
13.5 equiv) and diisopropylamine (11.8 mL, 84.0 mmol, 3.70 equiv) in 
anh. tetrahydrofuran (48 mL). The reaction mixture was warmed to 
NPh
OH
O
OTBS
I OTBS
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0 °C for 5 min and then recooled to −78 °C. A solution of (R,R)-(−)-pseudoephedrine propionamide 
(8.00 g, 36.9 mmol, 1.60 equiv) in anh. tetrahydrofuran (102 mL) was added dropwise via cannula 
and the reaction mixture was stirred for 1 h at −78 oC, 30 min at 0 °C and 5 min at 23 °C. Then, a 
solution of (R)-tert-butyl(3-iodo-2-methylpropoxy) dimethylsilane 65 (7.20 g, 22.8 mmol, 1 equiv) 
in anh. tetrahydrofuran (10 mL) was added dropwise at 0 °C and the reaction mixture was stirred 
for 22 h at 23 °C. The reaction was quenched by the addition of aq. sat. ammonium chloride 
solution (100 mL), the layers were separated and the aq. layer was extracted with ethyl acetate (2 
x 100 mL). The combined organic layers were washed with brine, dried over sodium sulfate filtered 
and concentrated. The crude product was purified by flash chromatography (hexane/ethyl acetate 
3:1) to afford 69 (9.10 g, 22.3 mmol, 98%) (mixture of rotamers 3:1). 
[]
	
 = −53.0 (c = 1.5, CHCl3); 1H NMR (400 MHz, CDCl3) (major rotamer): δ = 7.35–7.29 (m, 5H), 
3.60 (t, J = 7.2 Hz, 1H), 4.42 (bs, 1H), 3.39 (dd, J = 9.7, 5.2 Hz, 1H), 3.31 (dd, J = 9.7, 6.1 Hz, 1H), 2.85 
(s, 3H), 2.71 (q, J = 7.0 Hz, 1H), 1.74 (oct, J = 6.5 Hz, 1H), 1.41–1.37 (m, 2H), 1.12 (d, J = 7.2 Hz, 3H), 
1.06 (d, J = 6.8 Hz, 3H), 0.88 (s, 9H), 0.84 (d, J = 6.6 Hz, 3H), 0.020 (s, 3H), 0.018 (s, 3H) (OH signal is 
missing); 13C NMR (100 MHz, CDCl3) (Major rotamer): δ = 179.5, 142.8, 128.4 (2C), 127.7, 126.5 
(2C), 76.7, 68.5 (2C), 37.6, 34.6, 33.7, 26.1 (3C), 18.6, 17.4, 17.1, 14.6, −5.2 (2C) (due to 
overlapping one carbon is missing); IR (film): ν = 3374, 2955, 2930, 2857, 1620, 1471, 1461, 1408, 
1251, 1087, 835, 774, 701 cm−1; MS (EI) m/z (%): 392 (3), 350 (56), 300 (16), 243 (100); HRMS (ESI): 
m/z: calcd. for C23H41NO3SiNa [M+Na+]: 430.2747, found: 430.2751. 
 
(2S,4S)-5-((tert-Butyldimethylsilyl)oxy)-2,4-dimethylpentan-1-ol (73)[155] 
n-BuLi (1.6 M in hexanes, 55.8 mL, 89.2 mmol, 4.00 equiv) was slowly added over 15 min to a 
stirred suspension of diisopropylamine (13.3 mL, 95.5 mmol, 4.25 equiv) in 
anh. tetrahydrofuran (92 mL) at −78 °C. The solution was stirred at this 
temperature for 10 min and another 10 min at 0 °C before borane-ammonia complex (90%, 3.10 g, 
100 mmol, 4.50 equiv) was added. The solution was stirred for 15 min at 0 °C, was allowed to 
warm to 23 °C and stirring was continued for additional 15 min. Then, the reaction mixture was 
cooled to 0 °C and a solution of amide 69 (9.00 g, 22.3 mmol, 1 equiv) in anh. tetrahydrofuran 
(160 mL) was added over 15 min. The reaction mixture was warmed to 23 °C and stirred for an 
additional 2 h. After cooling to 0 °C, excess reagent was quenched by the addition of aq. sat. 
ammonium chloride solution (150 mL). The aq. layer was extracted with methyl tert-butyl ether 
(3 × 100 mL) and the combined organic layers were washed with brine (30 mL), dried over sodium 
74 Experimental Procedures 
 
sulfate, filtered and concentrated. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 10:1) to obtain 73 (4.90 g, 17.9 mmol, 89%). 
[]
	
 = −24.7 (c = 1.59, CHCl3); 1H NMR (400 MHz, CDCl3) δ = 3.5–3.42 (m, 2H), 3.40 (dd, J = 6.3, 1.8 
Hz, 2H), 1.78–1.67 (m, 2H), 1.47 (t, J = 5.9 Hz, 1H), 1.21 (ddd, J = 13.6, 8.8, 4.8 Hz, 1H), 1.12 (ddd, J 
= 13.6, 8.8, 4.8 Hz, 1H), 0.89 (s, 9H), 0.89 (d, J = 6.8 Hz, 3H), 0.85 (d, J = 6.7 Hz, 3H), 0.04 (s, 6H). 
(OH signal is missing); 13C NMR (100 MHz, CDCl3): δ = 69.3, 69.2, 37.0, 33.3, 33.1, 26.2 (3C), 18.5, 
16.8, 16.7, −5.1 (2C); IR (film): ν = 3375, 2954, 2929, 2857, 1620, 1471, 1454, 1405, 1095, 1050, 
836, 774, 701 cm−1; MS (EI) m/z (%): 215 (1), 189 (1), 55 (100); HRMS (CI): m/z: calcd. for 
C13H31NO2Si [M+H+]: 247.2093, found: 247.2094. 
 
((2S,4S)-5-((tert-Butyldimethylsilyl)oxy)-2,4-dimethylpentanal (70)[156] 
A solution of N-methylmorpholine-N-oxide monohydrate (1.41 g, 10.4 mmol, 1.30 equiv) and 
powdered molecular sieves (4 Å, 4 g) in anh. dichloromethane (66 mL) was 
stirred for 10 min. Then, a solution of the alcohol 73 (2.00 g, 8.1 mmol, 
1 equiv) in anh. dichloromethane (32 mL) followed by tetra-N-propylammonium perruthenate 
(140 mg, 0.39 mmol, 5 mol%) was added to the reaction mixture and stirring was continued for 
30 min. The resulting mixture was filtered through a plug of Celite which was carefully rinsed with 
dichloromethane (50 mL). The filtrate was evaporated and the crude product was purified by a 
quick flash chromatography (hexane/ethyl acetate 5:1) to yield 70 (1.72 g, 7.0 mmol, 88%), which 
was immediately used in the next reaction. The obtained characterization data were in full 
agreement with those reported in the literature.[66] 
1H NMR (400 MHz, CDCl3) δ = 9.59 (d, J = 2.0 Hz, 1H), 3.43 (dd, J = 9.8, 6.0 Hz, 1H), 3.39 (dd, J = 9.8, 
6.0 Hz, 1H), 2.45–2.36 (m, 1H), 1.71–1.63 (m, 1H), 1.47 (ddd, J = 13.7, 8.3, 6.0 Hz, 1H), 1.39 (ddd, J 
= 13.7, 8.3, 5.7 Hz, 1H), 1.04 (d, J = 6.8 Hz, 3H), 0.86 (s, 9H), 0.85 (d, J = 6.6 Hz, 3H), 0.01 (s, 6H); 
13C NMR (100 MHz, CDCl3): δ = 205.3, 68.2, 44.2, 34.0, 33.3, 26.0 (3C), 18.3, 16.6, 13.5, −5.3 (2C). 
 
tert-Butyl(((2S,4S)-6,6-dibromo-2,4-dimethylhex-5-en-1-yl)oxy)dimethylsilane (71)  
Zinc powder (835 mg, 12.8 mmol, 1.95 equiv) followed by triphenylphosphine (3.43 g, 13.1 mmol, 
2.00 equiv) was added to a solution of tetrabromomethane (4.34 g, 
13.1 mmol, 2.00 equiv) in anh. dichloromethane (70 mL) at 23 °C. After 
18 h, a solution of aldehyde 70 (1.60 g, 6.54 mmol, 1 equiv) in anh. dichloromethane (20 mL) was 
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slowly added at 23 °C and stirring was continued for 5 h. The reaction mixture was poured into a 
beaker containing hexane and the resulting precipitates were filtered off. Evaporation of the 
filtrate and purification of the crude product by flash chromatography (hexane/ethyl acetate 5:1) 
gave 71 (1.93 g, 4.82 mmol, 74%). 
[]
	
 = +4.20 (c = 1.00, CHCl3); 1H NMR (400 MHz, CDCl3) δ = 6.19 (d, J = 8.9 Hz, 1H), 3.44 (dd, J = 
9.8, 5.4 Hz, 1H), 3.40 (dd, J = 9.8, 5.9 Hz, 1H), 2.56–2.48 (m, 1H), 1.69–1.53 (m, 1H), 1.42 (dt, J = 
13.5, 6.8 Hz, 1H), 1.12 (dt, J = 14.7, 7.3 Hz, 1H), 0.98 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 0.89 (d, J = 6.7 
Hz, 3H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3): δ = 144.9, 87.2, 67.8, 39.6, 36.2, 33.6, 26.2 (3C), 
19.4, 18.5, 17.4, −5.1 (2C); IR (film): ν = 2956, 2929, 2827, 1471, 1461, 1251, 1095, 1080, 1006, 
836, 774, 667 cm−1; MS (EI) m/z (%): 343 (45), 107 (100); HRMS (CI): m/z: calcd. for C14H29OBr2Si 
[M+H+]: 399.0354, found: 399.0351. 
 
tert-Butyl(((2S,4S)-2,4-dimethylhept-5-yn-1-yl)oxy)dimethylsilane (72) 
n-BuLi (1.6 M in hexanes, 6.93 mL, 11.1 mmol, 2.30 equiv) was added to a solution of the dibromo-
olefin 71 (1.93 g, 4.82 mmol, 1 equiv) in anh. tetrahydrofuran (18 mL) at 
−78 oC. The reaction mixture was stirred at this temperature for 1 h and 
for 1 h at 23 °C. Then, methyl iodide (0.810 mL, 13.0 mmol, 2.70 equiv) was added. After 2.5 h, 
excess reagent was quenched by the addition of aq. sat. ammonium chloride solution (20 mL). The 
layers were separated and the aq. layer was extracted with diethyl ether (2 x 20 mL). The 
combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered and 
concentrated under vacuum. The crude product was purified by flash chromatography (pure 
hexane grading to hexane/ethyl acetate 10:1) to obtain 72 (1.19 g, 4.66 mmol, 97%, d.r. ≥95:5). 
[]
	
 = +24.7 (c = 1.05, CHCl3); 1H NMR (400 MHz, CDCl3) δ = 3.48 (dd, J = 9.7, 5.2 Hz, 1H), 3.39 (dd, 
J = 9.7, 6.2 Hz, 1H), 2.48–2.39 (m, 1H), 1.48–1.76 (m, 1H), 1.78 (d, J = 2.4 Hz, 3H), 1.41 (ddd, J = 
13,4, 7.1, 6.7 Hz, 1H), 1.23 (ddd, J = 14,7, 8.7, 6.6 Hz, 1H), 1.10 (d, J = 6.8 Hz, 3H), 0.90 (d, J = 6.7 
Hz, 3H), 0.89 (s, 9H), 0.03 (s, 6H); 13C NMR (100 MHz, CDCl3): δ = 84.4, 75.5, 67.7, 41.2, 33.8, 26.1 
(3C), 23.9, 21.8, 18.5, 17.6, 3.7, −5.2, −5.1; IR (film): ν = 2956, 2929, 2857, 1471, 1388, 1361, 1251, 
1092, 1019, 1006, 939, 835, 773, 666 cm−1; MS (EI) m/z (%): 197 (13), 75 (100); HRMS (CI): m/z: 
calcd. for C15H31OSi [M+H+]: 255.2144, found: 255.2145. 
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(2S,4S)-2,4-Dimethylhept-5-yn-1-ol (74) 
Tetrabutylammonium fluoride solution (1 M in tetrahydrofuran, 8.17 mL, 8.17 mmol, 2.00 equiv) 
was added to a solution of the alkyne 72 (1.04 g, 4.09 mmol, 1 equiv) in 
tetrahydrofuran (6.0 mL) at 23 °C. The reaction mixture was stirred at this 
temperature for 18 h. The excess reagent was quenched by the addition of aq. sat. ammonium 
chloride solution (5 mL) and extracted with methyl tert-butyl ether (2 x 10 mL). The combined 
organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered and 
concentrated. The residue was purified by flash chromatography (hexane/ethyl acetate 5:1) to 
yield 74 as a colorless liquid (550 mg, 3.92 mmol, 96%, d.r. ≥95:5). 
[]
	
 = +24.4 (c = 1.04, CHCl3); 1H NMR (400 MHz, CDCl3) δ = 3.53 (dd, J = 10.5, 5.5 Hz, 1H), 3.42 
(dd, J = 10.5, 6.0 Hz, 1H), 2.49–2.42 (m, 1H), 1.84 (oct, J = 6.5 Hz, 1H), 1.75 (d, J = 2.5 Hz, 3H), 1.72 
(bs, 1H), 1.39 (ddd, J = 13,4, 7.2, 6.1, 1H), 1.30 (ddd, J = 14,9, 8.6, 6.2, 1H), 1.10 (d, J = 6.7 Hz, 3H), 
0.92 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 84.1, 75.9, 67.7, 41.1, 33.7, 23.6, 21.7, 17.4, 
3.6; IR (film): ν = 3323, 2960, 2921, 2873, 1453, 1375, 1043, 999, 977, 943, 757, 667 cm−1; MS (EI) 
m/z (%): 67 (100), 31 (14); HRMS (CI): m/z: calcd. for C9H17O [M+H+]: 141.1279, found: 141.1277. 
 
(2S,4S)-2,4-Dimethylhept-5-ynoic acid (49) 
Tetra-N-propylammonium perruthenate (96.5 mg, 275 µmol, 10 mol%) was added to a solution of 
N-methylmorpholine-N-oxide monohydrate (3.22 g, 27.5 mmol, 10.0 equiv) 
and alcohol 74 (385 mg, 2.75 mmol, 1 equiv) in acetonitrile (5.6 mL). After 
stirring for 45 min at 23 °C, the resulting mixture was filtered through a pad of 
Celite, which was carefully rinsed with ethyl acetate (10 mL). The filtrate was evaporated and the 
remaining crude product was purified by flash chromatography (hexane/ethyl acetate 8:1) to give 
northern fragment 49 (391 mg, 2.54 mmol, 92%, d.r. ≥95:5). 
[]
	
 = +108.2 (c = 0.55, CHCl3); 1H NMR (400 MHz, CDCl3) δ = 2.82–2.73 (m, 1H), 2.52–2.43 (m, 
1H), 1.78 (ddd, J = 14,8, 9.8, 4.8 Hz, 1H), 1. 77 (d, J = 2.33 Hz, 3H), 1.13 (ddd, J = 14,8, 10.4, 4.5 Hz, 
1H), 1.23 (d, J = 6.8 Hz, 3H), 1.14 (d, J = 7.1 Hz, 3H) (1H signal from the acid is not observed); 
13C NMR (100 MHz, CDCl3): δ = 182.9, 82.9, 76.7, 41.2, 37.9, 24.6, 21.9, 18.2, 3.67; IR (film): ν = 
3100, 2972, 2921, 1706, 1456, 1377, 1248, 945 cm−1; MS (EI) m/z (%): 154 (1), 109 (26), 98 (100), 
74 (37), 45 (7); HRMS (EI): m/z: calcd. for C9H14O2 [M+]: 154.0993, found: 154.0994.  
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6.2.2. The Southern Fragment 
Racemic Route 
2-Butynal (75)[71b] 
Tetrabutylammonium chloride (3.97 g, 14.3 mmol, 0.10 equiv) and 2,2,6,6-tetramethyl-1-
piperidinyloxy (2.23 g, 14.3 mmol, 0.10 equiv) were added to a solution of 2-butin-1-ol 
(10.0 g, 143 mmol, 1 equiv) in a biphasic mixture of dichloromethane (200 mL) and aq. 
buffer solution (100 mL 0.5 M sodium hydrogen carbonate and 100 mL 0.05 M aq. potassium 
carbonate solution). N-Chlorosuccinimide (30.5 g, 228 mmol, 1.60 equiv) was added in several big 
portions causing a slight exotherm and an evolution of gas, which was discharged by passing the 
gas stream through a wash bottle containing aq. sodium hydroxide solution (1 M). After 17 h, the 
layers were separated and the aq. layer was extracted with dichloromethane (4 × 75 mL). The 
combined organic layers were washed with brine, dried over sodium sulfate and filtered. The 
filtrate was purified by distillation (25 °C, ≤ 150 mbar, Vigreux column, the collection flask cooled 
to −78 °C) to obtain 75 (60 % in dichloromethane, 10.9 g, 96.1 mmol, 67%) as a colorless solution. 
The compound is very sensitive and was kept under argon at −78 °C (decomposition commences 
with appearance of pink coloration). The analytical data were in full agreement with those 
reported in the literature.[71a] 
1H NMR (400 MHz, CDCl3): δ = 9.15 (q, J = 1.0 Hz, 1H), 2.07 (d, J = 0.9 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ =177.3, 95.1, 81.1, 4.46. 
 
2-(Chloromethyl)hept-1-en-5-yn-4-ol (226) 
Boron trifluoride diethyl etherate (2.91 mL, 23.6 mmol, 2.00 equiv) was added to a stirred solution 
of 2-butynal (803 mg, 11.8 mmol, 1 equiv) in dichloromethane (25 mL) at −60 °C 
followed by the addition of 2-(chloromethyl)allyl-trimethylsilane (3.20 mL, 
17.7 mmol 1.50 equiv). The reaction mixture was stirred for 1.5 h at this 
temperature. Then, the crude product was diluted with diethyl ether (20 mL) before sat. aq. 
sodium hydrogen carbonate solution (20 mL) was added and the reaction mixture was warmed to 
23 °C. The organic layer was separated and the aq. layer was extracted with diethyl ether (2 × 
20 mL). The combined organic layers were washed with sat. aq. ammonium chloride solution 
(10%, 20 mL), with brine (20 mL), dried over sodium sulfate and evaporated under reduced 
HO
Cl
H
O
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pressure (20 °C, ≥400 mbar). The crude product was purified by flash chromatography 
(pentane/diethyl ether 15:1) to give the secondary alcohol 226 (1.61 g, 7.10 mmol, 60%). 
1H NMR (400 MHz, CDCl3): δ = 5.29 (s, 1H), 5.13 (s, 1H), 4.54–4.50 (m, 1H), 4.13 (s, 2H), 2.58 (d, J = 
6.7 Hz, 2H), 1.84 (d, J = 1.8 Hz, 3H), 1.75 (br s, 1H); 13C NMR (100 MHz, CDCl3): δ = 141.2, 118.3, 
81.9, 79.8, 61.4, 48.5, 41.8, 3.72; IR (film): ν = 3367, 2919, 2930, 1646, 1437, 1258, 1136, 1113, 
1006, 913, 851, 749 cm−1; MS (EI) m/z (%): 123 (1.51), 90 (3.34), 69 (100); HRMS (CI): m/z: calcd. 
for C8H15NO [M++NH4]: 176.0842, found: 176.0840. 
 
2-(Chloromethyl)hept-1-en-5-yn-4-yl acetate (77) 
Triethylamine (707 µL, 5.04 mmol, 2.00 equiv) and acetic anhydride (357 µL, 3.78 mmol, 
1.50 equiv) were subsequently added to a solution of 4-dimethylaminopyridine 
(30.7 mg, 0.25 mmol, 10 mol%) and propargylic alcohol 226 (400 mg, 2.52 mmol, 
1 equiv) in dichloromethane (25 mL). The reaction mixture was stirred at 23 °C 
for 2 h, before the solvent was removed under reduced pressure (23 °C, ≥300 mbar). The crude 
product was purified by flash chromatography (pentane/diethyl ether 20:1) to yield 77 as a 
colorless oil (528 mg, 2.51 mmol, 99%). 
1H NMR (400 MHz, CDCl3): δ = 5.51–5.48 (m, 1H), 5.25 (s, 1H), 5.08 (s, 1H), 4.10 (d, J = 11.8 Hz, 1H), 
4.08 (d, J = 11.8 Hz, 1H), 2.66 (dd, J = 14.5, 7.2 Hz, 1H), 2.59 (dd, J = 14.5, 6.9 Hz, 1H), 2.06 (s, 3H), 
1.83 (dd, J = 1.9, 1.2 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 170.1, 140.3, 118.6, 82.7, 76.3, 62.9, 
48.2, 38.8, 21.2, 3.7; IR (film): ν = 2930, 2923, 1739, 1647, 1437, 1371, 1230, 1160, 1020, 989, 914, 
752 cm−1; MS (ESI) m/z (%): 222.59 (100) (M++Na); HRMS (ESI): m/z: calcd. for C10H13O2ClNa 
[M++Na]: 223.0496, found: 223.0494. 
 
2-(Iodomethyl)hept-1-en-5-yn-4-yl acetate (78) 
Allyl cholride 77 (500 mg, 2.50 mmol, 1 equiv) was added to a solution of sodium iodide (500 mg, 
3.35 mmol, 1.50 equiv) in acetone (3 mL). The reaction mixture was heated to 
70 °C for 18 h before it was cooled to 23 °C. Sat. aq. sodium thiosulfate solution 
(2 mL) was added to the reaction mixture, the layers were separated and the aq. 
phase was extracted with diethyl ether (2 × 3 mL). The combined organic layers were washed with 
brine (5 mL), dried over sodium sulfate and evaporated under reduced pressure (23 °C, 
AcO
I
AcO
Cl
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≥400 mbar). The remaining crude product was purified by flash chromatography (pentane/diethyl 
ether 10:1) to afford 78 (707 mg, 2.42 mmol, 95%). 
1H NMR (400 MHz, CDCl3): δ = 5.50–5.49 (m, 1H), 5.35 (d, J = 0.8 Hz,1H), 5.01 (d, J = 0.8 Hz, 1H), 
4.01 (dd, J = 9.6, 0.4 Hz, 1H), 3.97 (d, J = 9.6 Hz, 1H), 2.71 (ddd, J = 14.4, 6.1, 0.8 Hz, 1H), 2.63 (ddd, 
J = 14.4, 7.1, 0.8 Hz, 1H), 2.06 (s, 3H), 1.83 (d, J = 2.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 170.1, 
141.8, 117.7, 82.7, 76.3, 62.9, 39.8, 21.2, 10.4, 3.8; IR (film): ν = 2956, 2920,1739, 1636, 1431, 
1371, 1230, 1157, 1020, 986, 914 cm−1; MS (EI) m/z (%): 232 (72.05), 123 (47.29), 105 (100); HRMS 
(ESI): m/z: calcd. for C10H13O2INa [M++Na]: 314.9852, found: 314.9852. 
 
2-((Tributylstannyl)methyl)hept-1-en-5-yn-4-yl acetate (50) 
Bis(tributyltin) (1.70 mL, 3.30 mmol, 1.50 equiv) was added to a solution of the allyl iodine 78 
(650 mg, 2.20 mmol, 1 equiv) in tetrahydrofuran (2.6 mL) followed by the 
addition of tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct 
(114 mg, 0.11 mmol, 5 mol%). The reaction mixture was flushed with Argon 
for 25 min, before it was heated to 55 °C for 3 h. The reaction mixture was cooled to 23 °C and 
treated with sat. aq. sodium hydrogen carbonate solution (2 mL) and extracted with diethyl ether 
(2 × 3 mL). The combined organic layers were washed with brine, dried over sodium sulfate and 
concentrated. The crude product was purified by flash chromatography (hexane + 2% 
triethylamine) with silica gel which was previously washed with hexane containing 5% 
triethylamine to give 50 (700 mg, 1.54 mmol, 70%). 
1H NMR (400 MHz, CDCl3): δ = 5.49 (t, J = 7.2 Hz, 1H), 4.62 (s, 1H), 4.53 (s, 1H), 2.35 (dd, J = 14.1, 
7.3 Hz, 1H), 2.31 (dd, J = 14.1, 6.2 Hz, 1H), 2.06 (s, 3H), 1.84 (d, J = 1.6 Hz, 3H), 1.8 (s, 2H), 1.45 
(quint, J = 7.2 Hz, 6H), 1.30 (sext, J = 7.2 Hz, 6H), 0.89 (t, J = 7.7 Hz, 9H), 0.87 (t, J = 7.2 Hz, 6H); 13C 
NMR (100 MHz, CDCl3): δ = 170.5, 144.6, 108.4, 82.2, 77.1, 63.3, 44.0, 29.3, 27.5, 21.3, 19.1, 13.9, 
9.6, 3.9; IR (film): ν = 2956, 2923, 2853, 2872, 2742, 1629, 1464, 1371, 1230, 1018, 961, 866 cm−1; 
MS (EI) m/z (%): 456 (1.62), 399 (12.85), 179 (100), 57 (4.91), 43 (29.47); HRMS (ESI): m/z: calcd. 
for C22H40O2SnNa [M++Na]: 479.1956, found: 479.1954. 
  
AcO
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2-((Tributylstannyl)methyl)hept-1-en-5-yn-4-yl pivalate (227) 
Bis(tributyltin) (1.30 mL, 2.56 mmol, 1.50 equiv) was added to a solution of allyl iodine 78b (85% in 
diethyl ether, 671 mg, 1.71 mmol, 1 equiv) in tetrahydrofuran (2 mL) 
followed by tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct 
(78.1 mg, 85.3 µmol, 5 mol%). The reaction mixture was flushed with Argon 
for 25 min, before it was stirred at 55 oC for 4 h. The reaction mixture was cooled to 23 °C and 
treated with sat. aq. sodium hydrogen carbonate solution (10 mL) and extracted with diethyl ether 
(2 × 5 mL). The combined organic layers were washed with brine, dried over sodium sulfate and 
concentrated. The remaining crude product was purified by flash chromatography (hexane + 2% 
triethylamine) with silica gel which was previously washed with hexane containing 5% 
triethylamine to give 227 (490 mg, 0.99 mmol, 58%). 
1H NMR (400 MHz, CDCl3): δ = 5.38 (ddq, J = 8.0, 6.1, 2.1 Hz, 1H), 4.58-4.41 (m, 2H), 2.38–2.20 (m, 
2H), 1.76 (d, J = 2.1 Hz, 3H), 1.48–1.31 (m, 6H), 1.22 (dq, J = 14.5, 7.2 Hz, 6H), 1.12 (s, 9H), 0.82 (t, J 
= 7.3 Hz, 9H), 0.81–0.77 (m, 6H); 13C NMR (100 MHz, CDCl3): δ = 177.6, 144.6, 108.5, 81.4, 62.8, 
44.0, 38.9, 29.2 (JH-Sn = 10.0 Hz), 27.5, 27.2, 19.0, 13.8, 9.6 (JH-Sn = 151.3 Hz), 3.8; IR (film): ν = 2957, 
2923, 2872, 2854, 1734, 1462, 1280, 1147, 867 cm−1; HRMS (ESI): m/z: calcd. for C25H46O2SnNa 
[M+Na+]: 521.2411, found: 521.2417. 
 
Enantioselective Route 
(R)-2-(((tert-Butyldimethylsilyl)oxy)methyl)hept-1-en-5-yn-4-ol ((R)-81)[78] 
In a pressure tube, liquefied propyne (approx. 0.5 mL) was added to a solution of diethylzinc (15% 
in toluene, 252 µL, 0.280 mmol, 4.00 equiv) in anh. toluene (0.5 mL). After 
heating the closed system for 1 h to 110 °C, the reaction mixture was cooled 
to 23 °C and the vessel was carefully opened. (S)-(−)-1,1′-Bi(2-naphthol) 
(8.01 mg, 28.0 µmol, 40 mol%), anh. diethyl ether (4 mL) and titanium(IV) isopropoxide (20.7 µL, 
70.0 µmol, 1.00 equiv) were successively added to the reaction mixture and stirring was 
continued. After 1 h, aldehyde 80 (15.0 mg, 0.700 mmol, 1 equiv) was added and the reaction 
mixture was stirred for 20 h. The excess reagent was quenched by the addition of sat. aq. 
ammonium chloride solution (10 mL) and the layers were separated. The aq. layer was extracted 
with methyl tert-butyl ether (3 × 25 mL). The combined organic layers were washed with sat. aq. 
sodium chloride solution, dried over sodium sulfate, filtered and concentrated. The crude product 
PivO
SnBu3
(R)
HO
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as purified by flash chromatography (hexane/ethyl acetate 20:1 grading to 10:1) to afford (R)-81 
(10.6 mg, 0.042 mmol, 60%, e.e. ≥88%). 
1H NMR (400 MHz, CDCl3): δ = 5.07 (q, J = 1.6 Hz, 1H), 4.93–4.91 (m, 1H), 4.37 (dtq, J = 6.9, 4.4, 2.1 
Hz, 1H), 4.11–3.97 (m, 2H), 2.97 (d, J = 4.9 Hz, 1H), 2.49–2.28 (m, 2H), 1.75 (d, J = 2.1 Hz, 3H), 0.82 
(d, J = 3.4 Hz, 9H), 0.00 (d, J = 1.0 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ = 143.2, 114.2, 80.1, 79.3, 
66.0, 60.9, 42.0, 25.1 (3C), 17.6, 2.9, −6.1 (2C). 
 
Tributyl(2-(chloromethyl)allyl)stannane (83)[80] 
A solution of diisopropylamine (4.00 mL, 28.5 mmol, 1.10 equiv) in anh. tetrahydrofuran (60 mL) 
was cooled to 0 °C and treated dropwise with n-butyllithium (1.6 M in hexanes, 
16.2 mL, 25.9 mmol, 1.00 equiv). After 5 min, tributyltin hydride (6.28 mL, 
23.3 mmol, 0.90 equiv) was added and stirring was continued for 15 min at 0 °C. This solution was 
added dropwise over 1 h to a solution of 3-chloro-2-chloromethyl-1-propene (3.00 mL, 25.9 mmol, 
1 equiv) in anh. pentane (100 mL) at −78 °C. The reaction mixture was stirred for 1 h at −78 °C 
before the excess reagent was quenched by the addition of water (100 mL). The reaction mixture 
was diluted with a mixture of hexane/ethyl acetate (10:1, 240 mL), the layers were separated and 
the organic layer was washed with sat. aq. sodium chloride solution, dried over magnesium 
sulfate, filtered and concentrated. The crude product was purified by flash chromatography (pure 
hexane) to yield 83 (4.78 g, 12.6 mmol, 49%) as a colorless liquid. The spectral data were in full 
agreement with those reported in the literature.[157] 
1H NMR (400 MHz, CDCl3): δ = 4.84 (dt, J = 1.3, 0.7 Hz, JH-Sn = 17.3 Hz, 1H), 4.71 (dt, J = 1.3, 0.7 Hz, 
JH-Sn = 17.9 Hz, 1H), 3.96 (d, J = 0.9 Hz, JH-Sn = 5.8 Hz, 2H) 1.89 (d, J = 0.9 Hz, JH-Sn = 57.9 Hz, 2H), 
1.60–1.36 (m, 6H), 1.36–1.22 (m, 6H), 0.95–0.79 (m, 15H); 13C NMR (100 MHz, CDCl3): δ = 145.8 (JH-
Sn = 39.0 Hz), 110.0 (JH-Sn = 36.4 Hz), 50.4 (JH-Sn = 8.6 Hz), 29.2 (JH-Sn = 20.1 Hz), 27.5 (JH-Sn117 = 54.0 Hz, 
JH-Sn119 = 56.0 Hz), 16.0 (JH-Sn117 = 221.0 Hz, JH-Sn119 = 231.3 Hz), 13.9, 9.8 (JH-Sn117 = 306.5 Hz, JH-Sn119 = 
320.8 Hz); 119Sn NMR (150 MHz, CDCl3) δ = −12.9. 
  
82 Experimental Procedures 
 
(S)-2-(Chloromethyl)hept-1-en-5-yn-4-ol ((S)-226)[158] 
Powdered molecular sieves (4 Å, 5 g, activated for 5 days at 120 °C) and titanium(IV) isopropoxide 
(334 µL, 1.13 mmol, 10 mol%) were added to a solution of (S)-(−)-1,1′-bi(2-
naphthol)a (323 mg, 1.13 mmol, 10 mol%) in anh. dichloromethane (25 mL). The 
orange suspension was refluxed for 1 h at 43 °C. After cooling to 23 °C, a solution 
of aldehyde 75 (75% in dichloromethane, 1.02 g, 11.3 mmol, 1 equiv) in anh. dichloromethane 
(10 mL) was added to the reaction mixture. The mixture was cooled to −78 °C before stannane 83 
(4.48 g, 13.5 mmol, 1.20 equiv) was added dropwise. After 3 d at −20 °C, excess reagent was 
quenched by the addition sat. aq. potassium sodium tartrate solution (50 mL). After stirring 1 h at 
23 °C, the suspension was filtered through a plug of Celite which was rinsed with methyl tert-butyl 
ether (25 mL). The volume of the filtrate was reduced, the layers were separated and the aq. layer 
was extracted with methyl tert-butyl ether (2 × 25 mL). The combined organic layers were dried 
over magnesium sulfate, filtered and concentrated. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1 grading to 4:1) to give (S)-226 (1.50 g, 9.46 mmol, 
84%) as a colorless liquid. The absolute configuration was determined by Mosher ester analysis.[79] 
The enantiomeric excess was determined after the next step by chiral HPLC. 
[]
	
 = −28.7 (c = 1.05, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 5.29 (s, 1H), 5.13 (s, 1H), 4.54–4.50 
(m, 1H), 4.13 (s, 2H), 2.58 (d, J = 6.7 Hz, 2H), 1.84 (d, J = 1.8 Hz, 3H), 1.75 (br s, 1H); 13C NMR 
(100 MHz, CDCl3): δ = 141.2, 118.3, 81.9, 79.8, 61.4, 48.5, 41.8, 3.7; IR (film): ν = 3367, 2919, 2930, 
1646, 1437, 1258, 1136, 1113, 1006, 913, 851, 749 cm−1; MS (EI) m/z (%): 123 (2), 90 (3), 69 (100); 
HRMS (CI): m/z: calcd. for C8H15NO [M+NH4+]: 176.0842, found: 176.0840.  
 
(S)-2-(Chloromethyl)hept-1-en-5-yn-4-yl acetate ((S)-77) 
4-(Dimethylamino)pyridine (116 mg, 0.946 mmol, 10 mol%), triethylamine (2.64 mL, 18.9 mmol, 
2.00 equiv) and acetic anhydride (1.34 mL, 14.2 mmol, 1.50 equiv) were added 
to a solution of alcohol (S)-226 (1.50 g, 9.46 mmol, 1 equiv) in anh. 
dichloromethane (60 mL). After 1 h, the volume of the reaction mixture was 
reduced (40 °C, ≥600 mbar) and the residue was purified by flash chromatography 
(pentane/diethyl ether 10:1) to obtain (S)-77 (1.77 g, 8.81 mmol, 93 %) as a colorless liquid. The 
                                                          
a The (R)-226 was obtained with (R)-(+)-1,1′-bi(2-naphthol) in similar yields and e.e. 
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enantiomeric purity (e.e. ≥95%) was determined by HPLC analysis on a chiral column (150 × 
4.6 mm Chiralpak IC-3, 3 μm, n-heptane/2-propanol 99:1 (v/v), 1.0 ml/min, 293 K). 
[]
	
 = −75.3 (c = 0.95, CHCl3);  1H NMR (400 MHz, CDCl3): δ = 5.51–5.48 (ddq, J = 8.4 6.4, 2.2 Hz, 
1H), 5.25 (d, J = 1.1 Hz, 1H), 5.08 (d, J = 1.1 Hz, 1H), 4.10 (d, J = 11.8 Hz, 1H), 4.08 (d, J = 11.8 Hz, 
1H), 2.70–2.57 (m, 2H), 2.06 (s, 3H), 1.83 (d, J = 2.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 170.1, 
140.3, 118.6, 82.7, 76.3, 62.9, 48.2, 38.8, 21.2, 3.7; IR (film): ν = 2930, 2923, 1739, 1647, 1437, 
1371, 1230, 1160, 1020, 989, 914, 752 cm−1; MS (ESI) m/z (%): 223 (M+Na+, 100); HRMS (ESI): m/z: 
calcd. for C10H13O2ClNa [M+Na+]: 223.0496, found: 223.0494. 
 
(S)-2-(Iodomethyl)hept-1-en-5-yn-4-yl acetate ((S)-78) 
Sodium iodide (2.19 g, 14.6 mmol, 1.35 equiv) was added to a solution of chloride (S)-77 (2.18 g, 
10.8  mmol, 1 equiv) in acetone (15 mL) and the resulting suspension was stirred 
at reflux temperature for 20 h. After cooling to 23 °C, the excess reagent was 
quenched by the addition of sat. aq. sodium thiosulfate solution (25 mL) and the 
layers were separated. The aq. layer was extracted with ethyl acetate (3 × 25 mL) and the 
combined organic layers were dried over magnesium sulfate, filtered and concentrated (40 °C, 
≥150 mbar). The crude product was purified by flash chromatography (pentane/diethyl ether 20:1 
grading to 10:1) to yield the title compound (2.78 g, 9.52 mmol, 88%) as a pale yellow liquid. 
[]
	
 = −38.9 (c = 1.10, CHCl3);  1H NMR (400 MHz, CDCl3): δ = 5.50–5.49 (m, 1H), 5.35 (d, J = 0.8 
Hz, 1H), 5.01 (d, J = 0.8 Hz, 1H), 4.01 (dd, J = 9.6, 0.4 Hz, 1H), 3.97 (d, J = 9.6 Hz, 1H), 2.71 (ddd, J = 
14.4, 6.1, 0.8 Hz, 1H), 2.63 (ddd, J = 14.4, 7.1, 0.8 Hz, 1H), 2.06 (s, 3H), 1.83 (d, J = 2.2 Hz, 3H); 
13C NMR (100 MHz, CDCl3): δ = 170.1, 141.8, 117.7, 82.7, 76.3, 62.9, 39.8, 21.2, 10.4, 3.8; IR (film): 
ν = 2956, 2920,1739, 1636, 1431, 1371, 1230, 1157, 1020, 986, 914 cm−1; MS (EI) m/z (%): 232 
(72), 123 (47), 105 (100); HRMS (ESI): m/z: calcd. for C10H13O2INa [M+Na+]: 314.9852, found: 
314.9852. 
 
(S)-2-((Tributylstannyl)methyl)hept-1-en-5-yn-4-yl acetate ((S)-50) 
Bis(tributyltin) (5.53 mL, 10.9 mmol, 1.50 equiv) and tris-(dibenzylidenaceton)-dipalladium(0) 
(110 mg, 0.120 mmol, 1.7 mol%) were added to a solution of iodide (S)-78 
(2.13 g, 7.29 mmol, 1 equiv) in anh. tetrahydrofuran (10 mL). Argon was 
bubbled through the green-black suspension for 30 min, before it was stirred 
AcO
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for 3 h at 55 °C. Because TLC showed unreacted starting material, more tris-(dibenzyliden aceton)-
dipalladium(0) (110 mg, 0.120 mmol, 1.7 mol%) was added. Stirring at reflux temperature was 
continued for an additional 1.5 h before the reaction was quenched by the addition of sat. aq. 
sodium hydrogen carbonate solution (25 mL). The reaction mixture was filtered through a plug of 
Celite which was rinsed with methyl tert-butyl ether (2 × 25 mL). The layers were separated and 
the aq. layer was extracted with methyl tert-butyl ether (3 × 25 mL). The combined organic layers 
were dried over sodium sulfate, filtered and concentrated. The residue was purified by repeated 
flash chromatography (hexane + 2% triethylamine) to separate tin impurities and to yield (S)-50 
(2.42 g, 7.29 mmol, 73%) as a colorless liquid. 
[]
	
 = −28.1 (c = 0.98, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 5.49 (t, J = 7.2 Hz, 1H), 4.64–4.61(m, 
1H), 4.55–4.53 (m, 1H), 2.35 (dd, J = 14.1, 7.3 Hz, 1H), 2.31 (dd, J = 14.1, 6.2 Hz, 1H), 2.06 (s, 3H), 
1.84 (d, J = 1.6 Hz, 3H), 1.80 (s, 2H), 1.56–1.39 (m, 6H), 1.30 (sext, J = 7.2 Hz, 6H), 0.89 (t, J = 7.7 Hz, 
9H), 0.87 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ = 170.5, 144.6, 108.4, 82.2, 77.1, 63.3, 
44.0, 29.3 (JH-Sn = 10.1 Hz), 27.5 (JH-Sn117 = 26.9 Hz, JH-Sn119 = 28.1 Hz), 21.3, 19.1, 13.9, 9.6 (JH-Sn117 = 
151.6 Hz, JH-Sn119 = 158.7 Hz), 3.9; IR (film): ν = 2956, 2923, 2853, 2872, 2742, 1629, 1464, 1371, 
1230, 1018, 961, 866 cm−1; MS (EI) m/z (%): 456 (2), 399 (13), 179 (100), 57 (45), 43 (29); HRMS 
(ESI): m/z: calcd. for C22H40O2SnNa [M+Na+]: 479.1956, found: 479.1954. 
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6.2.3. The Eastern Fragment 
(R,Z)-4-Iodo-3-methylbut-3-en-2-ol (90)[83]  
A suspension of (R)-(+)-3-butin-2-ol (5.96 mL, 75.6 mmol, 1 equiv) and copper(I) iodide (14.4 g, 
75.6 mmol, 1.00 equiv) in anh. toluene (100 mL) was cooled to −78 °C and a solution of 
methyl magnesium bromide (1.4 M in tetrahydrofuran/toluene 1:3, 378 mL, 529 mmol, 
7.00 equiv) was added over the course of 75 min. Once the addition was complete, the 
reaction mixture was allowed to warm to 23 °C and stirring was continued for 3.5 h. The mixture 
was then cooled to −40 °C, before a solution of iodine (134 g, 529 mmol, 7.00 equiv) in anh. 
tetrahydrofuran (140 mL) was slowly added via a cannula. After stirring 1.5 h at 23 °C, excess 
reagent was carefully quenched by the addition of sat. aq. sodium thiosulfate solution (400 mL), 
the layers were separated and the aq. layer was extracted with diethyl ether (3 × 200 mL). The 
combined organic layers were dried over magnesium sulfate, filtered and concentrated by 
distillation (in portions, 40 °C, ≥90 mbar, Vigreux column, the collection flask cooled to −78 °C). 
The residue (200 mL) was purified by flash chromatography (pentane/diethyl ether 7:1 grading to 
6:1) and the product containing fractions were carefully concentrated by distillation (40 °C, 
≥200 mbar) to yield 90 (93% in diethyl ether, 12.7 g, 55.7 mmol, 74%) as an orange liquid. 
[]
	
 = +12.3 (c = 2.65, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 5.89-5.88 (m, 1H), 4.77 (qd, J = 6.5, 
2.8 Hz, 1H), 1.87 (d, J = 1.5 Hz, 3H), 1.79–1.78 (m, 1H) 1.25 (d, J = 6.5 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ = 149.4, 73.7, 72.6, 20.4, 18.4; IR (film): ν = 3331, 2973, 2916, 16134, 1441, 1369, 1278, 
1134, 1102, 1073, 1037, 1021, 975, 902, 770 cm−1; MS (EI) m/z (%): 127 (3), 85 (69),45 (57), 43 
(100); HRMS (EI): m/z: calcd. for C5H9OI [M]: 211.9698, found: 211.9700. 
 
(R,Z)-1-Iodo-3-methoxy-2-methylbut-1-ene (25)[159] 
A suspension of sodium hydride (2.67 g, 111 mmol, 2.00 equiv) and imidazole (379 mg, 5.57 mmol, 
10 mol%) in anh. tetrahydrofuran (150 mL) was cooled to 0 °C and treated over 10 min 
with a solution of alcohol 90 (93% in Et2O, 12.7 g, 55.7 mmol, 1 equiv) in anh. 
tetrahydrofuran (80 mL). The reaction mixture was allowed to warm to 23 °C and after 2 h, methyl 
iodide (31.6 g, 223 mmol, 4.00 equiv) was slowly added. After an additional 2 h, excess reagent 
was quenched by the addition of water (250 mL) and the aq. layer was extracted with pentane (2 × 
250 mL). The combined organic layers were washed with brine (200 mL), dried over magnesium 
sulfate, filtered and concentrated by distillation (25 °C, ≥ 350 mbar, Vigreux column, the collection 
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flask cooled to −78 °C). The residue (100 mL) was puriﬁed by flash chromatography 
(pentane/diethyl ether 20:1) and fractions containing product were concentrated by distillation 
(30 °C, ≥300 mbar) to yield 25 (95% in pentane, 8.44 g, 35.5 mmol, 64%) as a pale yellow liquid. 
[]
	
 = +5.30 (c = 2.55, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 6.03–6.02 (m, 1H), 4.26 (q, J = 6.5 Hz, 
1H), 3.22 (s, 3H), 1.79 (d, J = 1.5 Hz, 3H), 1.19 (d, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 
147.5, 80.9, 75.8, 56.4, 18.6, 18.1; IR (film): ν = 2978, 2928, 2820, 1613, 1441, 1369, 1339, 1279, 
1205, 1144, 1114, 1094, 1064, 1030, 968, 865, 773. cm−1; MS (EI) m/z (%): 195 (3), 127 (2), 99 
(100), 31 (14); HRMS (EI): m/z: calcd. for C6H11OI [M]: 225.9854, found: 225.9855. 
 
Ethyl (R,Z)-2-(3-methoxy-2-methylbut-1-en-1-yl)oxazole-4-carboxylate (92)[159] 
In a pressure tube, palladium(II) acetate (265 mg, 1.18 mmol, 5 mol%) was added to a suspension 
of caesium carbonate (15.4 g, 47.3 mmol, 2.00 equiv), ethyl-4-
oxazolcarboxylate (23.6 g, 23.6 mmol, 1 equiv), iodide 25 (95% in pentane, 
8.44 g, 35.5 mmol, 1.50 equiv) and 2-(dicyclohexylphosphino)biphenyl (829 mg, 
2.36 mmol, 0.10 equiv) in anh. dioxane (65 mL). The reaction mixture was 
stirred at 110 °C for 23 h. After cooling to 23 °C, the suspension was filtered through a plug of 
Celite which was rinsed with dichloromethane (50 mL). The filtrate was concentrated under 
reduced pressure (40 °C, ≥50 mbar) and the residue was purified by flash chromatography 
(hexane/ethyl acetate 20:1 grading to 4:1) to yield 92 (4.16 g, 23.6 mmol, 74%) as a colorless oil. 
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 = +41.7 (c = 1.76, CHCl3);  1H NMR (400 MHz, CDCl3): δ = 8.13 (s, 1H), 6.25 (s, 1H), 5.13 (q, J = 
6.4 Hz, 1H), 4.38 (q, J = 7.0 Hz, 2H), 3.22 (s, 3H), 1.92 (d, J = 1.5 Hz, 3H), 1.37 (d, J = 7.0 Hz, 3H), 1.32 
(d, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 161.6, 161.2, 153.4, 142.9, 134.4, 112.9, 75.0, 
61.4, 56.7, 19.6, 18.1, 14.5; IR (film): ν = 3154, 2981, 2932, 2821, 1743, 1720, 1654, 1575, 1562, 
1447, 1370, 1332, 1316, 1279, 1217, 1178, 1109, 1025, 971, 947, 839, 771 cm−1; MS (EI) m/z (%): 
224 (100), 194 (7), 180 (3), 59 (9); HRMS (ESI): m/z: calcd. for C12H17NO4Na [M+Na+]: 262.1049 
found: 262.1051. 
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(R,Z)-2-(3-Methoxy-2-methylbut-1-enyl)oxazole-4-carbaldehyde (52)[159] 
A solution of the oxazole 92 (4.20 g, 17.6 mmol, 1 equiv) in anh. dichloromethane (150 mL) was 
cooled to −90 °C and treated dropwise over 15 min with a diisobutylaluminium 
hydride solution (1 M in toluene, 35.1 mL, 35.1 mmol, 2.00 equiv). The reaction 
mixture was stirred at −90 °C unjl TLC showed complete consumpjon of the 
starting material (20 min). The excess reagent was quenched by the addition of 
methanol (15 mL) and sat. aq. potassium sodium tartrate solution (200 mL). The mixture was 
stirred for 18 h at 23 °C before the layers were separated and the aq. layer was extracted with 
dichloromethane (3 × 150 mL). The combined organic layers were washed with aq. sat. sodium 
chloride solution (200 mL), dried over magnesium sulfate, filtered and concentrated. The residue 
was purified by flash chromatography (hexane/ethyl acetate 15:1 grading to 10:1) to give 52 
(2.74 g, 14.0 mmol, 80%) as a pale yellow oil. 
[]
	
 = +46.8 (c = 2.18, CHCl3);  1H NMR (400 MHz, CDCl3): δ = 9.93 (s, 1H), 8.16 (s, 1H), 6.23–6.22 
(m, 1H), 5.24 (q, J = 6.5 Hz, 1H), 3.23 (s, 3H), 1.94 (d, J = 1.5 Hz, 3H), 1.32 (d, J = 6.6 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ = 184.7, 161.4, 154.7, 142.9, 141.7, 112.1, 74.9, 56.7, 19.3, 18.0; IR 
(film): ν = 3144, 3085, 2979, 2932, 2822, 1698, 1652, 1563, 1447, 1393, 1381, 1326, 1290, 1206, 
1149, 1113, 1096, 1069, 833, 759 cm−1; MS (EI) m/z (%): 195 (15), 180 (100), 59 (6); HRMS (ESI): 
m/z: calcd. for C10H13NO3Na [M+Na+]: 218.0787, found: 218.0789. 
 
(S)-1-(2-((R,Z)-3-Methoxy-2-methylbut-1-en-1-yl)oxazol-4-yl)but-3-en-1-ol (87)[158] 
Powdered molecular sieves (4 Å, 5 g, activated for 5 days at 120 °C) followed by titanium(IV) 
isopropoxide (411 µL, 1.39 mmol, 10 mol%) were added to a solution of (S)-
(−)-1,1′-bi(2-naphthol) (398 mg, 1.39 mmol, 10 mol%) in anh. dichloromethane 
(25 mL). The orange suspension was stirred for 1 h at 43 °C. After cooling to 
23 °C, a solution of aldehyde 52 (2.71 g, 13.9 mmol, 1 equiv) in anh. 
dichloromethane (15 mL) was added. The mixture was cooled to −78 °C before 
allyltributylstannane (5.25 mL, 16.9 mmol, 1.22 equiv) was added dropwise. After 3 days at −30 °C, 
TLC showed complete consumption of the starting material and the reaction was quenched by the 
addition sat. aq. sodium hydrogen carbonate solution (25 mL) and allowed to warm to 23 °C. The 
suspension was filtered through a plug of Celite which was rinsed with methyl tert-butyl ether 
(25 mL). The volume of the filtrate was reduced, the layers were separated and the aq. layer was 
extracted with methyl tert-butyl ether (2 × 25 mL). The combined organic layers were dried over 
OMe
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magnesium sulfate, filtered and concentrated. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 15:1 grading to 4:1) to give 87 (3.21g, 13.5 mmol, 98 %) as 
a pale yellow oil. (Mosher ester analysis revealed a d.e. >95%). 
[]
	
  = +22.3 (c = 0.50, CHCl3);  1H NMR (400 MHz, CDCl3): δ = 7.46 (s, 1H), 6.19 (s, 1H), 5.84 (ddt, J 
= 17.2, 10.3, 7.1 Hz, 1H), 5.20–5.14 (m, 3H), 4.73 (dd, J = 7.3, 5.6Hz, 1H), 3.22 (s, 3H), 2.69–2.62 (m, 
1H), 2.59–2.52 (m, 1H), 2.39 (br s, 1H), 1.89 (d, J = 1.4 Hz, 3H), 1.30 (d, J = 6.4 Hz, 3H); 13C NMR 
(100 MHz, CDCl3): δ = 160.7, 151.1, 144.0, 134.0, 133.2, 118.8, 113.5, 75.0, 66.7, 56.7, 41.1, 19.4, 
17.8; IR (film): ν = 3417, 2980, 2933, 1655, 1642, 1542, 1539, 1381, 1371, 1206, 1154, 1113, 1095, 
1068, 915, 862. cm−1; MS (EI) m/z (%): 237 (38), 222 (56), 204 (100); HRMS (ESI): m/z: calcd. for 
C13H19NO3Na [M+Na+]: 260.1257, found: 260.1257. 
 
tert-Butyl ((S)-1-(2-((R,Z)-3-methoxy-2-methylbut-1-en-1-yl)oxazol-4-yl)but-3-en-1-yl) carbonate 
(101) 
Di-tert-butyl dicarbonate (7.30 g, 33.5 mmol, 2.00 equiv) and 4-(dimethylamino)pyridine (1.02 g, 
8.37 mmol, 0.50 equiv) were added to a solution of alcohol 87 (3.79 g, 
17.7 mmol, 1 equiv) in anh. acetonitrile (150 mL). After stirring for 20 h, the 
mixture was concentrated and the residue was dissolved in methyl tert-butyl 
ether (100 mL) and water (100 mL). The layers were separated and the aq. 
layer was extracted with methyl tert-butyl ether (2 × 100 mL). The combined organic layers were 
dried over sodium sulfate, filtered and concentrated. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 15:1 grading to 10:1) to yield 101 (5.18 g, 15.4 mmol, 92%) 
as a yellowish oil. 
[]
	
= −8.80 (c = 0.60, CHCl3);  1H NMR (400 MHz, CDCl3): δ = 7.51 (d, J = 0.4 Hz, 1H), 6.19–6.18 (m, 
1H), 5.76 (ddt, J = 17.2, 10.1, 7.1 Hz, 1H), 5.62 (t, J = 6.5 Hz, 1H), 5.21 (q, J = 6.5 Hz, 1H), 5.13 (dq, J 
= 17.2, 1.6 Hz, 1H), 5.08–5.05 (m, 1H), 3.22 (s, 3H), 2.78 (ddt, J = 14.3, 6.6, 1.46 Hz, 1H), 2.71 (ddt, J 
= 14.2, 7.1, 1.2 Hz, 1H), 1.88 (d, J = 1.4 Hz, 3H), 1.47 (s, 9H), 1.31 (d, J = 6.5 Hz, 3H); 13C NMR (100 
MHz, CDCl3): δ = 160.6, 153.1, 151.2, 140.1, 134.9, 133.0, 118.5, 113.4, 82.6, 74.9, 71.2, 56.9, 37.8, 
28.0 (3C), 19.3, 17.8; IR (film): ν = 2980, 2933, 2820, 1740, 1644, 1544, 1449, 1369, 1342, 1280, 
1254, 1163, 1095, 1036, 973, 919, 845, 793, 762 cm−1; MS (EI) m/z (%): 337 (15.86), 281 (18.30), 
220 (57.00), 204 (100), 117 (2); HRMS (ESI): m/z: calcd. for C18H27NO5Na [M+Na+]: 360.1781, 
found: 360.1783. 
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(4R,6S)-4-(Iodomethyl)-6-(2-((R,Z)-3-methoxy-2-methylbut-1-en-1-yl)oxazol-4-yl)-1,3-dioxan-2-
one (102)[160] 
A solution of olefin 101 (3.97 g, 11.8 mmol, 1 equiv) in anh. toluene (140 mL) was cooled to −78 °C 
and treated dropwise with iodine monobromide (1 M in dichloromethane, 
35.3 mL, 35.3 mmol, 3.00 equiv) over 40 min (it was essential to store the 
iodine monobromide solution at 23 °C). After complete addition, stirring 
was continued until TLC showed complete consumption of the starting 
material (10 min). The excess reagent was quenched by the addition of sat. 
aq. sodium hydrogen carbonate solution (100 mL) and sat. aq. sodium thiosulfate solution 
(100 mL). After warming to 23 °C, the layers were separated and the aq. layer was extracted with 
methyl tert-butyl ether (2 × 150 mL). The combined organic layers were dried over sodium sulfate, 
filtered and concentrated. The crude product was purified by flash chromatography (hexane/ethyl 
acetate 2:1) to yield 102 (2.58 g, 6.34 mmol, 54%b) as a yellowish oil. 
[]
	
 = +21.7 (c = 0.79, CHCl3);  1H NMR (400 MHz, CDCl3): δ = 7.56 (d, J = 0.7 Hz, 1H), 6.19 (s, 1H), 
5.50 (ddd, J = 11.7, 3.1, 0.7 Hz, 1H), 5.15 (q, J = 6.3 Hz, 1H), 4.64–4.58 (m, 1H), 3.46 (dd, J = 10.5, 
4.4 Hz, 1H), 3.46 (dd, J = 10.5, 7.6 Hz, 1H), 3.23 (s, 3H), 2.78 (dt, J = 14.1, 3.19 Hz, 1H), 2.15 (dt, J = 
14.3, 11.1 Hz, 1H), 1.92 (d, J = 1.7 Hz, 3H), 1.30 (d, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 
161.3, 152.7, 147.9, 138.5, 134.9, 112.9, 74.9, 73.5, 69.5, 56.7, 33.0, 19.4, 17.9, 4.9; IR (film): ν = 
3482, 3135, 2978, 2931, 2820, 1745, 1656, 1602, 1543, 1519, 1446, 1382, 1239, 1184, 1109, 1092, 
1038, 971, 854, 760 cm−1; MS (ESI) m/z (%): 430 (M+Na+, 100); HRMS (ESI): m/z: calcd. for 
C14H18NO5INa [M+Na+]: 430.0121, found: 430.0120. 
 
(S)-1-(2-((R,Z)-3-Methoxy-2-methylbut-1-en-1-yl)oxazol-4-yl)-2-((R)-oxiran-2-yl)ethan-1-ol (103) 
A solution of iodide 102 (2.11 g, 5.18 mmol, 1 equiv) in anh. methanol (25 mL) was treated at 0 °C 
with anh. potassium carbonate (2.15 g, 15.5 mmol, 3.00 equiv). After 40 min, 
the reaction mixture was diluted with methyl tert-butyl ether (25 mL) and 
excess reagent was quenched by addition of sat. aq. ammonium chloride 
solution (50 mL). The layers were separated and the aq. layer was extracted 
with methyl tert-butyl ether (2 × 25 mL). The combined organic layers were dried over magnesium 
sulfate, filtered and concentrated. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 1:1) to yield 103 (1.03 g, 4.07 mmol, 79%) as a colorless oil. 
                                                          
b Smaller scales of approximately 200 mg of starting material $M6 gave yields between 70-80%. 
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 = +28.0 (c = 0.30, CHCl3);  1H NMR (400 MHz, CDCl3): δ = 7.51 (s, 1H), 6.19 (s, 1H), 5.18 (q, J = 
6.6 Hz, 1H), 4.94 (t, J = 5.7 Hz, 1H), 3.22 (s, 3H), 3.17–3.09 (m, 1H) 2.80 (dd, J = 4.8, 4.1 Hz, 1H), 
2.72 (d, J = 4.3 Hz, 1H), 2.57 (dd, J = 5.9, 2.6 Hz, 1H), 2.27 (dt, J = 14.4, 4.5 Hz, 1H), 1.90 (d, J = 1.5 
Hz, 3H), 1.92–1.81 (m, 1H), 1.30 (d, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 160.9, 151.3, 
143.9, 133.4, 113.5, 75.0, 66.3, 65.8, 50.3, 47.0, 39.4, 19.4, 18.9; IR (film): ν = 3417, 2980, 2824, 
2821, 1655, 1542, 1518, 1447, 1370, 1258, 1206, 1152, 1206, 1152, 1109, 1094, 1068, 1036, 971, 
856, 753 cm−1; MS (EI) m/z (%): 253 (13), 238 (53), 178 (100); HRMS (ESI): m/z: calcd. for 
C13H19NO4Na [M+Na+]: 276.1206, found: 276.1208. 
 
4-((S)-1-((tert-Butyldimethylsilyl)oxy)-2-((R)-oxiran-2-yl)ethyl)-2-((R,Z)-3-methoxy-2-methylbut-
1-en-1-yl)oxazole (104) 
tert-Butyldimethylsilyl chloride (1.25 g, 8.29 mmol, 1.50 equiv) was added to a solution of alcohol 
103 (1.40 g, 5.53 mmol, 1 equiv), imidazole (564 mg, 8.29 mmol, 
1.50 equiv) and 4-(dimethylamino)-pyridine (67.5 mg, 0.553 mmol, 
10mol%) in dichloromethane (5.5 mL) at 0 °C. The mixture was stirred at 
23 °C until TLC showed complete consumption of the starting material (ca. 
75 min). The reaction mixture was diluted with methyl tert-butyl ether 
(20 mL) and excess reagent was quenched by the addition of sat. aq. ammonium chloride solution 
(30 mL). The layers were separated and the aq. layer was extracted with methyl tert-butyl ether 
(2 × 30 mL). The combined organic layers were dried over sodium sulfate, filtered and 
concentrated. The crude product was purified by flash chromatography (pure hexane grading to 
hexane/ethyl acetate 30:1) to give 104 (1.99 g, 5.41 mmol, 98%) as a yellow oil. 
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 = +13.2 (c = 0.44, CHCl3);  1H NMR (400 MHz, CDCl3): δ = 7.45 (d, J = 0.7 Hz, 1H), 6.18 (dd, J = 
0.7, 1.2 Hz, 1H), 5.21 (q, J = 6.2 Hz, 1H), 4.92 (td, J = 5.8, 1.1 Hz, 1H), 3.23 (s, 3H), 3.04–3.03 (m, 
1H), 2.74 (t, J = 4.8 Hz, 1H), 2.50 (dd, J = 5.0, 2.7 Hz, 1H), 2.11 (dt, J = 13.9, 5.8 Hz, 1H), 1.93 (dt, J = 
13.9, 5.8 Hz, 1H), 1.89 (d, J = 1.4 Hz, 3H), 1.29 (d, J = 6.4 Hz, 3H), 0.9 (s, 9H), 0.1 (s, 3H), 0.04 (s, 3H); 
13C NMR (100 MHz, CDCl3): δ = 160.3, 150.7, 145.1, 133.7, 113.5, 74.9, 67.0, 56.6, 49.4, 47.0, 40.7, 
25.8 (3C), 19.2, 18.2, 17.7, −4.6, −4.8; IR (film): ν = 2954, 2929, 2887, 2857, 2820, 1654, 1542, 
1472, 1463, 1447, 1408, 1387, 1362, 1253, 1206, 1153, 1093, 1034, 1006, 968, 938, 913, 871, 833, 
811, 775, 811, 775 cm−1; MS (EI) m/z (%): 367 (5), 336 (2), 310 (100); HRMS (ESI): m/z: calcd. for 
C19H33NO4SiNa [M+Na+]: 390.2071, found: 390.2067. 
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(2-(1,3-dioxolan-2-yl)ethyl)magnesium bromide (105) [161] 
A solution of 2-(2-bromoethyl)-1,3-dioxolane (2.00 mL, 17.0 mmol, 1 equiv) in anh. 
tetrahydrofuran (8.5 mL) was added over 30 min to a suspension of magnesium 
powder (1.04 g, 42.6 mmol, 2.50 equiv) in anh. tetrahydrofuran (4.2 mL). The 
reaction temperature was kept by a water bath below 30 °C. After stirring 1.5 h, the mixture was 
filtered through a syringe filter and the flask rinsed with anh. tetrahydrofuran (2 mL) to give a 
yellowish solution (0.80 M in tetrahydrofuran, 16.7 mL, 13.4 mmol, 79%). The titer was determined 
by titration using lithium chloride and iodine.[162] 
 
(1S,3S)-1-((tert-Butyldimethylsilyl)oxy)-6-(1,3-dioxolan-2-yl)-1-(2-((R,Z)-3-methoxy-2-methylbut-
1-en-1-yl)oxazol-4-yl)hexan-3-ol (106) 
Copper(I) iodide (206 mg, 1.08 mmol, 0.20 equiv) was suspended in anh. tetrahydrofuran (30 mL) 
and the suspension was cooled to −78 °C before an aliquot of the 
freshly prepared Grignard reagent 105 (0.80 M in tetrahydrofuran, 
10.2 mL, 8.12 mmol, 1.50 equiv) was added dropwise. After stirring for 
5 min, a solution of epoxide 104 (1.99 g, 5.41 mmol, 1 equiv) in anh. 
tetrahydrofuran (30 mL) was added over 30 min. Once the addition was 
complete, the mixture was stirred at −40 °C for 50 min. The excess 
reagent was quenched by the addition of sat. aq. ammonium chloride 
solution (60 mL) and the mixture was allowed to warm to 23 °C. The layers were separated and 
the aq. layer was extracted with methyl tert-butyl ether (2 × 60 mL). The combined organic layers 
were dried over sodium sulfate, filtered and concentrated. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 5:1 grading to 2:1) to yield 106 (2.35 g, 5.00 mmol, 92%) as 
a yellowish oil. 
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 = −2.60 (c = 0.52, CHCl3);  1H NMR (400 MHz, CDCl3): δ = 7.42 (d, J = 0.7 Hz, 1H), 6.17 (dd, J = 
1.0, 0.7 Hz, 1H), 5.16 (q, J = 6.7 Hz, 1H), 4.93 (t, J = 6.7 Hz, 1H), 4.83 (t, J = 4.7 Hz, 1H), 3.97–3.3.78 
(m, 5H), 3.49 (d, J = 2.7 Hz, 1H), 3.23 (s, 3H), 1.93 (ddd, J = 13.9, 9.1, 7.1 Hz, 1H), 1.59 (ddd, J = 
13.9, 6.3, 2.7 Hz, 1H), 1.89 (d, J = 1.4 Hz, 3H), 1.68–1.43 (m, 6H), 1.29 (d, J = 6.3 Hz, 3H), 0.9 (s, 9H), 
0.1 (s, 3H), −0.01 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 160.3, 151.3, 145.4, 133.6, 113.3, 104.8, 
75.0, 69.5, 68.4, 65.0 (2C), 56.7, 45.2, 37.4, 34.0, 25.9 (3C), 20.3, 19.4, 18.2, 17.8, −4.5, −4.8; IR 
(film): ν = 3487, 2950, 3930, 2859, 1655, 1543, 1462, 1253, 1096, 970, 838, 778 cm−1; MS (ESI) 
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m/z (%): 492 (M+Na+, 100); HRMS (ESI): m/z: calcd. for C24H43NO6SiNa [M+Na+]: 492.2751, found: 
492.2751. 
 
4-((5S,7S)-7-(3-(1,3-Dioxolan-2-yl)propyl)-2,2,3,3,10,10-hexamethyl-9,9-diphenyl-4,8-dioxa-3,9-
disilaundecan-5-yl)-2-((R,Z)-3-methoxy-2-methylbut-1-en-1-yl)oxazole (228) 
A solution of alcohol 106 (2.35 g, 5.00 mmol, 1 equiv) in anh. dichloromethane (45 mL) was cooled 
to 0 °C before 2,6-lutidine (1.75 mL, 15.0 mmol, 3.00 equiv) and tert-
butyldimethylsilyl trifluoromethanesulfonate (1.77 mL, 5.75 mmol, 
1.15 equiv) were successively added. After stirring 20 min at 0 °C, the 
reaction was quenched by the addition of sat. aq. ammonium chloride 
solution (50 mL), the layers were separated and the aq. layer was 
extracted with methyl tert-butyl ether (2 × 50 mL). The combined 
organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was 
purified by flash chromatography (hexane/ethyl acetate 15:1 grading to 6:1) to obtain 228 (3.11 g, 
4.39 mmol, 88%) as a colorless oil. 
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 = −9.00 (c = 0.25, CHCl3);  1H NMR (400 MHz, CDCl3): δ = 7.62 (td, J = 7.8, 1.3 Hz, 4H), 7.40–
7.29 (m, 6H), 7.06 (s, 1H), 6.14 (s, 1H), 5.21 (q, J = 6.2 Hz, 1H), 4.80 (t, J = 6.6 Hz, 1H), 4.67 (t, J = 4.1 
Hz, 1H), 3.90-3.77 (m, 5H), 3.17 (s, 3H), 2.01 (td, J = 6.8, 1.3 Hz, 2H), 1.88 (d, J = 1.4 Hz, 3H), 1.48–
1.38 (m, 6H), 1.27 (d, J = 6.2 Hz, 3H), 1.02 (s, 9H), 0.81 (s, 9H), 0.01 (s, 3H), −0.09 (s, 3H); 13C NMR 
(100 MHz, CDCl3): δ = 159.6, 150.3, 144.9, 136.1 (2C), 136.0 (2C), 134.8, 134.6, 133.6, 129.6, 
129.57, 129.55, 127.55 (2C), 127.54 (2C), 113.7, 104.7, 74.9, 70.6, 65.8, 64.9, 56.5, 44.0, 36.6, 34.0, 
27.3 (3C), 26.0 (3C), 19.6, 19.3, 19.1, 18.3, 17.7, −4.3, −4.6; IR (film): ν = 2953, 2931, 2887, 2852, 
1428, 1257, 1107, 1066, 972, 939, 837, 820, 776, 702 cm−1; MS (ESI) m/z (%): 730 (M+Na+, 100); 
HRMS (ESI): m/z: calcd. for C40H61NO6SiNa [M+Na+]: 730.3929, found: 730.3938. 
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(5S,7S)-7-((tert-Butyldimethylsilyl)oxy)-5-((tert-butyldiphenylsilyl)oxy)-7-(2-((R,Z)-3-methoxy-2-
methylbut-1-en-1-yl)oxazol-4-yl)heptanal (63)  
2,4,6-Trimethylpyridine (1.10 mL, 8.31 mmol, 3.00 equiv) and TMSOTf (1.00 mL, 5.54 mmol, 
2.00 equiv) were added to a solution of 228 (2.21 g, 2.77 mmol, 
1 equiv) in anh. dichloromethane (50 mL) at 0 °C. After stirring for 1 h 
at 0 °C, water (50 mL) was added to the reaction mixture and stirring 
was continued for 2 h at 23 °C. The layers were separated and the aq. 
layer was extracted with methyl tert-butyl ether (3 × 50 mL). The 
combined organic layers were dried over sodium sulfate, filtered and 
concentrated. The crude product was purified by flash chromatography (hexane/ethyl acetate 
20:1 grading to 15:1) to obtain 63 (1.78 g, 2.68 mmol, 97%) as a yellowish oil.  
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 = −10.4 (c = 0.50, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 9.57 (t, J = 1.8 Hz, 1H), 7.64–7.60 (m, 
4H), 7.42–7.30 (m, 6H), 7.11 (s, 1H), 6.15 (qd, J = 1.4, 0.8 Hz, 1H), 5.20 (q, J = 6.5 Hz, 1H), 4.79 (t, J = 
6.5 Hz, 1H), 3.95–3.86 (m, 1H), 3.18 (s, 3H), 2.15–1.99 (m, 4H), 1.89 (d, J = 1.4 Hz, 3H), 1.61–1.42 
(m, 4H), 1.27 (d, J = 6.3 Hz, 3H), 1.04 (s, 9H), 0.81 (s, 9H), 0.01 (s, 3H), −0.08 (s, 3H); 13C NMR (100 
MHz, CDCl3): δ = 202.5, 160.0, 150.4, 145.0, 136.1 (2C), 136.0 (2C), 134.6, 134.4, 133.6, 129.7 (2C), 
127.62 (2C), 127. 61 (2C), 113.6, 74.9, 70.1, 65.8, 56.6, 44.1, 43.8, 36.0, 27.2 (3C), 25.9 (3C), 19.6, 
19.3, 18.2, 17.7, 17.2, −4.3, −4.7; IR (film): ν = 2953, 2930, 2891, 2857, 1727, 1655, 1589, 1544, 
1472, 1462, 1428, 1388, 1361, 1252, 1205, 1078, 1068, 1005, 971, 938, 836, 777 cm−1; MS (ESI) 
m/z (%): 686 (M+Na+, 100); HRMS (ESI): m/z: calcd. for C38H57NO5Si2Na [M+Na+]: 686.3667, found: 
686.3664. 
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6.2.4. Combination of Fragments 
(4S,8R,12S,14S)-14-((tert-Butyldimethylsilyl)oxy)-12-((tert-butyldiphenylsilyl)oxy)-8-hydroxy-14-
(2-((R,Z)-3-methoxy-2-methylbut-1-en-1-yl) oxazol-4-yl)-6-methylenetetradec-2-yn-4-yl acetate 
(111a) 
Boron tribromide (1 M in dichloromethane, 3.39 mL, 3.39 mmol, 1.50 equiv) was added to a 
solution of (S,S)-1,2-diphenyl-1,2-ethylenediamine bis(toluenesulfon-
amide)[103b] (1.76 g, 3.39 mmol, 1.50 equiv) in anh. dichloromethane 
(40 mL) at 0 °C. The mixture was stirred for 10 min at 0 °C and for 1 h 
at 23 °C before all volatile materials were removed in high vacuum. 
Allyl stannane (S)-50 (1.80 g, 3.95 mmol, 1.75 equiv) was added to a 
solution of the residue in anh. dichloromethane (40 mL) at 0 °C. After 
stirring for 17 h at 23 °C, the reaction mixture was cooled to −78 °C 
and a solution of aldehyde 63 (1.50 g, 2.26 mmol, 1 equiv) in anh. 
dichloromethane (10 mL) was added dropwise over 5 min. The mixture was stirred for 2 h before 
the reaction was quenched by the addition of aq. phosphate buffer solution (pH 7, 50 mL). Water 
(50 mL) was introduced and the aq. phase was extracted with dichloromethane (3 × 100 mL). The 
combined organic layers were washed with brine (150 mL), dried over magnesium sulfate, filtered 
and concentrated. The residue was suspended in diethyl ether (20 mL) and the colorless solid was 
filtered off to recover the chiral diamine ligand. The filtrate was concentrated and the crude 
product purified by flash chromatography (hexane/ethyl acetate 10:1 grading to 3:1) to give 111a 
(1.79 g, 2.15 mmol, 95%, d.r. >10:1) as a colorless oil. 
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 = −20.9 (c = 1.00, CHCl3); 1H NMR (600 MHz, CDCl3) δ = 7.62 (m, 2H), 7.59 (m, 2H), 7.37 (m, 
1H), 7.36 (m, 1H), 7.31 (m, 2H), 7.29 (m, 2H), 7.08 (d, J = 0.5 Hz, 1H), 6.14 (qd, J = 1.4, 1.0 Hz, 1H), 
5.45 (ddq, J = 7.8, 6.0, 2.2 Hz, 1H), 5.19 (qd, J = 6.5, 0.8 Hz, 1H), 4.95 (dt, J = 1.4, 1.2 Hz, 1H), 4.90 
(d, J = 1.1 Hz, 1H), 4.81 (td, J = 6.7, 0.7 Hz, 1H), 3.84 (tdd, J = 6.2, 5.8, 5.1 Hz, 1H), 3.52 (dddt, J = 
9.4, 7.6, 4.4, 3.2 Hz, 1H), 3.15 (s, 3H), 2.45 (ddd, J = 14.4, 7.8, 0.8 Hz, 1H), 2.40 (ddd, J = 14.4, 6.0, 
0.9 Hz, 1H), 2.14 (ddd, J = 14.3, 3.3, 1.2 Hz, 1H), 2.03 (s, 3H), 2.01 (t, J = 6.7 Hz, 2H), 1.95 (ddd, J = 
14.3, 9.4, 0.5 Hz, 1H), 1.86 (d J = 1.5 Hz, 3H), 1.82 (d, J = 2.2 Hz, 3H), 1.63 (d, J = 3.1 Hz, 1H), 1.47–
1.46 (m, 1H), 1.38–1.37 (m, 1H), 1.32–1.31 (m, 1H), 1.26 (d, J = 6.5 Hz, 3H), 1.24–1.23 (m, 1H), 
1.20–1.19 (m, 1H), 1.15–1.14 (m, 1H), 1.01 (s, 9H), 0.80 (s, 9H), 0.00 (s, 3H), −0.09 (s, 3H); 13C NMR 
(150 MHz, CDCl3): δ = 170.0, 159.8, 150.1, 144.7, 141.3, 135.90 (2C), 135.87 (2C), 134.6, 134.3, 
133.5, 129.5, 129.4, 127.41 (2C), 127.39 (2C), 116.1, 113.5, 82.2, 76.5, 74.7, 70.4, 68.8, 65.6, 62.8, 
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56.4, 44.3, 44.0, 41.6, 37.2, 36.7, 27.1 (3C), 25.8 (3C), 21.0, 20.7, 19.4, 19.2, 18.1, 17.5, 3.6, −4.5, 
−4.8; IR (film): ν = 3479, 2929, 2857, 1740, 1428, 1371, 1233, 1109, 837, 777, 703, 507 cm−1; MS 
(ESI) m/z (%): 852 (M+Na+, 100); HRMS (ESI): m/z: calcd. for C48H71NO7Si2Na [M+Na+]: 852.4661, 
found: 852.4673. 
 
(4S,8R,12S,14S)-14-((tert-Butyldimethylsilyl)oxy)-12-((tert-butyldiphenylsilyl)oxy)-14-(2-((R,Z)-3-
methoxy-2-methylbut-1-en-1-yl)oxazol-4-yl)-6-methylene-8-(((2,2,2-trichloroethoxy)carbonyl) 
oxy) tetra-dec-2-yn-4-yl acetate (112a) 
2,2,2-Trichlorethoxycarbonyl chloride (0.89 mL, 6.45 mmol, 3.00 equiv) was added at 0 °C to a 
solution of aclohol 111a (1.79 g, 2.15 mmol, 1 equiv), 
4-(dimethylamino)pyridine (26.3 mg, 215 µmol, 0.10 equiv) and 
pyridine (1.04 mL, 12.9 mmol, 6.00 equiv) in anh. dichloromethane 
(20 mL). After stirring for 20 min at 23 °C, the excess reagent was 
quenched by the addition of water (20 mL). The layers were separated 
and the aq. layer was extracted with ethyl acetate (3 × 25 mL). The 
combined organic layers were dried over magnesium sulfate, filtered 
and concentrated. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1) to give 112a (2.15 g, 2.14 mmol, quant.) as a 
colorless oil. 
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 = −21.0 (c = 1.00, CHCl3); 1H NMR (600 MHz, CDCl3) δ = 7.61 (m, 2H), 7.59 (m, 2H), 7.38 (m, 
1H), 7.37 (m, 1H), 7.32 (m, 2H), 7.30 (m, 2H), 7.08 (d, J = 0.6 Hz, 1H), 6.14 (qd, J = 1.4, 1.0 Hz, 1H), 
5.41 (tq, J = 6.9, 2.2 Hz, 1H), 5.18 (qd, J = 6.5, 0.7 Hz, 1H), 4.89 (dt, J = 1.3 Hz + not dissolved, 1H), 
4.88 (dt, J = 1.3 Hz + not dissolved, 1H), 4.78 (t, J = 6.7 Hz, 1H), 4.75 (m, 1H), 4.74 (d, J = 11.9 Hz, 
1H), 4.64 (d, J = 11.9 Hz, 1H), 3.84 (tt, J = 6.2, 5.4 Hz, 1H), 3.16 (s, 3H), 2.44 (d, J = 6.9 Hz, 2H), 2.26 
(ddd, J = 14.6, 8.2, 0.7 Hz, 1H), 2.22 (ddd, J = 14.6, 5.0, 0.9 Hz, 1H), 2.02 (s, 3H), 2.00 (dt, J = 13.7, 
6.7 Hz, 1H), 1.94 (dt, J = 13.7, 6.4 Hz, 1H), 1.87 (d, J = 1.4 Hz, 3H), 1.80 (d, J = 2.2 Hz, 3H), 1.46 (m, 
1H), 1.39 (m, 1H), 1.36 (m, 1H), 1.29 (m, 2H), 1.25 (d, J = 6.5 Hz, 3H), 1.24 (m, 1H), 1.01 (s, 9H), 0.79 
(s, 9H), 0.00 (s, 3H), −0.10 (s, 3H); 13C NMR (150 MHz, CDCl3): δ = 169.9, 159.8, 153.7, 150.2, 144.8, 
139.4, 135.90 (2C), 135.84 (2C), 134.5, 134.2, 133.5, 129.5 (2C), 127.44 (2C), 127.43 (2C), 117.1, 
113.5, 94.6, 82.1, 77.9, 76.53, 76.50, 74.7, 70.2, 65.6, 62.7, 56.4, 44.0, 41.4, 40.9, 36.4, 34.1, 27.1 
(3C), 25.8 (3C), 21.0, 20.3, 19.4, 19.2, 18.1, 17.5, 3.6, −4.5, −4.9; IR (film): ν = 2954, 2930, 2857, 
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1755, 1378, 1250, 1110, 836, 821, 704, 507 cm−1; MS (ESI) m/z (%): 1028 (M+Na+, 100); HRMS 
(ESI): m/z: calcd. for C51H72NO9Cl3Si2Na [M+Na+]: 1026.3703, found: 1026.3719.  
 
(4S,8R,12S,14S)-12-((tert-Butyldiphenylsilyl)oxy)-14-hydroxy-14-(2-((R,Z)-3-methoxy-2-
methylbut-1-en-1-yl)oxazol-4-yl)-6-methylene-8-(((2,2,2-trichloroethoxy)carbonyl)oxy)tetradec-
2-yn-4-yl acetate (113a) 
10-Camphorsulfonic acid (102 mg, 0.438 mmol, 0.10 equiv) was added to a solution of 112a (2.20 
g, 2.19 mmol, 1 equiv) in anh. dichloromethane/methanol 
(24 mL/8 mL). After stirring for 8 h, TLC control indicated that the 
acetate started to get cleaved. At this point the mixture was 
neutralized by the addition of aq. sat. sodium hydrogen carbonate 
solution (40 mL). The layers were separated and the aq. layer was 
extracted with methyl tert-butyl ether (3 × 25 mL). The combined 
organic layers were dried over magnesium sulfate, filtered and 
concentrated. The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1 grading to 2:1) to obtain unreacted starting material 
(823 mg, 0.818 mmol, 37%) and the desired product 113a (1.19 g, 1.34 mmol, 61%, 98% brsm). 
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 = −2.60 (c = 1.15, CHCl3); 1H NMR (600 MHz, CDCl3) δ = 7.67 (m, 2H), 7.67 (m, 2H), 7.42 (m, 
1H), 7.42 (m, 1H), 7.36 (m, 4H), 7.26 (d, J = 1.0 Hz, 1H), 6.15 (qd, J = 1.4, 1.0 Hz, 1H), 5.40 (tq, J = 
6.9, 2.2 Hz, 1H), 5.10 (qd, J = 6.5, 0.8 Hz, 1H), 4.88 (dt, J = 1.3, 1.1 Hz, 1H), 4.86 (dt, J = 1.2 Hz + not 
dissolved, 1H), 4.82 (dtd, J = 8.9, 3.8, 0.9 Hz, 1H), 4.72 (d, J = 11.9 Hz, 1H), 4.71 (m, 1H), 4.65 (d, J = 
11.9 Hz, 1H), 4.00 (tt, J = 7.2, 4.7 Hz, 1H), 3.18 (s, 3H), 3.06 (d, J = 3.8 Hz, 1H), 2.43 (dt, J = 6.9, 1.1 
Hz, 2H), 2.25 (ddd, J  = 14.5, 8.2, 0.6 Hz, 1H), 2.19 (ddd, J = 14.5, 4.8, 0.8 Hz, 1H), 2.02 (s, 3H), 1.99 
(ddd, J = 14.2, 4.7, 3.9 Hz, 1H), 1.90 (ddd, J = 14.3, 8.8, 7.7 Hz, 1H), 1.86 (d, J = 1.4 Hz, 3H), 1.80 (d, J 
= 2.2 Hz, 3H), 1.45 (m, 1H), 1.33 (m, 1H), 1.31 (m, 1H) 1.27 (d, J = 6.5 Hz, 3H), 1.20 (m, 3H), 1.04 (s, 
9H); 13C NMR (150 MHz, CDCl3): δ = 169.9, 160.4, 153.7, 150.5, 144.3, 139.3, 135.88 (2C), 135.87 
(2C), 134.1, 133.5, 133.0, 129.9, 129.8, 127.7 (2C), 127.6 (2C), 117.1, 113.5, 94.6, 82.2, 77.7, 76.53, 
76.46, 74.7, 72.8, 66.2, 62.7, 56.4, 42.6, 41.4, 40.9, 36.8, 33.9, 27.0 (3C), 21.0, 20.5, 19.29, 19.26, 
17.6, 3.6; IR (film): ν = 3422, 2932, 2858, 1754, 1652, 1428, 1378, 1250, 1109, 1067, 1021, 821, 
735, 704, 612, 508 cm−1; MS (ESI) m/z (%): 914 (M+Na+, 100); HRMS (ESI): m/z: calcd. for 
C45H58NO9Cl3SiNa [M+Na+]: 912.2838, found: 912.2843. 
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(1S,3S,7R,11S)-11-Acetoxy-3-((tert-butyldiphenylsilyl)oxy)-1-(2-((R,Z)-3-methoxy-2-methylbut-1-
en-1-yl)oxazol-4-yl)-9-methylene-7-(((2,2,2-trichloroethoxy)carbonyl)oxy)tetradec-12-yn-1-yl 
(2S,4S)-2,4-dimethylhept-5-ynoate (62a)[163] 
2,4,6-Trichlorobenzoyl chloride (413 µL, 2.64 mmol, 1.50 equiv) and triethylamine (368 µL, 2.64 
mmol, 1.50 equiv) were added at 0 °C to a solution of acid 49 (299 mg, 
1.94 mmol, 1.10 equiv) in anh. toluene (25 mL). The mixture was 
stirred at 23 °C for 1 h. After cooling to 0 °C, a solution of alcohol 113a 
(1.57 g, 1.76 mmol, 1 equiv) in anh. toluene (20 mL) and 
4-(dimethylamino)pyridine (215 mg, 1.76 mmol, 1.00 equiv) were 
successively added. Stirring was continued for 1 h at 23 °C before the 
mixture was diluted with ethyl acetate (30 mL) and the excess reagent 
was quenched by the addition hydrochloric acid (1 N, 80 mL). The 
layers were separated and the aq. layer was extracted with ethyl 
acetate (2 × 80 mL). The combined organic layers were dried over magnesium sulfate, filtered and 
concentrated. The crude product was purified by flash chromatography (hexane/ethyl acetate 
10:1 grading to 4:1) to yield 62a (1.81 g, quant.). 
[]
	
 = −7.40 (c = 1.00, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 7.64–7.57 (m, 4H), 7.44–7.29 (m, 
6H), 7.19 (br s, 1H), 6.17–6.14 (m, 1H), 5.94–5.85 (m, 1H), 5.44 (ddq, J = 6.6, 1.8 Hz, 1H), 5.11 (qd, J 
= 6.6, 0.9 Hz, 1H), 4.91 (br s, 2H), 4.83–4.74 (m, 2H), 4.68 (d, J = 11.9 Hz, 1H), 3.68 (dt, J = 11.7, 5.6 
Hz, 1H), 3.15 (s, 3H), 2.68–2.56 (m, 1H), 2.47 (d, J = 6.9 Hz, 2H), 2.36–2.08 (m, 5H), 2.05 (s, 3H), 
1.88 (d, J = 1.3 Hz, 3H), 1.83 (d, J = 2.1 Hz, 3H), 1.74 (d, J = 2.3 Hz, 3H), 1.67 (ddd, J = 14.8, 9.7, 5.1 
Hz, 1H), 1.54–1.30 (m, 7H), 1.28 (d, J = 6.5 Hz, 3H), 1.06 (s, 3H), 1.05 (s, 3H), 1.04 (s, 9H); 13C NMR 
(100 MHz, CDCl3): δ = 175.9, 170.1, 160.2, 153.9, 150.8, 140.1, 139.4, 136.03 (2C), 136.00 (2C), 
135.2, 134.2, 134.0, 129.8 (2C), 127.6 (4C), 117.4, 113.4, 94.7, 83.0, 82.3, 77.9, 76.64, 76.57, 76.4, 
74.8, 69.8, 65.7, 62.8, 56.6, 41.4, 41.2, 41.1, 39.6, 38.0, 36.4, 34.2, 27.1 (3C), 24.4, 21.8, 21.2, 20.5, 
19.5, 19.3, 18.2, 17.8, 3.8, 3.7; IR (film): ν = 2962, 2932, 2858, 1753, 1737, 1448, 1428, 1377, 1249, 
1162, 1110, 1064, 1021, 970, 821, 733, 704, 611, 507, 489 cm−1; MS (ESI) m/z (%): 1050 (M+Na+, 
100); HRMS (ESI): m/z: calcd. for C54H70Cl3NO10SiNa [M+Na+]: 1048.3727, found: 1048.3746. 
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(3S,5S,8S,12R,16S,18S)-16-((tert-Butyldiphenylsilyl)oxy)-18-(2-((R,Z)-3-methoxy-2-methylbut-1-
en-1-yl)oxazol-4-yl)-3,5-dimethyl-10-methylene-2-oxo-12-(((2,2,2-trichloroethoxy)carbonyl)oxy) 
oxacyclo-octadec-6-yn-8-yl acetate (114a) 
In a flame dried 1 L two-neck round-bottom flask, molecular sieves (4 Å, 8 g and 5 Å, 19 g) were 
added to a solution of diyne 62a (1.62 g, 1.57 mmol, 1 equiv) in anh. 
toluene (830 mL). After stirring for 1 h, alkyne metathesis catalyst[31] 116 
(640 mg, 0.483 mmol, 0.31 equiv) was dissolved in an aliquot (20 mL) of 
the reaction mixture and the resulting solution was added. The 
suspension was stirred for 45 min at 23 °C before it was filtered through 
a plug of Celite which was rinsed with methyl tert-butyl ether (100 mL). 
The filtrate was evaporated and the residue was purified by flash 
chromatography (hexane/ethyl acetate 15:1 grading to 4:1) to obtain 114a (1.21 g, 1.24 mmol, 
79%). 
[]
	
 = −1.50 (c = 1.02, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 7.65-7.59 (m, 4H), 7.46-7.30 (m, 7H), 
6.18-6.12 (m, 1H), 6.08 (dd, J = 9.3, 1.8 Hz, 1H), 5.46 (ddd, J = 9.0, 4.3, 1.4 Hz, 1H), 5.15 (qd, J = 6.4, 
0.8 Hz, 1H), 4.96 (br s, 1H), 4.94 (d, J = 1.1 Hz, 1H), 4.84-4.66 (m, 3H), 3.91-3.77 (m, 1H), 3.19 (s, 
3H), 2.63-2.18 (m, 7H), 2.06 (s, 3H), 1.95 (ddd, J = 15.0, 7.1, 2.2 Hz, 1H), 1.89 (d, J = 1.3 Hz, 4H), 
1.69-1.39 (m, 5H), 1.38-1.30 (m, 2H), 1.27 (d, J = 6.5 Hz, 3H), 1.10 (d, J = 6.9 Hz, 3H), 1.07 (d, J = 6.9 
Hz, 3H), 1.04 (s, 9H); 13C NMR (100 MHz, CDCl3): δ = 175.5, 169.9, 160.4, 153.9, 151.0, 140.9, 
139.5, 135.9 (4C), 135.1, 134.11, 134.06, 129.8 (2C), 127.7 (4C), 116.9, 113.3, 94.7, 90.6, 78.2, 
78.1, 76.6, 74.8, 70.2, 65.6, 63.4, 56.6, 41.9, 40.9, 40.7, 38.11, 38.09, 35.9, 34.1, 27.1 (3C), 24.1, 
21.7, 21.3, 20.5, 19.4, 19.3, 17.8, 17.1; IR (film): ν = 2932, 2859, 1743, 1650, 1428, 1379, 1250, 
1163, 1111, 1021, 821, 739, 704, 613, 570, 508 cm−1; MS (ESI) m/z (%): 996 (M+Na+, 100); HRMS 
(ESI): m/z: calcd. for C50H64Cl3NO10SiNa [M+Na+]: 994.3257, found: 994.3274. 
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(3S,5S,8S,12R,16S,18S)-16-((tert-butyldiphenylsilyl)oxy)-12-hydroxy-18-(2-((R,Z)-3-methoxy-2-
methylbut-1-en-1-yl)oxazol-4-yl)-3,5-dimethyl-10-methylene-2-oxooxacyclooctadec-6-yn-8-yl 
acetate (115a) 
Zinc dust (1.55 g, 23.6 mmol, 100 equiv, Sigma-Aldrich®, < 10 μm) was added to a solution of 114a 
(230 mg, 0.236 mmol, 1 equiv) in neat acetic acid (12 mL). The 
suspension was sonicated for 15 min (if TLC showed unconsumed 
starting material, more zinc dust (100 equiv) was added and sonication 
was continued). The suspension was filtered through a plug of Celite 
which was rinsed with ethyl acetate (20 mL). The filtrate was diluted with 
toluene (10 mL) and all volatile materials were evaporated. The crude 
product was purified by flash chromatography (hexane/ethyl acetate 4:1 
grading to 2:1) to give the title compound (175 mg, 0.219 mmol, 93%). 
[]
	
 = −5.00 (c = 1.03, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 7.64 (dd, J = 7.9, 1.3 Hz, 2H), 7.62 
(dd, J = 8.0, 1.3 Hz, 2H), 7.45-7.30 (m, 7H), 6.15 (dd, J = 1.5, 0.8 Hz, 1H), 6.06 (dd, J = 9.2, 1.8 Hz, 
1H), 5.44 (ddd, J = 8.3, 4.8, 1.4 Hz, 1H), 5.15 (qd, J = 6.4, 0.8 Hz, 1H), 4.99 (br s, 1H), 4.97 (br s, 1H), 
3.91-3.78 (m, 1H), 3.70-3.58 (m, 1H), 3.19 (s, 3H), 2.60 (q, J = 6.9 Hz, 1H), 2.56-2.38 (m, 4H), 2.32 
(ddd, J = 14.9, 9.4, 2.6 Hz, 1H), 2.05 (s, 3H), 2.04-1.94 (m, 2H), 1.89 (d, J = 1.2 Hz, 3H), 1.72-1.52 (m, 
4H), 1.51-1.42 (m, 1H), 1.42-1.30 (m, 4H), 1.27 (d, J = 6.4 Hz, 3H), 1.09 (d, J = 7.0 Hz, 3H), 1.06 (d, J 
= 7.1 Hz, 3H), 1.04 (s, 9H); 13C NMR (100 MHz, CDCl3): δ = 175.5, 169.8, 160.4, 150.9, 141.4, 140.9, 
135.9 (4C), 134.2, 134.14, 134.13, 129.78, 129.77, 127.7 (4C), 116.8, 113.4, 90.5, 78.3, 74.8, 70.4, 
68.8, 65.7, 63.7, 56.6, 45.0, 41.0, 40.6, 38.4, 38.0, 36.9, 35.9, 27.1 (3C), 24.0, 21.9, 21.3, 20.4, 19.4, 
19.3, 17.8, 17.0; IR (film): ν = 3467, 2932, 2858, 1737, 1649, 1449, 1428, 1373, 1232, 1162, 1105, 
1022, 969, 900, 856, 822, 757, 704, 612, 509, 489 cm−1; MS (ESI) m/z (%): 820 (M+Na+, 100); HRMS 
(ESI): m/z: calcd. for C47H63NO8SiNa [M+Na+]: 820.4215, found: 820.4223. 
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(R)- or (S)-DTBM-MeOH-Biphep-(AuCl)2 (121)[164] 
A solution of chloro(dimethylsulfide)gold(I) (56.6 mg, 192 µmol, 2.00 equiv) and the (R) or (S)-3,5-
tBu-4-MeO-MeO-Biphep-ligand (111 mg, 96.1 µmol, 1 equiv) in anh. 
dichloromethane (7 mL) was stirred for 24 h at 23 °C. The solvent was 
removed under a stream of argon and the colorless solid was dried in 
high vacuum to obtain 121 (quant.). The analytical data were in full 
agreement with those reported in the literature.[165] 
1H NMR (400 MHz, CDCl3): δ = 7.59 (td, J = 8.1, 2.5 Hz, 2H), 7.39 (d, J = 
13.7 Hz, 4H), 7.11 (br d, J = 14.0 Hz, 4H), 7.02-6.86 (m, 4H), 3.72 (s, 6H), 
3.69 (s, 6H), 2.72 (s, 6H), 1.33 (s, 72H); 31P NMR (160 MHz, CDCl3): δ = 21.87 (s). 
 
(1R,4S,6S,9S,11S,15R,E)-11-((tert-Butyldiphenylsilyl)oxy)-9-(2-((R,Z)-3-methoxy-2-methylbut-1-
en-1-yl)oxazol-4-yl)-4,6-dimethyl-17-methylene-7-oxo-8,19-dioxabicyclo[13.3.1]nonadec-2-en-3-
yl acetate (117a) 
A suspension of silver hexafluoroantimonate (2.94 mg, 8.56 µmol, 0.34 equiv) and gold catalyst 
(R)-DTBM-MeOH-Biphep-(AuCl)2 121 (6.89 mg, 4.26 µmol, 0.17 equiv) 
in anh. dichloromethane (0.30 mL) was sonicated for 5 min. The 
suspension was filtered through a plug of Celite (rinsed with anh. 
dichloromethane 2 × 0.25 mL) into a solution of compound 115a 
(20.0 mg, 25.1 µmol, 1 equiv) in anh. dichloromethane (0.5 mL). After 
stirring for 48 h at 23 °C, the solvent was removed by a stream of 
argon and the residue was purified by flash chromatography 
(hexane/ethyl acetate 10:1) to give 117a (18.1 mg, 22.7 µmol, 91%) as a colorless oil and a single 
isomer. 
[]
	
 = −28.9 (c = 0.98, CHCl3); 1H NMR (600 MHz, CDCl3): δ = 7.70 (m, 2H), 7.64 (m, 2H), 7.40 (m, 
1H), 7.37 (m, 1H), 7.34 (m, 2H), 7.32 (m, 2H), 7.15 (s, 1H), 6.08 (qd, J = 1.4, 1.0 Hz, 1H), 5.93 (dd, J = 
12.4, 3.4 Hz, 1H), 5.11 (qd, J = 6.5, 0.7 Hz, 1H), 5.04 (d, J = 3.5 Hz, 1H), 4.69 (t, J = 1.8 Hz, 2H), 4.06 
(ddd, J = 11.9, 3.5, 2.6 Hz, 1H), 3.74 (tdd, J = 10.2, 4.4, 1.8 Hz, 1H), 3.39 (tt, J = 11.3, 1.8 Hz, 1H), 
3.14 (s, 3H), 2.57 (dqd, J = 8.9, 7.0, 6.0 Hz, 1H), 2.53 (dqd, J = 9.2, 6.9, 6.2 Hz, 1H), 2.33 (ddd, J = 
13.9, 12.4, 4.4 Hz, 1H), 2.27 (ddd, J = 13.4, 2.5, 1.4 Hz, 1H), 2.09 (s, 3H), 2.08 (ddtd, J = 13.4, 11.9, 
1.6, 0.9, 1H), 2.08 (m,1H), 1.94 (ddtd, J = 13.3, 11.3, 1.6, 1.0 Hz, 1H), 1.87 (ddd, J = 13.9, 10.1, 3.5 
Hz, 1H), 1.84 (d, J = 1.6 Hz, 3H), 1.83 (m, 1H), 1.72 (t, J = 13.1 Hz, 1H), 1.67 (m, 1H), 1.33 (m, 2H), 
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1.25 (m, 1H), 1.23 (d, J = 6.5 Hz, 3H), 1.16 (dd, J = 9.1, 6.1 Hz, 2H), 1.03 (s, 9H), 0.91 (d, J = 6.9 Hz, 
3H), 0.69 (d, J = 6.8 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ = 175.0, 169.3, 160.1, 154.7, 151.0, 
144.2, 141.0, 136.1 (2C), 135.9 (2C), 134.9, 133.8, 133.4, 129.7, 129.5, 127.7 (2C), 127.4 (2C), 
119.9, 113.0, 109.1, 74.7, 74.6, 72.8, 71.7, 64.9, 56.5, 41.4, 40.95, 40.94, 40.0, 37.7, 34.5, 34.3, 
32.8, 27.1 (3C), 22.0, 21.0, 20.0, 19.4, 19.0, 18.1, 17.6; IR (film): ν = 2934, 2858, 1759, 1733, 1653, 
1456, 1428, 1367, 1258, 1194, 1163, 1106, 1056, 1024, 899, 821, 743, 704, 610, 511, 491, 451 
cm−1; MS (ESI) m/z (%): 820 (M+Na+, 100); HRMS (ESI): m/z: calcd. for C47H63NO8SiNa [M+Na+]: 
820.4215, found: 820.4217. 
 
(1S,3S,6S,8S,12R)-8-((tert-Butyldiphenylsilyl)oxy)-12-hydroxy-6-(2-((R,Z)-3-methoxy-2-
methylbut-1-en-1-yl)oxazol-4-yl)-1,3-dimethyl-4-oxo-1,2,3,4,6,7,8,9,10,11,12,13-dodecahydro-
14H-13a,16a-methanocyclopenta[f][1]oxacyclopentadecin-16-yl acetate (124) 
The reaction was performed analogously, using (S)-DTBM-MeOH-Biphep-(AuCl)2 121 (0.10 equiv) 
as precatalyst. 
Flash chromatography (hexane/ethyl acetate 10:1) gave 117a (50-
70%) as an inseparable mixture of the E and Z isomers (approx. 4:1) 
and product 124 (20-30%), which analyzed as follows: 
1H NMR (600 MHz, CDCl3): δ = 7.59 (m, 2H), 7.57 (m, 2H), 7.38 (m, 
1H), 7.36 (m, 1H), 7.31 (m, 2H), 7.28 (m, 2H), 7.24 (s, 1H), 6.09 (qd, 
J = 1.4, 1.0 Hz, 1H), 6.07 (dd, J = 9.2, 2.4 Hz, 1H), 5.13 (t, J = 2.5 Hz, 1H), 5.06 (qd, J = 6.4, 0.8 Hz, 
1H), 3.86 (dddd, J = 8.0, 6.9, 5.7, 2.3 Hz, 1H), 3.60 (m, 1H), 3.12 (s, 3H), 2.62 (dd, J = 17.5, 2.7 Hz, 
1H), 2.41 (dd, J = 17.5, 2.2 Hz, 1H), 2.39 (dqi, J = 7.0, 6.7 Hz,1H), 2.21 (ddd, J = 15.1, 9.2, 2.4 Hz, 
1H), 2.10 (s, 3H), 1.91 (ddd, J = 15.1, 8.0, 2.5 Hz, 1H), 1.85 (d, J = 1.4 Hz, 3H), 1.78 (m, 1H), 1.72 (m, 
1H) 1.66 (dd, J = 14.4, 3.1 Hz, 1H), 1.54 (m, 1H), 1.52 (ddd, J = 14.4, 10.2, 1.1, 1H), 1.45 (m, 2H), 
1.42 (m, 1H), 1.39 (m, 1H), 1.35 (m, 1H), 1.25 (d, J = 6.5 Hz, 3H), 1.21 (m, 1H), 1.05 (d, J = 7.0 Hz, 
3H), 1.04 (m, 1H), 1.02 (s, 9H), 0.93 (d, J = 7.1 Hz, 3H), 0.60 (dd, J = 4.0, 0.8 Hz, 1H), 0.41 (d, J = 4.0 
Hz, 1H); 13C NMR (150 MHz, CDCl3): δ = 176.0, 168.3, 160.1, 153.7, 150.6, 140.4, 135.8 (2C), 135.7 
(2C), 134.3, 134.2 (2C), 129.6 (2C), 127.49 (2C), 127.48 (2C), 113.2, 110.5, 74.7, 73.3, 70.7, 65.2, 
56.4, 40.9, 40.5, 39.8, 38.7, 37.6, 36.8, 36.6, 36.5, 31.0, 29.6, 27.0 (3C), 24.1, 21.3, 20.7, 20.4, 19.3, 
19.2, 18.1, 17.6. 
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(2S,4S,7S,9S,13R)-9-((tert-Butyldiphenylsilyl)oxy)-13-hydroxy-7-(2-((R,Z)-3-methoxy-2-
methylbut-1-en-1-yl)oxazol-4-yl)-2,4-dimethyl-6-oxa-1(1,3)-benzenacyclotetradecaphan-5-one 
(125) 
Prepared analogously starting with 115bc, using (R)-DTBM-MeOH-Biphep-(AuCl)2 121 as the 
precatalyst. The crude product was purified by preparative LC 
(Kromasil 100-5C18 5µm, 150 mm × 21.2 mm, ACN/H2O, 95:5, 35 °C, 
20 mL/min) to give 117a (10-20%) as an inseparable mixture of the E 
and Z isomer (approximately 4:1) and compound 125 (approx. 50%), 
which analyzed as follows: 
1H NMR (600 MHz, CDCl3): δ = 7.61 (m, 2H), 7.60 (m, 2H), 7.42 (s, 
1H), 7.39 (m, 1H), 7.38 (m, 1H), 7.32 (m, 4H), 7.25 (t, J = 7.6 Hz, 1H), 7.16 (t, J = 1.7, 1H), 7.08 (ddd, 
J = 7.5, 1.3, 1.3 Hz, 1H), 7.06 (ddd, , J = 7.4, 2.9 Hz, 1H), 6.17 (dd, J = 10.8, 2.4 Hz, 1H), 6.14 (qd, J = 
1.4, 0.9 Hz, 1H), 5.25 (qd, J = 6.4, 0.5 Hz, 1H), 3.94 (dddd, J = 10.3, 6.5, 4.8, 1.2 Hz, 1H), 3.83 (br s, 
1H), 3.19 (s, 3H), 2.89 (dd, J = 13.9, 4.4 Hz, 1H), 2.81 (dd, J = 13.9, 2.8 Hz, 1H), 2.61 (dqd, J = 12.2, 
7.0, 3.1 Hz, 1H), 2.56 (ddd, J = 15.2, 10.8, 1.2 Hz, 1H), 2.10 (dqd, J = 11.4, 6.9, 2.5 Hz, 1H), 1.85 (d, J 
= 1.5 Hz, 3H), 1.80 (ddd, J = 15.2, 6.5, 2.5 Hz, 1H), 1.74 (ddd, J = 13.8, 11.4, 3.1 Hz, 1H), 1.59 (m, 
1H), 1.51 (m, 1H), 1.44 (m, 1H), 1.42 (m, 1H), 1.34 (br s, 1H), 1.24 (m, 1H), 1.19 (d, J = 6.5 Hz, 3H), 
1.08 (d, J = 7.0 Hz, 3H), 1.03 (s, 9H), 1.01 (m, 2H), 1.00 (d, J = 6.9 Hz, 3H); 13C NMR (150 MHz, 
CDCl3): δ = 176.7, 160.2, 150.7, 146.4, 140.8, 135.78 (2C), 135.77 (2C), 135.4, 134.4, 134.2, 134.1, 
132.3, 129.7, 129.6, 128.7, 128.0, 127.6 (2C), 127.5 (2C), 122.9, 113.2, 74.7, 71.1, 70.7, 65.3, 56.5, 
45.6, 39.9, 37.4, 37.1, 36.8, 36.0, 35.6, 27.0 (3C), 22.5, 22.2, 19.3, 19.2, 18.3, 17.6. 
  
                                                          
c
 The preparation of 115b is described in 6.2.6. 
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(1R,4S,6S,9S,11S,15R)-11-((tert-Butyldiphenylsilyl)oxy)-9-(2-((R,Z)-3-methoxy-2-methylbut-1-en-
1-yl)oxazol-4-yl)-4,6-dimethyl-17-methylene-8,19-dioxabicyclo[13.3.1]nonadecane-3,7-dione 
(123) 
Potassium carbonate (32.7 mg, 237 µmol, 3.00 equiv) was added to a solution of compound 117a 
(63.0 mg, 78.9 µmol, 1 equiv) in methanol (10 mL). After stirring for 3 h 
at 23 °C, the reaction mixture was filtered through a plug of Celite which 
was rinsed with methyl tert-butyl ether (10 mL). The filtrate was 
concentrated and the residue was purified by flash chromatography 
(hexane/ethyl acetate 10:1) to obtain 123 (56.8 mg, 75.1 µmol, 95%) as a 
colorless oil. 
[]
	
 = −28.6 (c = 1.14, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 7.70 (dd, J 
= 7.9, 1.4 Hz, 2H), 7.64 (dd, J = 7.9, 1.4 Hz, 2H), 7.46–7.30 (m, 6H), 7.21 
(d, J = 0.8 Hz, 1H), 6.12 (qd, J = 1.4, 0.8 Hz, 1H), 5.95 (dd, J = 11.4, 2.8 Hz, 1H), 5.14 (qd, J = 6.4, 0.8 
Hz, 1H), 4.75–4.68 (m, 2H), 3.76–3.62 (m, 1H), 3.54 (dd, J = 10.4 Hz, 1H), 3.39 (dd, J = 10.4 Hz, 1H), 
3.16 (s, 3H), 2.81 (dd, J = 15.4, 9.9 Hz, 1H), 2.70–2.61 (m, 1H), 2.41–2.25 (m, 2H), 2.25–2.06 (m, 
3H), 2.01–1.90 (m, 3H), 1.87 (d, J = 1.4 Hz, 3H), 1.80–1.71 (m, 3H), 1.41–1.30 (m, 5H), 1.26 (d, J = 
6.6 Hz, 3H), 1.05 (s, 9H), 0.99 (d, J = 6.8 Hz, 3H), 0.85 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): 
δ = 212.9, 175.0, 160.3, 151.1, 144.0, 141.1, 136.2 (2C), 136.0 (2C), 134.7, 133.8, 133.7, 129.9, 
129.7, 127.8 (2C), 127.6 (2C), 113.2, 109.4, 75.2, 74.8, 74.3, 71.4, 65.0, 56.6, 48.5, 42.9, 41.4, 40.8, 
40.5, 39.0, 36.0, 35.0, 33.9, 27.2 (3C), 20.8, 19.6, 19.3, 18.8, 17.8, 17.7; IR (film): ν = 2932, 2857, 
1729, 1703, 1652, 1456, 1428, 1380, 1259, 1163, 1103, 1058, 892, 821, 804, 755, 702, 611, 509, 
488 cm−1; MS (ESI) m/z (%): 778 (M+Na+, 100); HRMS (ESI): m/z: calcd. for C45H61NO7SiNa [M+Na+]: 
778.4110, found: 778.4111. 
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(1R,3S,4S,6S,9S,11S,15R)-11-((tert-Butyldiphenylsilyl)oxy)-3-hydroxy-9-(2-((R,Z)-3-methoxy-2-
methylbut-1-en-1-yl)oxazol-4-yl)-4,6-dimethyl-17-methylene-8,19-
dioxabicyclo[13.3.1]nonadecan-7-one (126a) 
Sodium borohydride (12.5 mg, 331 µmol, 5.00 equiv) was added at −40 °C to a solution of ketone 
123 (50.0 mg, 66.1 µmol, 1 equiv) in anh. methanol (5 mL). After stirring 
for 3 h at this temperature, excess reagent was quenched by the 
addition of aq. phosphate buffer solution (pH 7, 10 mL) and the solution 
was allowed to warm to 23 °C. The aq. layer was extracted with methyl 
tert-butyl ether (3 x 10 mL) and the combined organic layers were dried 
over magnesium sulfate, filtered and concentrated. The crude product 
was purified by flash chromatography (hexane/ethyl acetate 8:1 
grading to 2:1) to yield 126a (30.8 mmol, 40.6 µmol, 61%) and 126b (16.4 mg, 21.6 µmol, 33%) as 
colorless oils. 
Desired diastereomer 126a: 
[]
	
 = −31.4 (c = 1.50, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 7.72 (dd, J = 7.9, 1.5 Hz, 2H), 7.67 
(dd, J = 7.9, 1.5 Hz, 2H), 7.45–7.32 (m, 6H), 7.28 (d, J = 0.6 Hz, 1H), 6.14–6.11 (m, 1H), 5.72 (dd, J = 
11.9, 3.3 Hz, 1H), 5.12 (qd, J = 6.5, 0.9 Hz, 1H), 4.70–4.64 (m, 2H), 3.85-3.66 (m, 2H), 3.35–3.19 (m, 
2H), 3.17 (s, 3H), 2.52 (dqd, J = 10.3, 7.0, 3.6 Hz, 1H), 2.41 (ddd, J = 14.0, 12.1, 3.9 Hz, 1H), 2.13 (br 
s, 1H), 2.09 (br s, 1H), 2.01–1.88 (m, 4H), 1.87 (d, J = 1.4 Hz, 3H), 1.77–1.50 (m, 7H),1.48–1.30 (m, 
4H), 1.26 (d, J = 6.5 Hz, 3H), 1.05 (s, 9H), 0.94 (d, J = 7.0 Hz, 3H), 0.71 (d, J = 6.7 Hz, 3H); 13C NMR 
(100 MHz, CDCl3): δ = 175.8, 160.2, 151.1, 145.0, 140.8, 136.2 (2C), 136.0 (2C), 134.7, 134.3, 134.0, 
129.8, 129.6, 127.8 (2C), 127.6 (2C), 113.3, 108.5, 77.2, 76.0, 75.2, 74.9, 71.2, 68.7, 65.9, 56.6, 
41.9, 41.7, 41.4, 41.0, 37.9, 36.3, 35.6, 33.8, 33.6, 27.3 (3C), 21.4, 19.6, 19.2, 17.7, 16.5, 13.5; IR 
(film): ν = 3468, 2933, 2857, 1726, 1652, 1549, 1454, 1428, 1380, 1248, 1204, 1150, 1103, 1044, 
1005, 976, 955, 891, 822, 756, 703, 611, 510, 488 cm−1; MS (ESI) m/z (%): 780 (M+Na+, 100); HRMS 
(ESI): m/z: calcd. for C45H63NO7SiNa [M+Na+]: 780.4266, found: 780.4279. 
Undesired C5-epimer 126b: 
1H NMR (400 MHz, CDCl3): δ = 7.71 (dd, J = 7.9, 1.5 Hz, 2H), 7.66 (dd, J = 7.9, 1.5 Hz, 2H), 7.46–7.33 
(m, 6H), 7.25 (d, J = 0.6 Hz, 1H), 6.14–6.11 (m, 1H), 5.84 (dd, J = 11.3, 3.2 Hz, 1H), 5.10 (qd, J = 6.4, 
0.8 Hz, 1H), 4.69 (br s, 2H), 3.8–3.75 (m, 1H), 3.57–3.24 (m, 4H), 3.17 (s, 3H), 2.92–2.81 (m, 1H), 
2.32 (ddd, J = 14.5, 11.4, 3.4 Hz, 1H), 2.13 (br d, J = 13.0 Hz, 1H), 2.10 (br d, J = 11.9 Hz, 1H), 2.04–
1.88 (m, 3H), 1.86 (d, J = 1.4 Hz, 3H), 1.79–1.29 (m, 11H), 1.25 (d, J = 6.4 Hz, 3H), 1.03 (s, 9H), 0.92 
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(d, J = 6.8 Hz, 3H), 0.77 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 176.9, 160.3, 151.1, 
144.9, 141.0, 136.1 (2C), 136.0 (2C), 134.7, 134.0 (2C), 129.8, 129.6, 127.8 (2C), 127.6 (2C), 113.3, 
108.6, 76.0, 75.5, 75.2, 74.9, 71.3, 65.8, 56.6, 41.9, 41.5, 40.9, 40.4, 40.2, 39.2, 35.7, 35.0, 33.9, 
27.2 (2C), 21.4, 19.6, 19.2, 18.0, 17.8, 17.2. 
 
Bis((9H-fluoren-9-yl)methyl) ((1R,3S,4S,6S,9S,11S,15R)-11-((tert-butyldiphenylsilyl)oxy) -9-(2-
((R,Z)-3-methoxy-2-methylbut-1-en-1-yl)oxazol-4-yl)-4,6-dimethyl-17-methylene-7-oxo-8,19-
dioxa bicyclo[13.3.1]nonadecan-3-yl) phosphate (128a)[51] 
A solution of tetrazole (0.45 M in acetonitrile, 264 µL, 119 µmol, 3.00 equiv) was added at 0 °C to a 
solution of alcohol 126a (30.0 mg, 39.6 µmol, 1 equiv) and 
iPr2NP(OFm)2[166] (62.9 mg, 119 µmol, 3.00 equiv) in anh. 
acetonitrile (0.75 mL) and anh. dichloromethane (0.75 mL). The 
mixture was stirred for 3 h at 23 °C, before it was cooled to 0 °C 
and aq. hydrogen peroxide (35% w/w, 115 µL, 1.19 mmol, 
30.0 equiv) was added. After stirring for additional 30 min, the 
reaction was quenched by the addition of aq. sat. sodium 
hydrogen carbonate solution (5 mL). The layers were separated 
and the aq. layer was extracted with dichloromethane (3 × 5 mL). The combined organic layers 
were washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude 
product was purified by flash chromatography (hexane/ethyl acetate 6:1 grading to 2:1) to afford 
128a (47.1 mg, 39.4 µmol, quant.) as a colorless solid. 
[]
	
 = −11.1 (c = 2.35, CHCl3); 1H NMR (600 MHz, CDCl3): δ = 7.74 (d, J = 7.6 Hz, 1H), 7.71 (d, J = 
7.6 Hz, 1H), 7.71 (d, J = 7.6 Hz, 1H), 7.69 (m, 3H), 7.63 (m, 2H), 7.52 (d, J = 7.5 Hz, 2H), 7.50 (d, J = 
7.5 Hz, 1H), 7.44 (d, J = 7.5 Hz, 1H),7.39–7.33 (m, 10H), 7.27 (td, J = 7.5, 1.0 Hz, 1H), 7.26 (td, J = 
7.4, 1.1 Hz, 1H), 7.25 (td, J = 7.4, 1.1 Hz, 1H), 7.21 (td, J = 7.5, 1.1 Hz, 1H), 7.15 (s, 1H), 6.08 (s, 1H), 
5.79 (dd, J = 12.5, 2.9 Hz, 1H), 5.11 (q, J = 6.5 Hz, 1H), 4.68 (m, 2H), 4.51 (dddd, J = 11.6, 6.8, 4.8, 
1.0 Hz, 1H), 4.23-4.14 (m, 4H), 4.10 (m, 2H), 3.59 (m, 1H), 3.23 (tt, J = 11.1, 2.0 Hz, 1H), 3.14 (s, 3H), 
2.98 (ddd, J = 11.4, 9.1, 2.3 Hz, 1H), 2.55 (dqd, J = 12.7, 6.7, 4.0 Hz, 1H), 2.26 (ddd, J = 13.7, 12.5, 
4.0 Hz, 1H), 2.07 (d, J = 13.3 Hz, 1H), 1.97 (d, J = 13.1 Hz, 1H), 1.84 (m, 1H), 1.84 (d, J = 1.5 Hz, 3H), 
1.84 (m, 1H), 1.83 (m, 1H), 1.82 (m, 1H), 1.80 (m, 1H), 1.64 (dd, J = 14.0, 4.7 Hz, 1H), 1.63 (ddd, J = 
12.4, 9.6, 1.6 Hz, 1H), 1.58 (m, 1H), 1.40 (m, 1H), 1.30 (m, 2H), 1.23 (d, J = 6.5 Hz, 3H), 1.21 (m, 1H), 
1.20 (m, 1H), 1.02 (s, 9H), 0.83 (td, J = 13.3, 3.0 Hz, 1H), 0.78 (d, J = 6.7 Hz, 3H), 0.60 (d, J = 6.5 Hz, 
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3H); 13C NMR (150 MHz, CDCl3): δ = 174.0, 160.1, 151.0, 144.5, 143.15, 143.13, 143.12, 143.05, 
141.34 (3C), 141.31, 141.2, 136.1 (2C), 135.9 (2C), 134.8, 133.6, 133.3, 129.7, 129.5, 127.90, 
127.87 (2C), 127.84, 127.7 (2C), 127.4 (2C), 127.14, 127.12, 127.11, 127.07, 125.2, 125.03, 125.00 
(2C), 120.09, 120.03, 120.02, 120.00, 113.0, 108.6, 78.5 (d, JC-P = 7.0 Hz), 74.72, 74.69, 74.3, 71.3, 
69.2 (d, JC-P = 5.9 Hz), 68.9 (d, JC-P = 6.1 Hz), 64.9, 56.5, 48.0 (d, JC-P = 5.4 Hz), 47.9 (d, JC-P = 5.8 Hz), 
41.7, 41.5, 41.2, 38.6, 37.9, 37.5, 35.1, 33.3, 33.2 (d, JC-P = 6.6 Hz), 27.1 (3C), 21.1, 19.5, 19.0, 17.6, 
17.4, 13.7; 31P NMR (160 MHz, CDCl3): δ = 0.00 (s); IR (film): ν = 3069, 2934, 2892, 2857, 1727, 
1450, 1428, 1381, 1261, 1205, 1150, 1105, 1045, 1003, 988, 914, 823, 757, 740, 704, 612, 511, 494 
cm−1; MS (ESI) m/z (%): 1217 (M+Na+, 100); HRMS (ESI): m/z: calcd. for C73H84NO10PSiNa [M+Na+]: 
1216.5494, found: 1216.5511. 
 
Enigmazole A (16) 
A solution of tetrabutylammonium fluoride (1 M in tetrahydrofuran, 188 µL, 188 µmol, 50.0 equiv) 
was added to a solution of the protected enigmazole 128a (4.50 mg, 
3.77 µmol, 1 equiv) in anh. tetrahydrofuran (0.5 mL) and acetic acid 
(16.2 µL, 283 µmol, 75.0 equiv) and the mixture was stirred at 40 °C for 
9 d. After reaching 23 °C, the solution was diluted with water (1 mL) 
and loaded onto a C18-cartridge (Strata® C18-U, 55 µm, 70 Å, 
500 mg/6 mL). The salts were eluted with water, followed by elution of 
the organic fraction with methanol. The combined organic fractions 
were concentrated and the residue was purified by preparative LC (Kromasil 100-5C18 5µm, 150 
mm × 21.2 mm, methanol/aq. TEAA pH 8.0, 70:30 grading to 100% methanol over 10 min, 35 °C, 
20 mL/min) to obtain the tetrabutylammonium salt of enigmazole A (2.6 mg, 3.09 µmol, 82%) as a 
colorless powder after lyophilisation.  
Purification by preparative LC (amount < 0.5 mg, Kromasil 100-5C18 5µm, 150 mm × 21.2 mm, 
acetonitrile/aq. TEAA pH 8.0, 30:70 grading to 50:50 over 6 min, 35 °C, 20 mL/min) afforded the 
triethylammonium salt of enigmazole A (quant.) after lyophilisation. 
The protonated form of enigmazole A was obtained by ion exchange chromatography (Adsorbex® 
SCX 400 mg) using methanol as eluent. 
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Triethylammonium salt: 
[]
	
 = −9.70 (c = 0.50, CHCl3); 1H NMR (600 MHz, CD3OD): δ = 7.70 (d, J = 0.7 Hz, 1H), 6.22 (dd, J = 
1.5, 0.9 Hz, 1H), 5.96 (ddd, J = 12.7, 2.8, 0.5 Hz, 1H), 5.25 (qd, J = 6.5, 0.9 Hz, 1H), 4.72–4.69 (m, 
2H), 4.46-4.41 (m, 1H), 3.62 (tdd, J = 10.8, 4.1, 1.8 Hz, 1H), 3.34–3.28 (m, 1H), 3.21 (s, 3H), 3.19 (q, 
J = 7.3 Hz, 6H), 3.13 (ddd, J = 11.0, 8.3, 2.0 Hz, 1H), 3.04-2.94 (m, 1H), 2.51 (ddd, J = 13.6, 12.7, 4.1 
Hz, 1H), 2.22 (br d, J = 13.1 Hz, 1H), 2.15 (br d, J = 13.1 Hz, 1H), 2.10 (dd, J = 14.3, 4.4 Hz, 1H), 2.02–
1.95 (m, 1H), 1.89 (d, J = 1.5 Hz, 3H), 1.89–1.87 (m, 1H), 1.86–1.85 (m, 1H), 1.85–1.83 (m, 1H), 
1.82–1.75 (m, 2H), 1.75–1.70 (m, 1H), 1.69–1.62 (m, 2H), 1.55 (tdt, J = 12.7, 13.0, 2.9 Hz, 1H), 
1.45–1.38 (m, 2H), 1.31 (t, J = 7.3 Hz, 9H), 1.27 (d, J = 6.5 Hz, 3H), 1.11 (d, J = 6.7 Hz, 3H), 1.05–1.01 
(m, 1H), 0.98 (d, J = 6.6 Hz, 3H) (3 protic H missing); 13C NMR (150 MHz, CD3OD): δ = 176.5, 161.9, 
152.7, 146.6, 142.4, 135.9, 113.9, 108.6, 77.5, 76.2, 75.7, 75.4 (d, J = 6.3 Hz), 69.8, 65.7, 56.8, 47.6 
(3C), 43.1, 42.6, 42.5, 40.2, 39.7, 39.4, 36.2, 34.7 (d, J = 6.4 Hz), 33.6, 21.8, 19.4, 18.3, 17.7, 15.0, 
9.2 (3C); 31P NMR (160 MHz, CDCl3): δ = 0.00 (s); IR (film): ν = 3402 (br), 2977, 2935, 2854, 1726, 
1651, 1455, 1252, 1203, 1150, 1109, 1076, 1017, 972, 936, 896, 657, 594, 515, 497 cm−1; MS (ESI) 
m/z (%): 598 (M−H−, 100); HRMS (ESI): m/z: calcd. for C29H45NO10P [M−H−]: 598.2787, found: 
598.2793. 
Protonated phosphate ester: 
1H NMR (600 MHz, CD3OD): δ = 7.70 (d, J = 0.6 Hz, 1H), 6.22 (qd, J = 1.5, 0.9 Hz, 1H), 5.96 (ddd, J = 
12.8, 2.9, 0.6 Hz, 1H), 5.25 (qd, J = 6.5, 0.8 Hz, 1H), 4.73–4.70 (m, 2H), 4.51–4.42 (m, 1H), 3.61 (tdd, 
J = 10.7, 3.9, 1.4 Hz, 1H), 3.33–3.28 (m, 1H), 3.21 (s, 3H), 3.13 (ddd, J = 11.4, 8.3, 2.2 Hz, 1H), 3.00–
2.92 (m, 1H), 2.51 (ddd, J = 13.6, 12.8, 4.0 Hz, 1H), 2.22 (br d, J = 13.0 Hz, 1H), 2.15 (br d, J = 12.5 
Hz, 1H), 2.08 (br d, J = 13.4 Hz, 1H), 2.02–1.96 (m, 1H), 1.89 (d, J = 1.5 Hz, 3H), 1.94–1.82 (m, 3H), 
1.78 (ddd, J = 13.8, 10.9, 3.0 Hz, 1H), 1.78–1.70 (m, 2H), 1.69–1.62 (m, 2H), 1.58–1.49 (m, 1H), 
1.46–1.35 (m, 2H), 1.27 (d, J = 6.5 Hz, 3H), 1.11 (d, J = 6.6 Hz, 3H), 1.07–1.00 (m, 1H), 0.98 (d, J = 
6.6 Hz, 3H) (2 protic H missing); 13C NMR (150 MHz, CD3OD): δ = 176.5, 161.9, 152.7, 146.5, 142.3, 
135.9, 113.9, 108.7, 77.4, 76.2, 75.9 (br), 75.8, 69.8, 65.8, 56.8, 43.1, 42.6, 42.5, 40.1, 39.7, 39.3, 
36.2, 34.71 (d, J = 4.5 Hz), 33.6, 21.8, 19.4, 18.3, 17.7, 14.9; 31P NMR (160 MHz, CDCl3): δ = 0.00 (s). 
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6.2.5. NMR Data of Enigmazole A 
Table 6.1: Comparison of 1H NMR (CD3OD) data of enigmazole A. 
Position Natural 
product[48] 
protonated 
Molinski 
Group[51] 
Na-salt 
Fürstner 
Group 
Et3NH-salt 
Fürstner 
Group 
protonated 
19 7.68, s 7.69, s 7.68, d, 0.5 7.68, d, 0.4 
21 6.21, s 6.22, br s 6.21, qd, 1.4, 1.0 6.20, qd, 1.4, 1.0  
17 5.95, dd, 12.8, 2.5 5.96, dd, 12.5, 2.5 5.95, ddd, 12.8, 2.8, 0.5 5.95, ddd, 12.8, 2.9, 0.4  
23 5.24, q, 6.5 5.25, q, 6.3 5.24, qd, 6.5, 0.9 5.23, qd, 6.5, 0.9 
28a 4.70, d, 1.5 4.71, br s 4.70, q, 2.0 4.70, q, 1.9 
28b 4.69, d, 1.5 4.70, br s 4.69, q, 2.0 4.69, q, 1.9 
5 4.42, m 4.43, m 4.42, dddd, 11.2, 8.8, 4.4, 1.0 4.47, m 
15 3.62, dt, 11.1, 4.3 3.63, m 3.60, tdd, 10.8, 4.1, 1.8 3.60, tdd, 10.8, 4.1, 1.8  
11 3.29 3.30 3.30, tt, 11.0, 2.4 3.29, tt, 11.1, 2.4  
23-OMe 3.20, s 3.21, s 3.20, s 3.19, s 
Et3NH - - 3.17, q, 7.3  - 
7 3.12, dd, 10.3, 9.8 3.13, m 3.12, ddd, 11.4, 8.6, 2.3  3.12, ddd, 11.4, 8.6, 2.0  
2 2.98 2.99, m 2.98, dqd, 12.5, 6.7, 3.8 2.95, m  
16a 2.50, dt, 13.2, 3.4 2.51, dt, 13.3, 3.8 2.50, ddd, 13.8, 12.8, 4.1 2.50, ddd, 13.8, 12.8, 4.1  
8a 2.21, d, 12.8 2.23, d, 13.0 2.21, ddd, 13.0, 2.3, 1.2 2.20, br d, 13.2  
10a 2.13, d, 12.8 2.14, d, 14.0 2.13, ddd, 13.1, 2.4, 1.2 2.13, br d, 13.2  
6a 2.10, m 2.11, m 2.09, dd, 14.4, 4.4 2.07, br d, 14.4  
8b 1.97, dd, 12.8, 12.3 1.98, t, 12.3 
1.97, ddtd, 13.0, 11.4, 1.7, 
1.0 1.97, m 
25 1.89, s 1.89, d, 1.5 1.88, d, 1.6 1.88, d, 1.5 
3a 1.88, m 1.89, m 1.88, m 1.87, m 
6b 1.87, m 1.88, m 1.87, m 1.90, m 
10b 1.84 1.86 1.85, m 1.84, m 
14a 1.76 1.79 1.78, m 1.78, tt, 12.9, 1.9  
16b 1.77 1.78 1.77, ddd, 13.8, 10.8, 2.9 1.77, ddd, 13.8, 10.8, 2.9 
13a 1.72 1.73 1.72, m 1.72, tq, 13.0, 3.8 
12a 1.64 1.66 1.65, m 
1.64, dddd, 14.0, 11.2, 3.8, 
2.8 
4 1.62 1.63 1.64, m 1.64, m 
13b 1.54, q, 12.4 1.55, q, 12.5 1.53, tdt, 13.0, 12.6, 2.9 1.52, tdt, 13.0, 12.7, 2.8 
3b 1.38, t, 10.8 1.39, m 1.40, m 1.41, td, 13.2, 2.5 
12b 1.37, t, 11.3 1.38, m 1.38, m 
1.37, dddd, 14.0, 13.2, 3.3, 
2.4 
Et3NH - - 1.30, t, 7.3  - 
24 1.26, d, 6.4 1.27, d, 6.5 1.26, d, 6.5  1.26, d, 6.5 
26 1.10, d, 6.4 1.11, d, 6.5 1.10, d, 6.7  1.10, d, 6.6 
14b 1.02, td, 12.0, 3.4 1.04, dt, 12.0, 3.2 1.02, m 1.02, tdd, 12.8, 11.2, 4.1 
27 0.97, d, 6.4 0.98, d, 6.5 0.97, d, 6.6  0.97, d, 6.5 
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Table 6.2: Comparison of 13C NMR (CD3OD) data of enigmazole A. 
Position Natural 
product[48] 
protonated 
Molinski 
Group[51] 
Na-salt 
Fürstner 
Group 
Et3NH-salt 
Fürstner 
Group 
protonated 
1 176.4 176.5 176.5 176.5 
20 161.7 161.9 161.9 161.9 
22 152.7 152.7 152.7 152.7 
9 146.3 146.6 146.6 146.5 
18 142.3 142.4 142.4 142.3 
19 136.0 135.9 135.9 135.9 
21 113.9 114.0 114.0 114.0 
28 108.8 108.6 108.7 108.7 
7 77.2 77.6 77.5 77.4 
23 77.0 76.2 76.2 76.2 
11 76.2 75.7 75.8 75.9 
5 75.8 75.2, d, 6.1 75.4,d ,6.3 75.8, br 
15 69.8 69.8 69.8 69.8 
17 65.9 65.6 65.7 65.8 
23-OMe 56.8 56.8 56.8 56.8 
Et3NH - - 47.6 - 
8 43.0 43.0 43.1 43.1 
16 42.6 42.7 42.7 42.6 
10 42.4 42.5 42.5 42.5 
6 40.1 40.1 40.2 40.1 
2 39.6 39.7 39.7 39.7 
3 39.3 39.3 39.4 39.3 
4 36.2 34.7, d, 6.1 34.7, d, 6.4 34.7 d, 4.6 
12 36.2 36.2 36.2 36.2 
14 33.6 33.6 33.6 33.6 
13 21.8 21.8 21.8 21.8 
24 19.4 19.4 19.4 19.4 
26 18.2 18.3 18.3 18.3 
25 17.6 17.7 17.7 17.7 
27 14.7 15.0 15.0 14.9 
Et3NH - - 9.2 - 
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6.2.6. Addenda to the Synthesis 
Syn-tetrahydropyran 122a 
Triethylamine (2.72 µL, 19.5 µmol, 3.00 equiv) and methanesulfonyl chloride (1.51 µL, 19.5 µmol, 
3.00 equiv) were successively added to a solution of alcohol 115a (5.20 mg, 
6.50 µmol, 1 equiv) in anh dichloromethane (0.5 mL). After stirring for 
30 min, the mixture was diluted with methanol (0.1 mL) and all volatile 
materials were removed in high vacuum.  
Potassium carbonate (4.50 mg, 32.6 mmol, 5.00 equiv) was added to a 
solution of the residue in dichloromethane/methanol (1:1, 1 mL). After 
stirring for 36 h, the mixture was neutralized by the addition of aq. 
hydrochloric acid (1 N, 1 mL) and the aq. layer was extracted with 
dichloromethane (4 × 3 mL). The combined organic layers were dried over magnesium sulfate, 
filtered and concentrated. The residue was purified by preperative LC (Kromasil 100-5C18 5 µm, 
150 mm × 21.2 mm, 100% acetonitrile, 35 °C, 20 mL/min) to obtain the title compound (2.20 mg, 
3.00 µmol, 46%). 
1H NMR (600 MHz, CDCl3): δ = 7.60–7.56 (m, 4H), 7.48 (d, J = 1.1 Hz, 1H), 7.38–7.34 (m, 2H), 7.32–
7.27 (m, 4H), 6.12 (dd, J = 1.4, 0.8 Hz, 1H), 5.84 (ddd, J = 5.5, 2.8, 1.1 Hz, 1H), 5.13 (qd, J = 6.4, 0.7 
Hz, 1H), 4.73–4.69 (m, 2H), 3.97 (dt, J = 11.4, 2.5 Hz, 1H), 3.57 (tt, J = 9.6, 3.2 Hz, 1H), 3.21 (s, 3H), 
3.15 (tt, J = 10.4, 2.5 Hz, 1H), 3.10–3.02 (m, 1H), 2.47–2.34 (m, 4H), 2.25 (t, J = 12.5 Hz, 1H), 2.10–
1.99 (m, 2H), 1.96–1.92 (m, 1H), 1.91 (d, J = 1.4 Hz, 3H), 1.81–1.69 (m, 2H), 1.50–1.43 (m, 1H), 
1.40–1.30 (m, 3H), 1.21 (d, J = 6.4 Hz, 3H), 1.20 (d, J = 7.0 Hz, 3H), 1.07 (d, J = 6.9 Hz, 3H), 1.00 (s, 
9H), 0.91–0.82 (m, 1H); 13C NMR (150 MHz, CDCl3): δ = 176.3, 160.2, 150.3, 143.7, 140.7, 136.07 
(2C), 136.06 (2C), 134.8, 134.3, 133.8, 129.5, 129.4, 127.4 (4C), 113.6, 109.5, 88.1, 82.3, 81.3, 74.7, 
71.9, 68.8, 67.7, 56.6, 41.2, 41.0, 40.9, 40.1, 38.1, 37.6, 34.7, 27.3 (3C), 25.0, 24.1, 20.9, 19.6, 19.3, 
18.8, 17.8. 
  
Experimental Procedures 111 
 
(1R,3S,4S,6S,9S,11S,15R)-11-Hydroxy-9-(2-((R,Z)-3-methoxy-2-methylbut-1-en-1-yl)oxazol-4-yl)-
4,6-dimethyl-17-methylene-7-oxo-8,19-dioxabicyclo[13.3.1]nonadecan-3-yl carbamate (130) 
Trichloroacetyl isocyanate (6.20 mg, 33.0 µmol, 5.00 equiv) was added at 0 °C to a solution of 
alcohol 126a (5.00 mg, 6.60 µmol, 1 equiv) in anh. dichloromethane 
(1 mL). After stirring for 1.5 h at 0 °C, the mixture was directly loaded 
onto a plug of neutral aluminum oxide to cleave the protecting group. 
After 1.5 h, the crude product was carefully rinsed with ethyl acetate 
(10 mL) and concentrated. 
The residue was dissolved in anh. THF (0.5 mL) and acetic acid 
(28.4 µL, 496 µmol, 75.0 equiv) before a solution of 
tetrabutylammonium fluoride (1 M in tetrahydrofuran, 331 µL, 331 µmol, 50.0 equiv) was added. 
After stirring at 40 °C for 13 d, the reaction was quenched by the addition of aq. phosphate buffer 
solution (pH 7, 5 mL) and the aq. layer was extracted with ethyl acetate (3 × 5 mL). The combined 
organic layers were dried over magnesium sulfate, filtered and concentrated. The crude product 
was purified by preparative LC (Kromasil 100-5C18 5µm, 150 mm × 21.2 mm, acetonitrile/water 
60:40, 35 °C, 20 mL/min) to obtain 130 (2.6 mg, 4.62 µmol, 70%).  
1H NMR (600 MHz, CDCl3): δ = 7.42 (d, J = 0.6 Hz, 1H), 6.17–6.15 (m, 1H), 5.98 (dd, J = 11.7, 3.3 Hz, 
1H), 5.20–5.15 (m, 1H), 5.07 (ddd, J = 11.0, 4.5, 1.4 Hz, 1H), 4.70 (dt, J = 3.4, 1.8 Hz, 2H), 4.59 (br s, 
1H), 3.72–3.63 (m, 1H), 3.39–3.30 (m, 1H), 3.26–3.22 (m, 1H), 3.22 (s, 3H), 2.85–2.72 (m, 1H), 2.51 
(ddd, J = 13.9, 11.9, 4.2 Hz, 1H), 2.14 (dd, J = 29.4, 13.1 Hz, 2H), 1.99 (t, J = 12.6 Hz, 1H), 1.92–1.83 
(m, 6H), 1.78 (t, J = 12.9 Hz, 1H), 1.75–1.63 (m, 6H), 1.56–1.35 (m, 4H), 1.28 (d, J = 6.5 Hz, 3H), 1.11 
(d, J = 6.8 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H) (2 protic H missing); 13C NMR (150 MHz, CDCl3): δ = 
174.4, 160.4, 151.2, 144.3, 140.8, 133.8, 113.0, 108.7, 75.5, 74.8, 74.4, 73.39, 73.37, 69.1, 64.7, 
56.5, 41.8, 41.2, 41.1, 38.4, 38.2, 37.7, 34.9, 32.92, 32.87, 20.6, 19.1, 17.9, 17.6, 14.7; HRMS (ESI): 
m/z: calcd. for C30H47N2O8 [M+H+]: 563.3327, found: 563.3331. 
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(8R,12S,14S)-14-((tert-Butyldimethylsilyl)oxy)-12-((tert-butyldiphenylsilyl)oxy)-8-hydroxy-14-(2-
((R,Z)-3-methoxy-2-methylbut-1-en-1-yl) oxazol-4-yl)-6-methylenetetradec-2-yn-4-yl acetate 
(111) 
Analoguos to preparation of 111a, the title compound was made by using boron tribromide (1 M in 
dichloromethane, 904 µL, 0.904 mmol, 1.50 equiv), (S,S)-1,2-diphenyl-1,2-ethylenediamine 
bis(toluenesulfon-amide)[103b] (470 mg, 0.904 mmol, 1.50 equiv), 
racemic allyl stannane 50 (480 mg, 1.05 mmol, 1.75 equiv), and 
aldehyde 63 (400 mg, 0.602 mmol, 1 equiv). The crude product was 
purified by flash chromatography (hexane/ethyl acetate 15:1 grading 
to 6:1) to give 111 (517 mg, 0.592 mmol, 98%, d.r. >9:1d) as a colorless 
oil. 
1H NMR (400 MHz, CDCl3) δ = 7.69–7.58 (m, 4H), 7.44–7.29 (m, 6H), 
7.10 (s, 1H), 6.17 (s, 1H), 5.50–5.42 (m, 1H), 5.21 (q, J = 6.4 Hz, 1H), 
4.98 (s, 1H), 4.93 (d, J = 3.3 Hz, 1H), 4.83 (t, J = 6.7 Hz, 1H), 3.88–3.79 
(m, 1H), 3.61–3.48 (m, 1H), 3.21–3.12 (m, 3H), 2.56–2.35 (m, 2H), 2.15 (dd, J = 14.3, 3.5 Hz, 1H), 
2.07 (s, 1.5H), 2.06 (s, 1.5H), 2.05–1.95 (m, 3H), 1.88 (d, J = 1.4 Hz, 3H), 1.85–1.82 (m, 3H), 1.76–
1.68 (m, 1H), 1.68–1.63 (m, 1H), 1.51–1.31 (m, 2H), 1.28 (d, J = 6.4 Hz, 3H), 1.26–1.13 (m, 3H), 1.03 
(s, 9H), 0.82 (s, 9H), 0.03 (s, 3H), −0.07 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 170.19, 170.16, 
159.9, 150.2, 144.8, 141.4, 136.02, 135.99, 134.7, 134.3, 133.7, 129.59, 129.57, 127.54, 127.52, 
116.4, 116.3, 113.7, 82.5, 82.3, 76.61, 76.58, 74.8, 70.5, 69.0, 68.8, 65.7, 63.2, 62.8, 56.5, 44.8, 
44.4, 44.0, 41.6, 41.4, 37.3, 37.2, 36.8, 27.2, 25.9, 21.24, 21.20, 20.9, 19.5, 19.3, 18.3, 17.71, 17.65, 
3.8, −4.4, −4.7 (some carbon signals of the two sets of signals expected for the two 
diasteroisomers are missing due to overlapping); IR (film): ν = 2930, 2857, 1738, 1428, 1371, 1233, 
1106, 836, 754, 702, 610, 505, 488 cm−1; HRMS (ESI): m/z: calcd. for C48H71NO7Si2Na [M+Na+]: 
852.4661, found: 852.4669. 
  
                                                          
d
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(8R,12S,14S)-14-((tert-Butyldimethylsilyl)oxy)-12-((tert-butyldiphenylsilyl)oxy)-14-(2-((R,Z)-3-
methoxy-2-methylbut-1-en-1-yl)oxazol-4-yl)-6-methylene-8-(((2,2,2-trichloroethoxy)carbonyl) 
oxy)tetradec-2-yn-4-yl acetate (112) 
Analoguos to preparation of 112a, the title compound was made by using 111 (492 mg, 
0.592 mmol, 1 equiv), 2,2,2-trichlorethoxycarbonyl chloride (245 µL, 
1.78 mmol, 3.00 equiv), 4-(dimethylamino)pyridine (7.23 mg, 
59.2 µmol, 0.10 equiv) and pyridine (287 µL, 3.55 mmol, 6.00 equiv). 
The crude product was purified by flash chromatography 
(hexane/ethyl acetate 10:1) to give 112 (593 mg, 0.592 mmol, quant.) 
as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 7.67–7.57 (m, 4H), 7.45–7.29 (m, 6H), 
7.09 (d, J = 1.4 Hz, 1H), 6.18–6.15 (m, 1H), 5.47–5.39 (m, 1H), 5.20 (q, J 
= 6.4 Hz, 1H), 4.93–4.88 (m, 2H), 4.83–4.72 (m, 3H), 4.71–4.64 (m, 1H), 3.89–3.80 (m, 1H), 3.18 (s, 
3H), 2.48–2.44 (m, 2H), 2.36–2.18 (m, 2H), 2.05 (d, J = 0.7 Hz, 3H), 2.03–1.92 (m, 2H), 1.89 (d, J = 
1.4 Hz, 3H), 1.83 (dd, J = 2.1, 0.7 Hz, 3H), 1.54–1.30 (m, 6H), 1.28 (d, J = 6.5 Hz, 3H), 1.03 (s, 9H), 
0.81 (s, 9H), 0.01 (s, 3H), −0.09 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 169.4, 159.2, 153.2, 149.6, 
144.1, 138.9, 138.8, 135.34, 135.29, 133.8, 133.6, 132.9, 129.0, 126.9, 116.6, 116.3, 112.9, 94.0, 
81.7, 81.6, 77.5, 77.3, 75.94, 75.89, 75.8, 75.7, 74.1, 69.59, 69.56, 65.0, 62.4, 62.1, 55.9, 43.4, 
40.73, 40.68, 40.4, 35.8, 35.6, 33.6, 33.5, 26.5, 25.3, 20.52, 20.50, 19.73, 19.67, 18.8, 18.7, 17.6, 
17.1, 3.1, −5.1, −5.4 (some carbon signals of the two sets of signals expected for the two 
diasteroisomers are missing due to overlapping); IR (film): ν = 2954, 2930, 2857, 1754, 1428, 1378, 
1249, 1109, 836, 821, 703, 611, 507 cm−1; HRMS (ESI): m/z: calcd. for C51H72NO9Cl3Si2Na [M+Na+]: 
1026.3703, found: 1026.3692. 
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(8R,12S,14S)-12-((tert-Butyldiphenylsilyl)oxy)-14-hydroxy-14-(2-((R,Z)-3-methoxy-2-methylbut-1-
en-1-yl)oxazol-4-yl)-6-methylene-8-(((2,2,2-trichloroethoxy)carbonyl)oxy)tetradec-2-yn-4-yl 
acetate (113) 
Analoguos to preparation of 113a, the title compound was made by using 112 (592 mg, 
0.589 mmol, 1 equiv) and 10-camphorsulfonic acid (27.4 mg, 
0.118 mmol, 0.20 equiv). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1 grading to 2:1) to give 
113 (208 mg, 0.233 mmol, 40%, 74% brsm) and recovered starting 
material 112 (277 mg, 0.275 mmol, 47%). 
1H NMR (400 MHz, CDCl3) δ = 7.68–7.61 (m, 4H), 7.46–7.28 (m, 6H), 
7.23 (s, 1H), 6.11 (s, 1H), 5.35 (tq, J = 6.9, 2.2 Hz, 1H), 5.06 (q, J = 6.4 
Hz, 1H), 4.86–4.75 (m, 3H), 4.71–4.58 (m, 3H), 4.01–3.91 (m, 1H), 
3.22–3.16 (m, 1H), 3.13 (s, 3H), 2.45–2.30 (m, 2H), 2.29–2.08 (m, 2H), 
1.98 (d, J = 2.0 Hz, 3H), 1.95–1.83 (m, 2H), 1.82 (d, J = 1.3 Hz, 3H), 1.76 (dd, J = 2.0, 1.1 Hz, 3H), 
1.45–1.33 (m, 1H), 1.33–1.20 (m, 2H), 1.23 (d, J = 6.5 Hz, 3H), 1.20–1.07 (m, 3H), 0.99 (s, 9H); 13C 
NMR (75 MHz, CDCl3): δ = 170.0, 160.5, 153.9, 150.6, 144.5, 139.6, 139.5, 136.0, 134.3, 133.7, 
133.1, 130.0, 129.9, 127.9, 127.7, 117.2, 117.0, 113.6, 94.8, 82.4, 82.3, 78.2, 77.9, 76.6, 74.9, 72.9, 
66.2, 63.1, 62.9, 56.6, 42.8, 41.6, 41.0, 37.0, 34.0, 27.2, 21.1, 20.6, 19.5, 19.4, 17.7, 3.7 (some 
carbon signals of the two sets of signals expected for the two diasteroisomers are missing due to 
overlapping); IR (film): ν = 2953, 2932, 2858, 1754, 1651, 1428, 1377, 1250, 1110, 1067, 1021, 821, 
737, 704, 612, 508 cm−1; HRMS (ESI): m/z: calcd. for C45H58NO9Cl3SiNa [M+Na+]: 912.2838, found: 
912.2835. 
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(1S,3S,7R)-11-Acetoxy-3-((tert-butyldiphenylsilyl)oxy)-1-(2-((R,Z)-3-methoxy-2-methylbut-1-en-
1-yl)oxazol-4-yl)-9-methylene-7-(((2,2,2-trichloroethoxy)carbonyl)oxy)tetradec-12-yn-1-yl 
(2S,4S)-2,4-dimethylhept-5-ynoate (62) 
Analoguos to preparation of 62a, the title compound was made by using 113 (320 mg, 
0.359 mmol, 1 equiv), 49 (60.9 mg, 0.395 mmol, 1.10 equiv), 
triethylamine (75.1 µL, 0.539 mmol, 1.50 equiv), 2,4,6-trichlorobenzoyl 
chloride (84.1 µL, 0.539 mmol, 1.50 equiv) and 
4-(dimethylamino)pyridine (43.9 mg, 0.395 mmol, 1.00 equiv). The 
crude product was purified by flash chromatography (hexane/ethyl 
acetate 10:1 grading to 6:1) to give 62 (342 mg, 0.333 mmol, 93%) as a 
colorless oil. 
1H NMR (400 MHz, CDCl3): δ = 7.63–7.58 (m, 4H), 7.43–7.31 (m, 6H), 
7.19 (d, J = 1.6 Hz, 1H), 6.14 (s, 1H), 5.89 (t, J = 7.0 Hz, 1H), 5.47–5.39 (m, 1H), 5.10 (q, J = 6.5 Hz, 
1H), 4.91 (br s, 2H), 4.82–4.73 (m, 2H), 4.68 (dd, J = 11.9, 5.2 Hz, 1H), 3.72–3.63 (m, 1H), 3.14 (s, 
3H), 2.67–2.56 (m, 1H), 2.52–2.41 (m, 2H), 2.39–2.07 (m, 5H), 2.05 (d, J = 0.7 Hz, 3H), 1.87 (d, J = 
1.2 Hz, 3H), 1.84–1.81 (m, 3H), 1.73 (d, J = 2.3 Hz, 3H), 1.66 (ddd, J = 14.7, 9.8, 5.1 Hz, 1H), 1.54–
1.29 (m, 7H), 1.27 (d, J = 6.5 Hz, 3H), 1.05 (d, J = 3.2 Hz, 3H), 1.03 (br s, 12H); 13C NMR (100 MHz, 
CDCl3): δ = 175.7, 169.97, 169.96, 160.1, 153.8, 150.7, 140.0, 139.5, 139.4, 135.93, 135.91, 135.1, 
134.1, 133.9, 129.7, 127.6, 117.3, 117.0, 113.3, 94.7, 82.9, 82.3, 82.2, 78.0, 77.8, 76.6, 76.51, 
76.46, 76.3, 74.7, 69.8, 65.6, 63.0, 62.7, 56.5, 41.34, 41.31, 41.1, 41.0, 39.5, 38.0, 36.3, 34.1, 34.0, 
27.1, 24.3, 21.7, 21.11, 21.09, 20.4, 20.3, 19.4, 19.2, 18.1, 17.7, 3.7, 3.6 (some carbon signals of the 
two sets of signals expected for the two diasteroisomers are missing due to overlapping); IR (film): 
ν = 2963, 2932, 2858, 1754, 1739, 1429, 1378, 1250, 1111, 1065, 821, 738, 704, 612, 507 cm−1; 
HRMS (ESI): m/z: calcd. for C54H70Cl3NO10SiNa [M+Na+]: 1048.3727, found: 1048.3737. 
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(3S,5S,12R,16S,18S)-16-((tert-Butyldiphenylsilyl)oxy)-18-(2-((R,Z)-3-methoxy-2-methylbut-1-en-
1-yl)oxazol-4-yl)-3,5-dimethyl-10-methylene-2-oxo-12-(((2,2,2-trichloroethoxy)carbonyl)oxy) 
oxacyclooctadec-6-yn-8-yl acetate (114) 
Analoguos to preparation of 114a, the title compound was made by using 62 (290 mg, 
0.282 mmol, 1 equiv) and alkyne metathesis catalyst 116 (74.8 mg, 
56.4 µmol, 0.20 equiv). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1 grading to 4:1) to give 114 
(223 mg, 0.229 mmol, 81%) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ = 7.66–7.59 (m, 4H), 7.46–7.30 (m, 7H), 
6.18–6.05 (m, 2H), 5.66–5.59 (m, 0.5H), 5.50–5.43 (m, 0.5H), 5.19–5.11 
(m, 1H), 5.01–4.89 (m, 1H), 4.82–4.67 (m, 3H), 3.90–3.79 (m, 1H), 3.19 
(d, J = 1.2 Hz, 3H), 2.63–2.23 (m, 7H), 2.06 (d, J = 4.3 Hz, 3H), 2.00–1.91 
(m, 1H), 1.89 (t, J = 1.4 Hz, 3H), 1.60–1.38 (m, 6H), 1.36 (s, 2H), 1.27 (d, J = 6.4 Hz, 3H), 1.13–1.01 
(m, 16H); 13C NMR (100 MHz, CDCl3): δ = 175.54, 175.49, 169.92, 169.87, 160.4, 153.89, 153.85, 
151.0, 150.9, 141.0, 140.9, 139.5, 139.2, 135.9, 134.10, 134.06, 134.0, 129.8, 127.7, 117.9, 116.9, 
113.4, 94.7, 90.9, 90.6, 78.7, 78.2, 78.05, 77.99, 76.7, 76.6, 74.78, 74.75, 70.3, 70.2, 65.6, 65.4, 
63.4, 62.9, 56.6, 42.2, 41.9, 41.2, 40.9, 40.7, 38.1, 38.0, 37.9, 36.2, 35.9, 34.0, 27.1, 24.1, 22.2, 
21.7, 21.29, 21.28, 20.6, 20.5, 19.4, 19.3, 17.8, 17.14, 17.07 (some carbon signals of the two sets of 
signals expected for the two diasteroisomers are missing due to overlapping); IR (film): ν = 2932, 
2859, 1741, 1428, 1378, 1247, 1162, 1110, 1067, 1021, 821, 735, 703, 612, 509, 488 cm−1; HRMS 
(ESI): m/z: calcd. for C50H64Cl3NO10SiNa [M+Na+]: 994.3257, found: 994.3261. 
 
(3S,5S,12R,16S,18S)-16-((tert-Butyldiphenylsilyl)oxy)-12-hydroxy-18-(2-((R,Z)-3-methoxy-2-
methylbut-1-en-1-yl)oxazol-4-yl)-3,5-dimethyl-10-methylene-2-oxooxacyclooctadec-6-yn-8-yl 
acetate (115) 
Analoguos to preparation of 115a, the title compound was made by 
using 114 (223 mg, 0.229 mmol, 1 equiv) and zinc dust (two times 1.50 g, 
22.9 mmol, 100 equiv, Sigma-Aldrich®, <10 μm). The crude product was 
purified by flash chromatography (hexane/ethyl acetate 4:1 grading to 
2:1) to give 115 (180 mg, 0.225 mmol, 98%) as a colorless oil.  
The two C7-diastereomers, 115a and 115b, were separated by 
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preparative LC (Kromasil 100-5C18 5 µm, 150 mm × 30.0 mm, ACN/H2O, 90:10, 35 °C, 35 mL/min) 
to give 115a (56.0 mg, 70.0 µmol, 31%) and 115b (28.9 mg, 66.0 µmol, 29%). 
1:1 Mixture of diastereomers 115: 
1H NMR (400 MHz, CDCl3): δ = 7.70–7.58 (m, 4H), 7.48–7.29 (m, 7H), 6.19–6.02 (m, 2H), 5.51 (ddd, 
J = 7.2, 4.9, 2.1 Hz, 0.5H), 5.44 (ddd, J = 8.2, 4.7, 1.3 Hz, 0.5H), 5.15 (qd, J = 6.4, 2.3 Hz, 1H), 4.98 (d, 
J = 6.8 Hz, 2H), 3.93–3.79 (m, 1H), 3.71–3.59 (m, 1H), 3.19 (d, J = 1.2 Hz, 3H), 2.60 (q, J = 6.9 Hz, 
1H), 2.55–2.38 (m, 4H), 2.37–2.26 (m, 1H), 2.06 (d, J = 6.5 Hz, 3H), 2.03–1.91 (m, 2H), 1.88 (s, 3H), 
1.71–1.29 (m, 9H), 1.27 (d, J = 6.5 Hz, 3H), 1.04 (s, 15H); 13C NMR (100 MHz, CDCl3): δ = 175.5, 
175.4, 170.0, 169.8, 160.4, 160.3, 150.92, 150.85, 141.4, 141.1, 141.0, 140.9, 135.9, 134.20, 
134.18, 134.1, 129.8, 127.6, 117.2, 116.7, 113.4, 113.3, 90.5, 78.3, 78.2, 74.8, 70.7, 70.4, 68.83, 
68.80, 65.7, 65.5, 63.7, 63.1, 56.6, 45.1, 45.0, 41.4, 40.9, 40.6, 40.5, 38.4, 38.2, 38.1, 38.0, 36.95, 
36.88, 36.2, 35.9, 27.1, 24.1, 24.0, 22.4, 21.9, 21.28, 21.26, 20.5, 20.4, 19.4, 19.3, 17.8, 17.2, 17.0 
(some carbon signals of the two sets of signals expected for the two diasteroisomers are missing 
due to overlapping); IR (film): ν = 3493, 2932, 2858, 1738, 1428, 1373, 1233, 1164, 1109, 969, 822, 
742, 704, 612, 508 cm−1; HRMS (ESI): m/z: calcd. for C47H63NO8SiNa [M+Na+]: 820.4215, found: 
820.4214. 
 
Diastereomer 115b:  
[]
	
 = +25.0 (c = 1.00, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 7.67-7.58 (m, 4H), 7.46-7.28 (m, 7H), 
6.16-6.09 (m, 2H), 5.51 (ddd, J = 7.1, 4.8, 2.0 Hz, 1H), 5.16 (q, J = 6.4 Hz, 
1H), 4.98 (br s, 1H), 4.96 (br s, 1H), 3.91-3.80 (m, 1H), 3.72-3.60 (m, 1H), 
3.19 (s, 3H), 2.64-2.55 (m, 1H), 2.53-2.41 (m, 4H), 2.32 (ddd, J = 14.8, 
9.6, 2.1 Hz, 1H), 2.12-2.03 (m, 1H), 2.07 (s, 3H), 1.94 (ddd, J = 15.0, 6.9, 
2.1 Hz, 1H), 1.88 (d, J = 1.3 Hz, 3H), 1.84-1.71 (m, 1H), 1.66-1.56 (m, 2H), 
1.55-1.41 (m, 2H), 1.38-1.29 (m, 4H), 1.27 (d, J = 6.5 Hz, 3H), 1.25 (br s, 
1H), 1.10 (d, J = 7.0 Hz, 3H), 1.06 (d, J = 7.0 Hz, 3H), 1.04 (s, 9H); 13C NMR 
(100 MHz, CDCl3): δ = 175.4, 170.0, 160.3, 150.8, 141.1, 141.0, 135.9, 134.2, 134.1, 129.8, 129.7, 
127.6, 117.2, 113.4, 90.5, 78.2, 74.8, 70.7, 68.8, 65.5, 63.1, 56.6, 45.1, 41.4, 40.5, 38.2, 38.1, 36.9, 
36.2, 27.1, 24.1, 22.4, 21.3, 20.4, 19.4, 19.3, 17.8, 17.2; IR (film): ν = 3478, 2931, 2858, 1739, 1648, 
1451, 1428, 1373, 1233, 1164, 1109, 1026, 970, 902, 858, 822, 741, 704, 613, 509, 488 cm−1; MS 
(ESI) m/z (%): 820 (M+Na+, 100); HRMS (ESI): m/z: calcd. for C47H63NO8SiNa [M+Na+]: 820.4215, 
found: 820.4214. 
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6.2.7. (7S,11S)-Enigmazole A  
(8S,12S,14S)-14-((tert-Butyldimethylsilyl)oxy)-12-((tert-butyldiphenylsilyl)oxy)-8-hydroxy-14-(2-
((R,Z)-3-methoxy-2-methylbut-1-en-1-yl) oxazol-4-yl)-6-methylenetetradec-2-yn-4-yl acetate 
(111c)[74] 
Analoguos to preparation of 111a, the title compound was made by using boron tribromide (1 M in 
dichloromethane, 3.84 mL, 3.84 mmol, 1.50 equiv), (R,R)-1,2-diphenyl-
1,2-ethylenediamine bis(toluenesulfon-amide)[103b] (2.00 g, 3.84 mmol, 
1.50 equiv), racemic allyl stannane 50 (2.04 g, 4.48 mmol, 1.75 equiv), 
and aldehyde 63 (1.70 g, 2.56 mmol, 1 equiv). The crude product was 
purified by flash chromatography (hexane/ethyl acetate 10:1 grading 
to 4:1) to give 111c (2.13 g, 2.56 mmol, quant.) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 7.65–7.61 (m, 4H), 7.41–7.29 (m, 6H), 
7.10 (s, 1H), 5.48–5.43 (m, 1H), 5.20 (q, J = 6.2 Hz, 1H), 4.97 (s, 1H), 
4.93 (s, 1H), 4.82 (t, J = 6.2 Hz, 1H), 3. 86 (quint, J = 5.9 Hz, 1H), 3.54 
(br s, 1H), 3.18 (s, 3H), 2.50–2.38 (m, 2H), 2.17-2.12 (m, 1H), 2.05–1.97 (m, 6H), 1.88 (d, J = 1.3 Hz, 
3H), 1.83–1.82 (m, 3H), 1.67–1.21 (m, 8H), 1. 28 (d, J = 6.3 Hz, 3H), 1.04 (s, 9H), 0.82 (s, 9H), 0.02 
(s, 3H), −0.07 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 170.1, 160.0, 150.3, 145.0, 141.5, 136.14, 
136.11, 134.8, 134.6, 133.7, 129.6, 127.6, 116.2, 113.7, 82.4, 82.3, 76.8, 76.7, 74.9, 70.7, 69.0, 
68.8, 65.8, 63.3, 63.0, 56.6, 44.8, 44.6, 37.3, 36.8, 27.3, 26.0, 21.25, 21.21, 20.8, 19.6, 19.4, 18.3, 
17.7, 3.8, −4.3, −4.6 (some carbon signals of the two sets of signals expected for the two 
diasteroisomers are missing due to overlapping); IR (film): ν = 3468, 2931, 2857, 1741, 1428, 1371, 
1234, 1110, 837, 777, 741, 705 cm−1; MS (ESI) m/z (%): 852 (M+Na+, 100); HRMS (ESI): m/z: calcd. 
for C48H71NO7Si2Na [M++Na]: 852.4661, found: 852.4658. 
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(8S,12S,14S)-14-((tert-Butyldimethylsilyl)oxy)-12-((tert-butyldiphenylsilyl)oxy)-14-(2-((R,Z)-3-
methoxy-2-methylbut-1-en-1-yl)oxazol-4-yl)-6-methylene-8-(((2,2,2-trichloroethoxy)carbonyl) 
oxy)tetradec-2-yn-4-yl acetate (112c)[74] 
Analoguos to preparation of 112a, the title compound was made by using 111c (2.13 g, 2.56 mmol, 
1 equiv), 2,2,2-trichlorethoxycarbonyl chloride (1.06 mL, 7.68 mmol, 
3.00 equiv), 4-(dimethylamino)pyridine (31.3 mg, 0.256 mmol, 
0.10 equiv) and pyridine (1.24 mL, 15.4 mmol, 6.00 equiv). The crude 
product was purified by flash chromatography (hexane/ethyl acetate 
10:1) to give 112c (2.57 g, 2.56 mmol, quant.) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 7.64–7.60 (m, 4H), 7.41–7.30 (m, 6H), 
7.09 (s, 1H), 6.16 (s, 1H), 5.44–5.41 (m, 1H), 5.19 (q, J = 6.3 Hz, 1H), 
4.91 (s, 1H), 4.90 (s, 1H), 4.80–4.73 (m, 3H), 4.66 (dd, J = 11.8, 4.9 Hz, 
1H), 3. 87–3.81 (m, 1H), 3.18 (s, 3H), 2.47–2.45 (m, 2H), 2.35–2.20 (m, 2H), 2.04–1.96 (m, 5H), 1.89 
(d, J = 1.3 Hz, 3H), 1.82 (d, J = 2.2 Hz, 3H), 1.41–1.28 (m, 6H), 1.28 (d, J = 7.4 Hz, 3H), 1.03 (s, 9H), 
0.81 (s, 9H), 0.01 (s, 3H), −0.08 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 170.1, 160.0, 150.4, 145.0, 
139.8, 139.7, 136.1, 136.0, 135.7, 134.7, 134.4, 133.7, 129.7, 127.9, 129.8, 129.7, 117.0, 113.7, 
94.9, 78.2, 74.9, 70.4, 65.8, 63.2, 63.0, 56.6, 44.2, 41.5, 41.2, 36.5, 34.3, 27.3, 27.0, 26.0, 21.2, 
20.2, 19.6, 19.4, 18.3, 17.7, 3.83, −4.3, −4.6 (some carbon signals of the two sets of signals 
expected for the two diasteroisomers are missing due to overlapping); IR (film): ν = 2929, 2857, 
1753, 1428, 1376, 1248 1104, 1020, 970, 938, 910, 835, 819, 777, 732, 702, 610, 571, 505, 
488 cm−1; HRMS (ESI): m/z: calcd. for C51H72NO9Cl3Si2Na [M+Na+]: 1026.3703, found: 1026.3702. 
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(8S,12S,14S)-12-((tert-Butyldiphenylsilyl)oxy)-14-hydroxy-14-(2-((R,Z)-3-methoxy-2-methylbut-1-
en-1-yl)oxazol-4-yl)-6-methylene-8-(((2,2,2-trichloroethoxy)carbonyl)oxy)tetradec-2-yn-4-yl 
acetate (113c) 
Analoguos to preparation of 113a, the title compound was made by using 112c (2.57 g, 2.56 mmol, 
1 equiv) and 10-camphorsulfonic acid (512 mg, 0.512 mmol, 
0.20 equiv). The crude product was purified by flash chromatography 
(hexane/ethyl acetate 10:1 grading to 2:1) to give 113c (1.18 mg, 
1.32 mmol, 52%, 77% brsm) and recovered starting material 112c 
(843 mg, 0.838 mmol, 33%). 
1H NMR (400 MHz, CDCl3) δ = 7.60–7.67 (m, 4H), 7.43–7.36 (m, 6H), 
7.27 (s, 1H), 6.17 (s, 1H), 5.44–5.39 (m, 1H), 5.12 (q, J = 6.5 Hz, 1H), 
4.90 (s, 1H), 4.88 (s, 1H), 4.84–4.72 (m, 1H), 4.75–4.72 (m, 2H), 4.67 
(dd, J = 11.8, 4.3 Hz, 1H), 4.05–4.01 (m, 1H), 3.20 (s, 3H), 3.04 (t, J = 
3.4 Hz, 1H), 2.48–2.40 (m, 2H), 2.33–2.18 (m, 2H), 2.04 (s, 3H), 2.03–1.91 (m, 2H), 1.88 (d, J = 1.3 
Hz, 3H), 1.81 (d, J = 2.2 Hz, 3H), 1.41–1.13 (m, 6H), 1. 29 (d, J = 6.4 Hz, 3H), 1.06 (s, 9H); 13C NMR 
(100 MHz, CDCl3): δ = 170.1, 170.0, 160.6, 153.9, 150.7, 144.5, 139.6, 139.5, 136.1, 136.0, 134.3, 
133.72, 133.73, 133.1, 130.0, 129.9, 127.9, 127.8, 117.3, 117.0, 113.6, 94.8, 82.4, 82.3, 78.0, 77.8, 
76.7, 74.9, 72.91, 72.88, 66.35, 66.31, 63.1, 62.9, 56.6, 42.8, 41.5, 41.0, 36.9, 34.1, 34.0, 27.2, 
21.19, 21.17, 20.5, 20.4, 19.5, 19.46, 17.8, 3.79 (some carbon signals of the two sets of signals 
expected for the two diasteroisomers are missing due to overlapping); IR (film): ν = 3459, 3072, 
2932, 2858, 1754, 1650, 1428, 1377, 1251, 1110, 1067, 1021, 821, 737, 704, 612 cm−1; HRMS (ESI): 
m/z: calcd. for C45H58NO9Cl3SiNa [M+Na+]: 912.2838, found: 912.2844. 
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(1S,3S,7S)-11-Acetoxy-3-((tert-butyldiphenylsilyl)oxy)-1-(2-((R,Z)-3-methoxy-2-methylbut-1-en-1-
yl)oxazol-4-yl)-9-methylene-7-(((2,2,2-trichloroethoxy)carbonyl)oxy)tetradec-12-yn-1-yl (2S,4S)-
2,4-dimethylhept-5-ynoate (62c) 
Analoguos to preparation of 62a, the title compound was made by using 113c (1.75 g, 1.96 mmol, 
1 equiv), 49 (333 mg, 2.16 mmol, 1.10 equiv), triethylamine (410 µL, 
2.95 mmol, 1.50 equiv), 2,4,6-trichlorobenzoyl chloride (460 µL, 
2.95 mmol, 1.50 equiv) and 4-(dimethylamino)pyridine (240 mg, 
1.96 mmol, 1.00 equiv). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 10:1 grading to 6:1) to give 62c 
(1.95 g, 1.90 mmol, 97%) as a colorless oil. 
1H NMR (400 MHz, CDCl3): δ = 7.62–7.60 (m, 4H), 7.40–7.32 (m, 6H), 
7.19 (s, 0.5H), 7.19 (s, 0.5H), 6.14 (s, 1H), 5.89 (t, J = 6.9 Hz, 1H), 5.49–
5.42 (m, 1H), 5.10 (q, J = 6.2 Hz, 1H), 4.92 (s, 1H), 4.91 (s, 1H), 4.79–4.74 (m, 2H), 4.67 (dd, J = 12.1, 
4.8 Hz, 1H), 3.73–3.69 (m, 1H), 3.16 (s, 3H), 2.63–2.58 (m, 1H), 2.48–2.45 (m, 2H), 2.37–2.14 (m, 
6H), 2.05 (s, 1.5H), 2.04 (s, 1.5H), 1.88 (d, J = 1.4 Hz, 3H), 1.82 (d, J = 2.0 Hz, 3H), 1.74 (d, J = 2.2 Hz, 
3H), 1.70–1.63 (m, 1H), 1.47–1.30 (m, 6H), 1.28 (d, J = 6.2 Hz, 3H), 1.05 (d, J = 6.4 Hz, 3H), 1.04 (d, 
J = 6.6 Hz, 3H), 1.04 (s, 9H); 13C NMR (100 MHz, CDCl3): δ = 175.8, 170.0, 160.3, 153.9, 150.8, 
140.3, 139.7, 139.5, 136.1, 136.0, 135.2, 134.3, 134.1, 129.7, 127.7, 117.3, 117.0, 113.4, 94.8, 83.1, 
82.4, 82.3, 78.2, 77.9, 76.7, 76.4, 74.9, 69.9, 65.8, 63.1, 62.9, 56.6, 41.5, 41.2, 41.1, 39.6, 38.1, 
36.3, 34.22, 34.17, 27.2, 24.5, 21.8, 21.18, 21.16, 20.33, 20.28, 19.5, 19.3, 18.2, 17.7, 3.8, 3.6 
(some carbon signals of the two sets of signals expected for the two diasteroisomers are missing 
due to overlapping); IR (film): ν = 3073, 2960, 2931, 2858, 2821, 1753, 1737, 1650, 1547, 1449, 
1428, 1376, 1248, 1163, 1109, 1063, 1020, 970, 911, 820, 732, 703 cm−1; HRMS (ESI): m/z: calcd. 
for C54H70Cl3NO10SiNa [M+Na+]: 1048.3727, found: 1048.3728. 
  
122 Experimental Procedures 
 
(3S,5S,12S,16S,18S)-16-((tert-Butyldiphenylsilyl)oxy)-18-(2-((R,Z)-3-methoxy-2-methylbut-1-en-1-
yl)oxazol-4-yl)-3,5-dimethyl-10-methylene-2-oxo-12-(((2,2,2-trichloroethoxy)carbonyl)oxy) 
oxacyclooctadec-6-yn-8-yl acetate (114c) 
Analoguos to preparation of 114a, the title compound was made by using 62c (1.40 g, 1.36 mmol, 
1 equiv) and alkyne metathesis catalyst 116 (406 mg, 299 µmol, 
0.22 equiv). The crude product was purified by flash chromatography 
(hexane/ethyl acetate 10:1 grading to 6:1) to give 114c (1.01 g, 
1.03 mmol, 76%) and recovered starting material 62c (120 mg, 0.117 
mmol, 8.6%). 
1H NMR (600 MHz, CDCl3): δ = 7.65–7.56 (m, 4H), 7.42–7.27 (m, 6H), 7.25 
(s, 0.5H), 7.24 (s, 0.5H), 6.11 (dq, J = 2.2, 1.3 Hz, 1H), 6.03 (dt, J = 8.3, 
3.6 Hz, 1H), 5.54 (ddd, J = 6.6, 4.7, 1.7 Hz, 1H), 5.45 (ddd, J = 8.4, 5.8, 2.2 Hz, 1H), 5.13 (qd, J = 6.5, 
0.8 Hz, 1H), 5.01–4.86 (m, 3H), 4.75 (dd, J = 11.9, 6.3 Hz, 1H), 4.69 (dd, J = 11.9, 2.0 Hz, 1H), 3.86–
3.80 (m, 1H), 3.16 (s, 3H), 2.70–2.59 (m, 1H), 2.53–2.43 (m, 3H), 2.43–2.34 (m, 2H), 2.29–2.20 (m, 
1H), 2.05 (s, 1.5H), 2.04–1.97 (m, 2.5H), 1.87 (d, J = 1.5 Hz, 1.5H), 1.86 (d, J = 1.6 Hz, 1.5H), 1.70–
1.59 (m, 2H), 1.59–1.47 (m, 3H), 1.43–1.28 (m, 2H), 1.24 (d, J = 6.4 Hz, 1.5H), 1.23 (d, J = 6.5 Hz, 
1.5H), 1.11 (d, J = 7.0 Hz, 1.5H), 1.10 (d, J = 7.0 Hz, 1.5H), 1.04 (d, J = 6.9 Hz, 1.5H), 1.04 (d, 
J = 6.9 Hz, 1.5H), 1.02 (s, 4.5H), 1.01 (s, 4.5H); 13C NMR (150 MHz, CDCl3): δ = 175.6, 175.5, 169.9, 
169.8, 160.4, 153.9, 153.8, 151.0, 150.9, 140.9, 139.9, 139.6, 136.0, 134.18, 134.16, 134.15, 
134.13, 134.08, 133.98, 129.78, 129.77, 129.74, 127.7, 115.89, 115.86, 113.34, 113.30, 94.81, 
94.79, 90.8, 90.7, 78.5, 78.3, 77.9, 77.5, 76.7, 74.84, 74.83, 70.2, 70.1, 66.10, 66.08, 63.3, 63.1, 
56.6, 42.6, 41.6, 41.2, 41.0, 40.2, 39.3, 38.7, 38.5, 38.28, 38.25, 36.2, 36.1, 33.5, 33.4, 27.2, 24.4, 
24.3, 21.3, 21.24, 21.21, 20.7, 20.6, 20.5, 19.4, 19.3, 17.8, 17.6 (some carbon signals of the two 
sets of signals expected for the two diasteroisomers are missing due to overlapping); IR (film): ν = 
2932, 2858, 1739, 1428, 1377, 1247, 1162, 1106, 1065, 1021, 909, 820, 730, 612, 572, 507, 
488 cm−1; HRMS (ESI): m/z: calcd. for C50H64Cl3NO10SiNa [M+Na+]: 994.3257, found: 994.3268. 
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(3S,5S,12S,16S,18S)-16-((tert-Butyldiphenylsilyl)oxy)-12-hydroxy-18-(2-((R,Z)-3-methoxy-2-
methylbut-1-en-1-yl)oxazol-4-yl)-3,5-dimethyl-10-methylene-2-oxooxacyclooctadec-6-yn-8-yl 
acetate (229) 
Analoguos to preparation of 115a, the title compound was made by using 114c (311 mg, 
0.320 mmol, 1 equiv) and zinc dust (2.09 g, 31.9 mmol, 100 equiv, Sigma-
Aldrich®, <10 μm). The crude product was purified by flash 
chromatography (hexane/ethyl acetate 4:1) to give 229 (243 mg, 
0.304 mmol, 95%) as a colorless oil.  
A mixture of the two C7-diastereomers 229 (603 mg, 0.756 mmol) was 
separated by preparative LC (Nucleosil10-100 C18/A 10 µm, 203 mm × 
48.0 mm, MeOH/H2O, 85:15, 35 °C, 75 mL/min) to give 115c (195 mg, 
0.244 mmol, 32%) and 115d (200 mg, 0.251 mmol, 33%) as enantiopure compounds. 
Diastereomer 115c:  
[]
	
 = +31.0 (c = 1.15, CHCl3); 1H NMR (600 MHz, CDCl3): δ = 7.65–7.59 (m, 4H), 7.44–7.31 (m, 
6H), 7.30 (s, 1H), 6.16–6.13 (m, 1H), 6.09 (dd, J = 8.8, 2.9 Hz, 1H), 5.48 
(ddd, J = 9.2, 5.5, 2.2 Hz, 1H), 5.16 (qd, J = 6.5, 0.9 Hz, 1H), 5.03 (d, J = 
1.6 Hz, 1H), 4.96 (d, J = 1.6 Hz, 1H), 3.86 (tdd, J = 7.5, 5.5, 2.5 Hz, 1H), 
3.82 (ddt, J = 8.6, 4.1, 6.0 Hz, 1H), 3.19 (s, 3H), 2.66 (ddq, J = 9.7, 5.1, 
7.0 Hz, 1H), 2.52–2.43 (m, 2H), 2.42–2.35 (m, 2H), 2.27 (ddd, J = 14.9, 
8.9, 2.6 Hz, 1H), 2.08 (s, 3H), 2.07–2.01 (m, 2H), 1.89 (d, J = 1.5 Hz, 3H), 
1.72–1.64 (m, 2H), 1.56–1.49 (m, 1H), 1.43–1.34 (m, 3H), 1.34–1.28 (m, 
2H), 1.27 (d, J = 6.4 Hz, 3H), 1.13 (d, J = 7.0 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 1.05 (s, 9H) (one protic 
H missing); 13C NMR (150 MHz, CDCl3): δ = 175.6, 169.9, 160.3, 150.9, 141.5, 141.0, 135.98 (2C), 
135.97 (2C), 134.3, 134.1, 134.0, 129.8, 129.67 (2C), 127.65 (2C), 127.7, 115.4, 113.3, 90.7, 78.4, 
74.8, 70.5, 68.2, 66.1, 63.3, 56.6, 42.8, 42.6, 41.1, 38.3, 38.2, 36.4, 36.2, 27.2 (3C), 24.3, 21.3, 20.9, 
20.7, 19.4, 19.3, 17.8, 17.7; IR (film): ν = 3479, 2930, 2857, 1737, 1450, 1428, 1373, 1231, 1162, 
1105, 1066, 1022, 970, 822, 756, 703, 612, 508, 488 cm−1; HRMS (ESI): m/z: calcd. for 
C47H63NO8SiNa [M+Na+]: 820.4215, found: 820.4221. 
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Diastereomer 115d:  
[]
	
 = +1.40 (c = 1.03, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 7.67–7.57 (m, 4H), 7.44–7.28 (m, 
7H), 6.14 (s, 1H), 6.07 (dd, J = 8.6, 2.7 Hz, 1H), 5.56 (t, J = 5.7 Hz, 1H), 5.15 
(q, J = 6.4 Hz, 1H), 5.00 (br s, 1H), 4.96 (br s, 1H), 3.92–3.75 (m, 2H), 3.18 
(s, 3H), 2.77–2.60 (m, 1H), 2.56–2.39 (m, 4H), 2.27 (ddd, J = 14.9, 8.6, 2.7 
Hz, 1H), 2.13–2.04 (m, 2H), 2.03 (s, 2H), 1.89 (s, 3H), 1.75 – 1.49 (m, 4H), 
1.46–1.30 (m, 5H), 1.26 (d, J = 6.2 Hz, 3H), 1.12 (d, J = 7.0 Hz, 3H), 1.08–
1.01 (m, 12H); 13C NMR (150 MHz, CDCl3): δ = 175.3, 169.7, 160.2, 150.8, 
141.5, 140.9, 135.9 (4C), 134.2, 134.1, 133.8, 129.58, 129.56, 127.5 (4C), 
115.6, 113.2, 90.4, 78.3, 74.7, 70.3, 68.2, 66.0, 63.2, 56.4, 44.0, 41.3, 40.6, 38.5, 38.2, 36.2, 36.0, 
27.0 (3C), 24.2, 21.1, 20.8, 20.5, 19.3, 19.1, 17.6, 17.5; IR (film): ν = 3478, 2931, 2858, 1739, 1451, 
1428, 1373, 1233, 1164, 1109, 1026, 970, 822, 741, 704, 613, 509, 488 cm−1; HRMS (ESI): m/z: 
calcd. for C47H63NO8SiNa [M+Na+]: 820.4215, found: 820.4211. 
 
(1S,4S,6S,9S,11S,15S,)-11-((tert-Butyldiphenylsilyl)oxy)-9-(2-((R,Z)-3-methoxy-2-methylbut-1-en-
1-yl)oxazol-4-yl)-4,6-dimethyl-17-methylene-8,19-dioxabicyclo[13.3.1]nonadecane-3,7-dione 
(131) 
Silver hexafluoroantimonate (7.80 mg, 22.7 µmol, 0.40 equiv) and gold catalyst (S)-DTBM-MeOH-
Biphep-(AuCl) (S)-121 (12.1 mg, 11.2 µmol, 0.20 equiv) were suspended 
in anh. dichloromethane (0.50 mL) and the mixture was sonicated for 
10 min. The suspension was filtered through a plug of Celite (rinsing with 
anh. dichloromethane, 2 × 0.40 mL) into a solution of diastereomer 115c 
(45.0 mg, 56.4 µmol, 1 equiv) in anh. dichloromethane (2.0 mL). After 
stirring for 48 h, the solvent was removed under a stream of argon and 
the residue was purified by flash chromatography (hexane/ethyl acetate 
10:1 grading to 4:1) to give 117d (35.0 mg, 44.0 µmol, 78%, d.r. ≥95:5) as a colorless oil.  
 Potassium carbonate (18.2 mg, 132 µmol, 3.00 equiv) was added to a solution of 117d in 
anh. dichloromethane/methanol (2:1, 6.0 mL). After stirring for 4.5 h, the mixture was filtered 
through a plug of silica which was rinsed with methyl tert-butyl ether (10 mL). The filtrate was 
concentrated and the residue purified by flash chromatography (hexane/ethyl acetate 10:1) to 
afford 131 (31.0 mg, 41.0 µmol, 94%). 
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1H NMR (600 MHz, CDCl3): δ = 7.66–7.63 (m, 2H), 7.63–7.60 (m, 2H), 7.51 (d, J = 0.8 Hz, 1H), 7.43–
7.30 (m, 6H), 6.15 (br s, 1H), 6.00 (dd, J = 9.2, 2.4 Hz, 1H), 5.18 (dq, J = 6.4, 0.8 Hz, 1H), 4.69 (br s, 
2H), 3.81 (ddt, J = 7.5, 2.8, 6.4 Hz, 1H), 3.72–3.66 (m, 1H), 3.20 (s, 3H), 3.12 (ddt, J = 11.8, 9.7, 2.2 
Hz, 1H), 2.78–2.69 (m, 1H), 2.62 (dd, J = 14.5, 8.4 Hz, 1H), 2.53 (ddq, J = 10.1, 4.6, 6.9 Hz, 1H), 2.40 
(dd, J = 14.5, 2.7 Hz, 1H), 2.36–2.28 (m, 1H), 2.16–2.11 (m, 2H), 2.07 (dd, J = 13.4, 2.3 Hz, 1H), 1.98 
(ddd, J = 14.9, 7.6, 2.6 Hz, 1H), 1.89 (d, J = 1.5 Hz, 3H), 1.89–1.81 (m, 1H), 1.72 (ddd, J = 14.6, 10.3, 
4.7 Hz, 1H), 1.59 (s, 1H), 1.56–1.41 (m, 4H), 1.27 (d, J = 6.5 Hz, 3H), 1.27–1.24 (m, 1H), 1.23–1.16 
(m, 1H), 1.08 (d, J = 6.9 Hz, 3H), 1.04 (s, 9H), 0.95 (d, J = 7.0 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ = 
213.3, 175.6, 160.2, 150.6, 144.5, 141.3, 136.01 (2C), 135.99 (2C), 134.4, 134.34, 134.26, 129.7 
(2C), 127.7 (2C), 127.6 (2C), 113.5, 108.9, 78.7, 75.1, 74.8, 71.0, 65.9, 56.6, 46.0, 45.4, 41.1, 40.6, 
39.1, 38.0, 37.7, 37.0, 36.4, 27.2 (3C), 21.8, 19.5, 19.3, 17.8, 17.7, 17.5; IR (film): ν = 2962, 2933, 
2858, 1736, 1709, 1428, 1362, 1166, 1109, 704, 512 cm−1; HRMS (ESI): m/z: calcd. for 
C45H61NO7SiNa [M+Na+]: 778.4110, found 778.4102. 
 
(7S,11S)-Enigmazole A (132) 
Sodium borohydride (6.21 mg, 164 µmol, 4.00 equiv) was added at −5 °C to a solution of ketone 
131 (31.0 mg, 41.0 µmol, 1 equiv) in anh. methanol (1.4 mL). After 
stirring for 2.5 h at this temperature, excess reagent was quenched by 
the addition of aq. phosphate buffer solution (pH 7, 5 mL) and the 
solution was allowed to warm to 23 °C. The aq. layer was extracted 
with dichloromethane (5 x 10 mL) and the combined organic layers 
were dried over magnesium sulfate, filtered and concentrated. The 
crude product was purified by flash chromatography (hexane/ethyl 
acetate 10:1 grading to 2:1) to yield 230 (30.8 mmol, 40.6 µmol, 61%) as a single diastereomer. 
 A solution of tetrazole (0.45 M in acetonitrile, 422 µL, 190 µmol, 15.0 equiv) was added at 
0 °C to a solution of alcohol 230 (9.60 mg, 12.7 µmol, 1 equiv) and iPr2NP(OFm)2[166] (132 mg, 
253 µmol, 20.0 equiv) in anh. acetonitrile (0.25 mL) and anh. dichloromethane (0.70 mL). The 
mixture was stirred for 1 h at 23 °C, before it was cooled to 0 °C and aq. hydrogen peroxide (35% 
w/w, 246 µL, 2.53 mmol, 200 equiv) was added. After stirring for additional 15 min, the reaction 
was quenched by the addition of aq. sat. sodium hydrogen carbonate solution (5 mL). The layers 
were separated and the aq. layer was extracted with dichloromethane (5 × 3 mL). The combined 
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organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. 
The crude product was purified by flash chromatography (hexane/ethyl acetate 4:1 grading to 1:1) 
and subsequent preparative LC (Kromasil 100-5C18 5µm, 150 mm × 30.0 mm, 100% acetonitrile, 
35 °C, 35 mL/min) to afford fully protected (7S,11S)-enigmazole 231 (11.1 mg, 9.00 µmol, 73%). 
Potassium carbonate (18.2 mg, 131 µmol, 10.0 equiv) was added to a solution of the 
protected enigmazole 231 (15.7 mg, 13.1 µmol, 1 equiv) in a mixture of methanol/water (10:1, 
3.3 mL). After stirring at 23 °C for 18 h, the suspension was diretly loaded onto a C18-cartridge 
(Strata® C18-U, 55 µm, 70 Å, 500 mg/6 mL) and the salts were eluted with water, followed by 
elution of the organic fraction with methanol. The combined organic fractions were concentrated 
and the residue pufiried by preparative LC (Kromasil 100-5C18 5µm, 150 mm × 21.2 mm, 
acetonitrile/water 70:30, 35 °C, 20 mL/min) to afford 232 (8.00 mg, 9.55 µmol, 73%). 
A solution of tetrabutylammonium fluoride (1 M in tetrahydrofuran, 190 µL, 191 µmol, 
50.0 equiv) was added to a solution of the TBDPS-protected 232 (3.20 mg, 3.80 µmol, 1 equiv) in 
anh. tetrahydrofuran (0.5 mL) and acetic acid (17.2 µL, 286 µmol, 75.0 equiv). After stirring at 23 
°C for 3 d, the solution was diluted with water (1 mL) and loaded onto a C18-cartridge (Strata® C18-
U, 55 µm, 70 Å, 500 mg/6 mL). The salts were eluted with water, followed by elution of the organic 
fraction with methanol. The combined organic fractions were concentrated and the residue was 
purified by preparative LC (Kromasil 100-5C18 5µm, 150 mm × 21.2 mm, methanol/aq. TEAA 
pH 8.0, 70:30 grading to 100% methanol over 10 min, 35 °C, 20 mL/min) to obtain 132 (1.00 mg, 
2.00 µmol, 44%) and recovered starting material 232 (1.50 mg, 2.00 µmol, 42%).  
[]
	
 = −7.00 (c = 0.10, CHCl3); 1H NMR (600 MHz, MeOD): δ = 7.70 (s, 1H), 6.22 (d, J = 1.5 Hz, 1H), 
5.95 (dd, J = 9.4, 2.9 Hz, 1H), 5.25 (qd, J = 6.5, 0.9 Hz, 1H), 4.71–4.65 (m, 2H), 4.39 (br s, 1H), 3.80 
(4d, J = 8.5, 7.8, 5.0, 3.6 Hz, 1H), 3.55–3.48 (m, 1H), 3.30–3.27 (m, 1H),3.21 (s, 3H), 2.90–2.82 (m, 
1H), 2.39 (ddd, J = 13.8, 9.6, 3.6 Hz, 1H), 2.25–2.18 (m, 1H), 2.15–2.13 (m, 2H), 2.08–2.01 (m, 2H), 
2.00–1.93 (m, 3H), 1.89 (s, 3H), 1.86–1.75 (m, 3H), 1.75–1.68 (m, 1H), 1.60 (qui, J = 7.0 Hz, 2H), 
1.50–1.38 (m, 3H), 1.28 (d, J = 6.5 Hz, 3H), 1.14 (d, J = 6.9 Hz, 3H), 0.96 (d, J = 6.6 Hz, 3H) (3 protic 
H missing); 13C NMR (150 MHz, MeOD): δ = 177.6, 161.8, 152.5, 147.1, 142.3, 136.1, 114.0, 108.2, 
79.6, 76.6, 76.2, 74.8, 68.8, 66.6, 56.8, 49.6, 42.2, 41.9, 41.5, 40.1, 39.6, 39.1, 37.4, 36.1, 35.7, 
35.6, 33.1, 30.8, 21.9, 19.5, 18.2, 17.6, 16.3, 14.4, 13.9; IR (film): ν = 3379, 2924, 2854, 1713, 1652, 
1595, 1455, 1378, 1261, 1094, 972, 808, 759, 546 cm−1; HRMS (ESI): m/z: calcd. for C29H45NO10P 
[M−H−]: 598.2787, found: 598.2793.  
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(1S,4S,6S,9S,11S,15S,E)-11-((tert-Butyldiphenylsilyl)oxy)-9-(2-((R,Z)-3-methoxy-2-methylbut-1-
en-1-yl)oxazol-4-yl)-4,6-dimethyl-17-methylene-7-oxo-8,19-dioxabicyclo[13.3.1]nonadec-2-en-3-
yl acetate (117c) 
1H NMR (400 MHz, CDCl3): δ = 7.64–7.56 (m, 4H), 7.43–7.29 (m, 6H), 
7.17 (s, 1H), 6.15–6.12 (m, 1H), 5.99 (dd, J = 7.0, 3.3 Hz, 1H), 5.22 (d, 
J = 7.7 Hz, 1H), 5.14 (q, J = 6.4 Hz, 1H), 4.94 (d, J = 4.2 Hz, 0H), 4.74–
4.67 (m, 2H), 3.97 (ddd, J = 10.7, 7.7, 2.5 Hz, 1H), 3.91 (dt, J = 6.9, 3.4 
Hz, 1H), 3.24–3.21 (m, 1H), 3.18 (s, 3H), 2.92 (dt, J = 9.7, 6.5 Hz, 1H), 
2.62 (p, J = 6.4 Hz, 1H), 2.31 (dt, J = 13.5, 1.8 Hz, 1H), 2.22 (ddd, J = 
15.0, 7.0, 3.3 Hz, 1H), 2.13 (s, 3H), 2.11–1.93 (m, 2H), 1.88 (d, J = 1.5 Hz, 3H), 1.76 (dt, J = 13.9, 5.7 
Hz, 1H), 1.65–1.40 (m, 4H), 1.39–1.29 (m, 2H), 1.26 (d, J = 6.5 Hz, 3H), 1.11 (d, J = 6.9 Hz, 3H), 1.03 
(s, 3H), 1.00 (s, 9H), 0.93 (d, J = 6.8 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ = 175.7, 169.2, 160.2, 
154.1, 150.6, 144.3, 140.6, 135.8 (4C), 134.3, 134.1, 133.9, 129.53, 129.50, 127.45 (2C), 127.43 
(2C), 119.8, 113.3, 108.7, 77.9, 74.7, 73.6, 70.3, 65.5, 56.5, 41.3, 41.2, 38.5, 38.3, 37.4, 36.2, 36.08, 
34.03, 26.9 (3C), 21.0, 20.7, 19.2, 19.1, 17.8, 17.6, 16.9. 
 
(1S,4S,6S,9S,11S,15S)-11-((tert-Butyldiphenylsilyl)oxy)-3-hydroxy-9-(2-((R,Z)-3-methoxy-2-
methylbut-1-en-1-yl)oxazol-4-yl)-4,6-dimethyl-17-methylene-8,19-dioxabicyclo[13.3.1] 
nonadecan-7-one (230) 
1H NMR (600 MHz, CDCl3): δ = 7.63–7.57 (m, 4H), 7.40–7.34 (m, 2H), 
7.34–7.28 (m, 4H), 7.26 (s, 1H), 6.13 (d, J = 2.2 Hz, 1H), 5.90 (dd, J = 7.8, 
4.7 Hz, 1H), 5.11 (q, J = 6.4 Hz, 1H), 4.65 (dq, J = 7.4, 2.0 Hz, 2H), 3.88 
(qd, J = 6.4, 4.4 Hz, 1H), 3.79 (td, J = 6.1, 3.1 Hz, 1H), 3.29 (ddt, J = 11.5, 
9.0, 2.7 Hz, 1H), 3.15 (s, 3H), 3.13–3.07 (m, 1H), 2.63–2.56 (m, 1H), 2.50 
(br s, 1H), 2.36 (ddd, J = 14.5, 8.0, 4.2 Hz, 1H), 2.10 (dt, J = 13.3, 2.1 Hz, 
1H), 2.06–1.97 (m, 3H), 1.94–1.87 (m, 1H), 1.86 (d, J = 1.5 Hz, 3H), 1.82 (ddd, J = 13.9, 9.9, 3.5 Hz, 
1H), 1.76–1.68 (m, 2H), 1.68–1.52 (m, 2H), 1.46–1.30 (m, 6H), 1.24 (d, J = 6.5 Hz, 3H), 1.05 (d, J = 
7.1 Hz, 3H), 0.99 (s, 9H), 0.81 (d, J = 6.8 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ = 176.2, 160.2, 150.6, 
145.1, 140.7, 136.05 (2C), 136.04 (2C), 134.8, 134.5, 134.4, 129.64, 129.63, 127.6 (4C), 113.5, 
108.4, 78.4, 76.6, 74.9, 70.8, 69.7, 66.1, 56.6, 41.3, 41.1, 40.3, 39.5, 37.3, 37.0, 36.0, 35.5, 33.6, 
29.9, 27.2 (3C), 21.4, 19.4, 19.3, 17.7, 16.1, 14.5. 
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(1S,4S,6S,9S,11S,15S)-11-((tert-Butyldiphenylsilyl)oxy)-9-(2-((R,Z)-3-methoxy-2-methylbut-1-en-
1-yl)oxazol-4-yl)-4,6-dimethyl-17-methylene-7-oxo-8,19-dioxabicyclo[13.3.1]nonadecan-3-yl 
dihydrogen phosphate (232) 
1H NMR (600 MHz, MeOD): δ =7.67–7.64 (m, 2H), 7.63–7.60 (m, 
2H), 7.49 (s, 1H), 7.45–7.32 (m, 6H), 6.18 (d, J = 2.2 Hz, 1H), 5.97 
(dd, J = 8.9, 3.1 Hz, 1H), 5.20 (q, J = 6.4 Hz, 1H), 4.68 (q, J = 1.9 Hz, 
1H), 4.66 (q, J = 2.0 Hz, 1H), 4.26 (tt, J = 7.9, 3.8 Hz, 1H), 3.96 (ddt, 
J = 11.6, 7.9, 3.2 Hz, 1H), 3.57–3.45 (m, 1H), 3.20–3.14 (m, 1H), 
3.14 (s, 3H), 2.77 (ddd, J = 9.8, 6.9, 5.1 Hz, 1H), 2.31 (ddd, J = 14.7, 
8.9, 3.1 Hz, 1H), 2.21–2.16 (m, 1H), 2.10–1.89 (m, 7H), 1.88 (d, J = 1.5 Hz, 3H), 1.75–1.64 (m, 2H), 
1.62–1.52 (m, 2H), 1.52–1.43 (m, 2H), 1.37–1.26 (m, 1H), 1.24 (d, J = 6.5 Hz, 3H), 1.22–1.18 (m, 
1H), 1.06 (d, J = 6.9 Hz, 3H), 1.03 (s, 9H), 0.83 (d, J = 6.7 Hz, 3H) (2 protic H missing); 13C NMR 
(150 MHz, MeOD): δ = 177.6, 161.5, 152.3, 147.0, 142.1, 137.02 (2C), 136.96 (2C), 136.0, 135.4, 
135.2, 130.9, 130.8, 128.7 (2C), 128.6 (2C), 114.1, 108.3, 79.1, 76.24, 76.15, 75.6 (d, J = 6.3 Hz) , 
71.9, 66.4, 56.8, 49.8, 41.9, 41.9, 40.6, 40.0, 39.5, 38.9, 37.8, 36.4, 35.8 (d, J = 6.6 Hz), 27.6 (3C), 
21.7, 20.1, 19.5, 17.7, 17.6, 16.6. 
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6.3. Rhizoxin D 
6.3.1. The Western Fragment 
(2S,3S,5S)-5-((tert-Butyldimethylsilyl)oxy)-3-hydroxy-N-methoxy-N,2-dimethyldeca-6,8-
diynamide (214a)[128] 
Trimethylaluminum (2 M in toluene, 7.83 mL, 16.7 mmol, 2.00 equiv) was added dropwise over 
15 min at 0 °C to a solution of freshly dried N,O-dimethylhydroxylamin-
hydrochloride (1.56 g, 16.0 mmol, 2.05 equiv) in anh. dichloromethane 
(100 mL). The mixture was stirred for 30 min at 0 °C and additional 
30 min at 23 °C before it was cooled to 0 °C. A solution of lactones 213a/b (2.40 g, 7.83 mmol, 
1 equiv) in anhydrous dichloromethane (20 mL) was added over 15 min and the cooling bath was 
removed. After stirred for 1 h at 23 °C, excess reagent was quenched by the addition of sat. aq. 
sodium potassium tartrate solution (100 mL). The mixture was stirred for 1 h until clean phase 
separation was observed. The aq. layer was diluted with ethyl acetate (150 mL) and the layers 
were separated. The aq. layer was extracted with ethyl acetate (3 x 150 mL) and the combined 
organic layers were dried over magnesium sulfate, filtered and concentrated. The crude product 
was purified by flash chromatography (hexane/ethyl acetate 4:1) yielding the desired isomer 214a 
(1.90 g, 5.17 mmol, 66%) and the undesired isomer 214b (274 mg, 0.745 mmol, 10%). 
major-isomer (214a)[128] 
[]
	
 = −44.6 (c = 1.00, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 4.77–4.68 (m, 1H), 3.90 (ddd, J = 8.1, 
5.6, 2.6 Hz, 1H), 3.71 (s, 3H), 3.58 (d, J = 7.1 Hz, 1H), 3.19 (s, 3H), 2.96–2.83 (m, 1H), 1.93 (d, J = 1.0 
Hz, 3H), 1.85 (ddd, J = 13.9, 9.0, 2.3 Hz, 1H), 1.73 (ddd, J = 13.7, 10.2, 3.0 Hz, 1H), 1.22 (d, J = 7.0 
Hz, 3H), 0.90 (s, 9H), 0.16 (s, 3H), 0.13 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = δ 177.1, 76.7, 76.6, 
70.1, 69.3, 63.9, 61.6, 60.3, 43.9, 40.2, 31.8, 25.8(3C), 18.2, 14.8, 4.3, −4.6, −5.2; IR (film): ν = 
2956, 2929, 2857, 1641, 1462, 1389, 1252, 1089, 996, 838, 811, 780 cm−1; MS: m/z calcd for 
C19H33NO4SiNa [M+Na+]: 390.2077, found 390.2071. 
minor-isomer (214b) 
[]
	
 = −51.9 (c = 1.00, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 4.69 (t, J = 7.5 Hz, 1H), 3.88 (dtd, J = 
9.3, 6.0, 3.8 Hz, 1H), 3.71 (s, 3H), 3.58 (d, J = 6.5 Hz, 1H), 3.20 (s, 3H), 2.98–2.90 (m, 1H), 1.93 (d, J = 
1.0 Hz, 3H), 1.89–1.83 (m, 2H), 1.21 (d, J = 7.1 Hz, 3H), 0.89 (s, 9H), 0.16 (s, 3H), 0.13 (s, 3H); 
13C NMR (100 MHz, CDCl3): δ = 177.0, 77.0, 76.0, 71.6, 70.3, 64.0, 62.3, 61.7, 44.0, 40.4, 30.4, 
OH
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25.9(3C), 18.3, 14.7, 4.5, −4.4, −4.9; IR (film): ν = 2956, 2930, 2857, 1639, 1463, 1389, 1253, 1082, 
994, 868, 836, 779 cm−1; MS: m/z calcd for C19H33NO4SiNa [M+Na+]: 390.2077, found 390.2071. 
 
(2S,3S,5S)-5-((tert-Butyldimethylsilyl)oxy)-N-methoxy-N,2-dimethyl-3-((trimethylsilyl)oxy)deca-
6,8-diynamide (221) 
Freshly distilled trimethylsilyl chloride (373 µL, 2.94 mmol, 1.20 equiv) was added at 0 °C to a 
solution of Weinreb amide 214a (901 mg, 2.45 mmol, 1 equiv), 
4-dimethylaminopyridine (29.9 mg, 0.245 mmol, 10 mol%) and 
triethylamine (512 µL, 3.68 mmol, 1.50 equiv) in anh. dichloromethane 
(20 mL). After stirring for 1 h at 0 °C, the reaction mixture was allowed to warm to 23 °C. After 
additional 2 h, excess reagent was quenched by the addition of aq. phosphate buffer solution 
(pH 7, 20 mL). The layers were separated and the aq. layer was extracted with methyl tert-butyl 
ether (3 × 25 mL). The combined organic layers were dried over magnesium sulfate, filtered and 
concentrated to yield the title compound (1.08 g, 2.45 mmol, quant.) as a colorless liquid. 
[]
	
 = −4.90 (c = 0.65, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 4.59–4.52 (m, 1H), 4.11 (ddd, J = 7.9, 
7.9, 2.6 Hz, 1H), 3.70 (s, 3H), 3.16–3.09 (m, 1H), 3.17 (s, 3H), 1.93 (d, J = 0.9 Hz, 3H), 1.93–1.85 (m, 
1H), 1.77 (ddd, J = 14.1, 8.2, 4.1 Hz, 1H), 1.06 (d, J = 6.9 Hz, 3H), 0.89 (s, 9H), 0.17 (s, 3H), 0.14 (s, 
3H), 0.10 (s, 9H); 13C NMR (100 MHz, CDCl3): δ = 175.4, 77.0, 76.9, 70.3, 70.2, 64.0, 61.5, 59.8, 43.4, 
41.8, 32.1, 26.0 (3C), 18.2, 12.5, 4.5, 0.6 (3C), −3.6, −4.3; IR (film): ν = 2957, 2858, 1664, 1463, 
1377, 1250, 1093, 1042, 840, 778 cm−1; MS: m/z calcd for C22H42O4Si2 [M+H+]: 440.2647, found 
440.2642. 
 
0.30 M CeCl3·2LiCl solution[145] 
A suspension of anh. lithium chloride (1.29 g, 0.030 mmol, 2.00 equiv) and commercially available 
anh. cerium(III) chloride (3.74 g, 0.015 mmol, 1 equiv) in anh. tetrahydrofuran (50 mL) was stirred 
for 2 d at 23 °C. The stirring was stopped to allow undissolved material to settle and molecular 
sieves (3 Å, pellets) were added to the colorless suspension. After 1 d, the solution was ready to be 
used in the following reactions.  
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Direct addition to the β-lactone 213[128] 
(9S,10S,12S,E)-10-Hydroxy-2,2,3,3,7,9,14,14,15,15-decamethyl-12-(penta-1,3-diyn-1-yl)-4,13-
dioxa-3,14-disilahexadec-6-en-8-one (216) 
n-BuLi (1.6 M in hexanes, 67.3 µL, 0.108 mmol, 2.20 equiv) was added dropwise at −78 °C to a 
solution of alkenyl iodide 215 (30.6 mg, 98.0 µmol, 2.00 equiv) 
in anh. diethyl ether (500 µL). After stirring for 30 min, the 
solution was transferred at −78 °C via cannula into a solution 
of CeCl3·2LiCl (0.21 M in diethyl ether, 2.00 mL, 0.425 mmol, 8.70 equiv). The colorless suspension 
was stirred for 2 h at −78 °C before a solution of lactone 213 (15.0 mg, 49.0 µmol, 1 equiv) in anh. 
diethyl ether (400 µL) was added. After stirring for 1 h, the mixture was diluted with ethyl acetate 
(5 mL) and excess reagent was quenched by the addition of water (10 mL). The layers were 
separated and the aq. layer was extracted with ethyl acetate (3 × 10 mL). The combined organic 
layers were dried over magnesium sulfate, filtered and concentrated. The crude product was 
purified by flash chromatography (hexane/ethyl acetate 10:1) and subsequent preparative LC 
(Kromasil 100-5C18 5 µm, 150 mm × 30.0 mm, MeOH/H2O, 90:10, 35 °C, 35 mL/min) to give the 
title compound (6.90 mg, 14.0 µmol, 29%) 
[]
	
 = −12.3 (c = 0.50, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 6.67 (td, J = 5.1, 1.4 Hz, 1H), 4.74–
4.70 (m, 1H), 4.45–4.41 (m, 2H), 4.04 (dtd, J = 10.2, 5.9, 2.1 Hz, 1H), 3.30 (p, J = 6.8 Hz, 1H), 3.23 (d, 
J = 5.9 Hz, 1H), 1.93 (d, J = 1.0 Hz, 3H), 1.83 (ddd, J = 14.0, 8.3, 2.2 Hz, 1H), 1.73 (d, J = 1.2 Hz, 3H), 
1.14 (d, J = 7.2 Hz, 3H), 0.92 (s, 9H), 0.90 (s, 9H), 0.16 (s, 3H), 0.13 (s, 3H), 0.10 (m, 6H); 13C NMR 
(100 MHz, CDCl3): δ = 206.4, 143.8, 135.5, 77.0, 76.3, 70.6, 69.7, 64.0, 61.2, 60.9, 44.2, 43.1, 
26.0(3C), 25.9(3C), 18.5, 18.3, 15.7, 11.7, 4.5, −4.5, −5.1, −5.1(2C); IR (film): ν = 2955, 2930, 2857, 
1663, 1463, 1254, 1103, 1061, 1006, 836, 778 cm−1; MS: m/z calcd for C27H48O4Si2Na [M+Na+]: 
515.2988, found 515.2983.  
 
Using the unprotected Weinreb amide 214a: 
Freshly titrated t-BuLi (2.18 M in pentane, 2.45 mL, 5.33 mmol, 9.80 equiv) was carefully added to 
anh. diethyl ether (3 mL) at −78 °C (color change to yellow). After stirring for 10 min, a solution of 
alkenyl iodide 215 (811 mg, 2.72 mmol, 5.00 equiv) in anh. diethyl ether (2 mL) was added 
dropwise over 10 min. Stirring was continued for 30 min at −78 °C. In parallel, a solution of 
CeCl3·2LiCl (0.30 M in tetrahydrofuran, 7.25 mL, 2.18 mmol, 4.00 equiv) was added at −78 °C to a 
132 Experimental Procedures 
 
solution of Weinreb amide 214a (200 mg, 0.544 mmol, 1 equiv) in anh. tetrahydrofuran (3 mL). 
After 5 min, the organolithium-solution was added via cannula dropwise to the mixture causing a 
color change to deep orange. After stirring for 4 h at −78 °C, the reaction was quenched by the 
addition of sat. aq. ammonium chloride solution (10 mL). The mixture was allowed to warm to 23 
°C, before the layers were separated and the aq. layer was extracted with ethyl acetate (3 × 15 
mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated. 
The crude product was purified by flash chromatography (hexane/ethyl acetate 10:1) to give the 
title compound (140 mg, 0.292 mmol, 54%) and recovered starting material 214a (37.0 mg, 
0.101 mmol, 19%). 
 
Using the TMS-protected Weinreb amide 221: 
Freshly titrated t-BuLi (2.18 M in pentane, 5.62 mL, 12.3 mmol, 5.00 equiv) was added to anh. 
tetrahydrofuran at −78 °C (color change to yellow). After 10 min, alkenyl iodide 215 (1.91 g, 
6.13 mmol, 2.50 equiv) was added dropwise and stirring was continued for 30 min at −78 °C. In 
parallel, a solution of CeCl3·2LiCl (0.30 M in tetrahydrofuran, 16.3 mL, 4.90 mmol, 2.00 equiv) was 
added at −78 °C to a solution of Weinreb amide 221 (1.08 g, 2.45 mmol, 1 equiv) in anh. 
tetrahydrofuran (25 mL). After 5 min, the solution of 215 was added via cannula dropwise to the 
mixture causing a color change to deep orange. After stirring for 1.5 h at −78 °C, the reaction was 
quenched by the addition of aq. phosphate buffer solution (pH 7, 50 mL). The mixture was allowed 
to warm to 23 °C before the layers were separated and the aq. layer was extracted with methyl 
tert-butyl ether (3 × 50 mL). The combined organic layers were dried over magnesium sulfate, 
filtered and concentrated. 
Camphorsulfonic acid (56.9 mg, 0.245 mmol, 10 mol%) was added at 0 °C to a solution of the 
residue in anh. dichloromethane (50 mL) and anh. methanol (10 mL). After stirring for 5 min, 
excess reagent was neutralized by the addition of aq. phosphate buffer solution (pH 7, 50 mL). The 
layers were separated and the aq. layer was extracted with methyl tert-butyl ether (3 × 50 mL). 
The combined organic layers were dried over magnesium sulfate, filtered and concentrated. 
Purification of the crude product by flash chromatography (hexane/ethyl acetate 20:1 grading to 
10:1) afforded the desired product 216 (1.00 g, 2.02 mmol, 83%).  
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(5S,7S,8R,9R,E)-9-Hydroxy-2,2,3,3,8,10,14,14,15,15-decamethyl-5-(penta-1,3-diyn-1-yl)-4,13-
dioxa-3,14-disilahexadec-10-en-7-yl 4-nitrobenzoate (217) 
4-Nitrobenzaldehyde (548 mg, 3.63 mmol, 3.00 equiv) was added at −25 °C to a solution of 
compound 216 (596 mg, 1.21 mmol, 1 equiv) in anh. 
tetrahydrofuran (degassed, 18 mL). After stirring for 10 min, a 
solution of samarium(II) iodide (0.10 M in tetrahydrofuran, 
2.42 mL, 0.242 mmol, 20 mol%) was added and the mixture was stirred in the dark at −25 °C. The 
progress of the reaction was followed by HPLC-MS (Zorbax Eclipse Plus C18, 125 × 4.6 mm, 1.8 µm, 
methanol/water 95:5). After complete consumption of the starting material (approx. 3 h) sat. aq. 
sodium hydrogen carbonate solution (20 mL) was added. The layers were separated and the aq. 
layer was extracted with methyl tert-butyl ether (3 × 50 mL). The combined organic layers were 
dried over magnesium sulfate, filtered and concentrated. The residue was diluted with hexane 
(10 mL) and the supernatant containing the product was carefully removed from precipitated 
benzaldehyde. This procedure was repeated three times. The combined organic layers were 
concentrated and the crude product was purified by flash chromatography to obtain 217 (635 mg, 
0.986 mmol, 82%) as yellowish oil. 
[]
	
 = −7.50 (c = 1.00, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 8.32–8.27 (m, 2H), 8.24–8.19 (m, 
2H), 5.64 (t, J = 6.3 Hz, 1H), 5.24 (q, J = 6.2 Hz, 1H), 4.44 (t, J = 6.5 Hz, 1H), 4.24 (qd, J = 13.0, 6.1 Hz, 
2H), 3.93 (t, J = 4.4 Hz, 1H), 2.15–2.10 (m, 3H), 2.00 (d, J = 3.5 Hz, 1H), 1.88 (d, J = 0.9 Hz, 3H), 1.67–
1.64 (m, 3H), 0.97 (d, J = 6.9 Hz, 3H), 0.90 (s, 9H), 0.85 (s, 9H), 0.07 (s, 12H); 13C NMR (100 MHz, 
CDCl3): δ = 164.7, 150.8, 150.1 136.4, 135.7, 131.0 (2C), 126.9, 123.7 (2C), 77.3, 76.1, 76.1, 74.5, 
70.1, 63.7, 60.2, 60.1, 39.7, 39.4, 26.1 (3C), 25.9 (3C), 18.2, 13.0, 9.5, 4.4, −4.3, −5.0, −5.0, −5.2; IR 
(film): ν = 2955, 2929, 2857, 1723, 1530, 1471, 1348, 1277, 1101, 1014, 837, 779, 720 cm−1; MS: 
m/z calcd for C34H53NO7Si2Na [M+Na+]: 666.3254, found 666.3253. 
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6.3.2. The Eastern Fragment 
Penta-1,3-diyne (170)[136b] 
Ammonia (300mL) was condensed into a 1 L three-necked-cooling flask at −78 °C equipped with a 
mechanical stirrer and an addition funnel. The solution was allowed to warm to 
−47 °C, before a catalytic amount of Fe(NO3)3·9H2O (400 mg) was added. Small pieces 
of sodium (20.8 g, 905 mmol, 3.00 equiv) were added one by one, awaiting vanish of the blue color 
of the solution. After the sodium was completely dissolved, the 1,4-dichloro-2-butyne (29.5 mL, 
302 mmol, 1 equiv) was added over 45 min.e The mixture became a thick suspension and stirring 
was continued for another 15 min at −47 °C, before methyl iodide (26.3 mL, 142 mmol, 1.40 equiv) 
was added over 20 min via a cannula.f The mixture became liquid again and stirring was continued 
for 15 min. The flask was attached to a cooling trap and the mixture was allowed to slowly warm 
to 23 °C. Undecane (150 mL) was added in several portions (cooling trap still attached). After 
stirring for 30 min, the mixture was poured onto ice (300 mL). The layers were separated and the 
aq. layer was extracted with undecane (7 × 35 mL). The combined organic layers were washed 
with aq. hydrochloric acid (2 N, 250 mL), dried over magnesium sulfate and filtered. The product 
was distilled off from the filtrate (25–50 °C, 10 mbar, long Vigreux column, the dist. bridge cooled 
to 0 °C and the collection flask to −78 °C) to give diyne 170 (95% in undecane, 10.3 g, 153 mmol, 
51%) as a colorless liquid.  
1H NMR (400 MHz, CDCl3): δ = 1.93–1.91 (m, 4H); 13C NMR (100 MHz, CDCl3): δ = 74.3, 68.6, 64.0 
(2C), 4.2. 
 
(2S,3R)-3-Methylocta-4,6-diyne-1,2-diol (204a) 
n-BuLi (1.6 M in hexanes, 44.4 mL, 71.0 mmol, 2.00 equiv) was added dropwise over 30 min at 
−78 °C to a solution of diyne 170 (95% in decane, 5.27 g, 78.1 mmol, 2.20 equiv) 
in anh. dichloromethane (200 mL). After stirring for 30 min, the mixture was 
warmed to 0 °C and diethylaluminium chloride (25 wt% in toluene, 35.7 mL, 
71.0 mmol, 2.00 equiv) was added. After stirring for 3 h at 0 °C, a solution of 
epoxide 169[131] (3.12 g, 35.5 mmol, 1 equiv) in anh. dichloromethane (14 mL) was added over 
15 min. The reaction was left to proceed overnight at 0 °C before excess reagent was quenched by 
                                                          
e At each step the reaction was so exothermic, that the evaporation of ammonia gas could be observed. 
Slow addition prevented the evaporation of product. 
f
 The cannula was longing directly above the surface of the reaction mixture to avoid exposure of the methyl 
iodide to ammonia gas. 
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the careful addition of aq. hydrochloric acid (1.0 N, 150 mL) and sat. aq. potassium sodium tartrate 
solution (150 mL). The biphasic mixture was stirred for 4 h until the two layers could be separated. 
The aq. layer was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were 
dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification of 
the crude product by flash chromatography (hexane/ethyl acetate 4:1 grading to 1:1) afforded diol 
204a (5.12 g, 33.6 mmol, 95%). 
[]
	
 = +53.0 (c = 1.79, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 3.84 (ddd, J = 11.0, 6.6, 3.1 Hz, 1H), 
3.69 (ddd, J = 11.2, 6.9, 4.6 Hz, 1H), 3.59 (dddd, J = 10.4, 7.2, 5.6, 3.2 Hz, 1H), 2.66 (qdq, J = 7.0, 7.0, 
1.1 Hz, 1H), 2.41 (br s, 1H), 1.96 (br s, 1H), 1.91 (d, J = 1.1 Hz, 3H), 1.26 (d, J = 7.0 Hz, 3H); 13C NMR 
(100 MHz, CDCl3): δ = 74.9, 74.8 (2C), 67.9, 64.7, 64.2, 30.3, 16.8, 4.3; IR (film): ν = 3345, 2940, 
1453, 1053, 563 cm−1; MS: m/z calcd for C9H12O2Na [M+Na+]: 175.0730, found 175.0730. 
 
(2S,3R)-2-Hydroxy-3-methylocta-4,6-diyn-1-yl 4-methylbenzenesulfonate (203) 
Dibutyltin(IV) oxide (29.3 mg, 0.118 mmol, 10 mol%) was added to a solution of diol 204a (179 mg, 
1.18 mmol, 1 equiv) in anh. dichloromethane (6 mL). After stirring for 5 min, 
triethylamine (180 µL, 1.30 mmol, 1.10 equiv) and 4-toluolsulfonyl chloride 
(246 mg, 1.30 mmol, 1.10 equiv) were added. Stirring was continued for 18 h, 
before the excess reagent was quenched by the addition of sat. aq. ammonium 
chloride solution (10 mL). The layers were separated and the aq. layer was extracted with 
dichloromethane (3 × 10 mL). The combined organic layers were dried over magnesium sulfate, 
filtered and concentrated. The crude product was purified by flash chromatography (hexane/ethyl 
acetate 4:1 grading to 2:1) to afford 203 (351 mg, 1.15 mmol, 97%). 
[]
	
 = +68.6 (c = 1.05, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 7.81 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 
8.6 Hz, 2H), 4.30 (dd, J = 10.5, 3.0 Hz, 1H), 4.08 (dd, J = 10.5, 6.5 Hz, 1H), 3.74–3.67 (m, 1H), 2.65–
2.56 (m, 1H), 2.46 (br s, 3H), 2.22 (br s, 1H), 1.91 (d, J = 1.1 Hz, 3H), 1.23 (d, J = 7.0 Hz, 3H); 
13C NMR (100 MHz, CDCl3): δ = 145.3, 132.6, 130.1 (2C), 128.2 (2C), 75.7, 75.2, 72.6, 72.2, 68.3, 
64.1, 29.9, 21.9, 16.8, 4.3; IR (film): ν = 3528, 2980, 1598, 1358, 1190, 1175, 1096, 959, 814, 667, 
555 cm−1; MS: m/z calcd for C16H18O4SNa [M+Na+]: 329.0818, found 329.0817.  
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(S)-2-((R)-Hepta-3,5-diyn-2-yl)oxirane (206) 
1,8-Diazabicyclo[5.4.0]undec-7-ene (1.10 mL, 7.35 mmol, 2.00 equiv) was added at 0 °C to a 
solution of tosylate 203 (1.13 g, 3.68 mmol, 1 equiv) in anh. dichloromethane 
(30 mL). After complete consumption of the starting material (approx. 1 h), water 
(30 mL) was added, the layers were separated and the aq. layer was extracted with 
diethyl ether (2 × 20 mL). The combined organic layers were dried over magnesium 
sulfate, filtered and concentrated under reduced pressure (40 °C, >500 mbar) to afford the title 
compound (426 mg, 3.18 mmol, 86%). 
Direct transformation from the diol 204a: 
Dibutyltin(IV) oxide (425 mg, 1.71 mmol, 5 mol%) was added to a solution of diol 204a (5.20 g, 
34.2 mmol, 1 equiv) in anh. dichloromethane (175 mL). After stirring for 5 min, triethylamine (5.00 
mL, 35.9 mmol, 1.05 equiv) and 4-toluolsulfonyl chloride (6.84 g, 35.9 mmol, 1.05 equiv) were 
added. Stirring was continued for 14 h at 23 °C, before 1,8-diazabicycloundec-7-ene (10.2 mL, 68.3 
mmol, 2.00 equiv) was added. After complete consumption of the starting material (approx. 2 h), 
water (150 mL) was added, the layers were separated and the aq. layer was extracted with diethyl 
ether (3 × 100 mL). The combined organic layers were dried over magnesium sulfate, filtered and 
concentrated under reduced pressure (40 °C, >500 mbar). The crude product was purified by flash 
chromatography (pentane/diethyl ether 10:1) to afford epoxide 206 (3.30 g, 24.6 mmol, 72%). 
[]
	
 = +59.7 (c = 0.50, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 2.91 (ddd, J = 6.4, 3.8, 2.6 Hz, 1H), 
2.78 (dd, J = 4.9, 3.9 Hz, 1H), 2.67 (dd, J = 4.9, 2.5 Hz, 1H), 2.51–2.39 (m, 1H), 1.91 (d, J = 1.1 Hz, 
3H), 1.32 (d, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 75.3, 74.9, 67.6, 64.1, 54.7, 46.4, 29.9, 
17.7, 4.3; IR (film): ν = 2982, 2932, 1722, 1455, 1258, 1073, 1025, 922, 882, 828 cm−1; MS: m/z 
calcd for C9H10O [M]: 134.0733, found 134.0732. 
 
4-Bromocyclopent-1-ene (199)[141] 
Bromine (1.60 mL, 31.2 mmol, 1.05 equiv) was added over 60 min at −30 °C to a solution of 
triphenylphosphine (8.19 g, 31.2 mmol, 1.05 equiv) in anh. dichloromethane (30 mL). After 
stirring for additional 30 min, a premixed solution of 3-cyclopenten-1-ol (2.50 g, 29.7 mmol, 
1 equiv) and pyridine (2.50 mL, 29.7 mmol, 1.00 equiv) was added over 1 h at such a rate as to 
keep the reaction temperature below −15 °C. The mixture was allowed to warm to 23 °C. After 
stirring for 18 h, the excess reagent was quenched by the addition of sat. aq. sodium thiosulfate 
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solution (30 mL). The layers were separated and the aq. layer was extracted with diethyl ether (3 × 
20 mL). The combined organic layers were dried over magnesium sulfate, filtered and the organic 
solvent was removed by distillation (35 °C, ≥600 mbar, Vigreux column). The precipitate was 
filtered off and the filtrate was purified by flash chromatography (pure pentane). The fractions 
containing the product were concentrated by distillation to afford 199 (4.22 g, 28.7 mmol, 97%) as 
a colorless liquid. The obtained NMR spectra were in full agreement with those reported in the 
literature.[167] 
1H NMR (400 MHz, CDCl3): δ = 5.79–5.74 (m, 2H), 4.60 (tt, J = 6.7, 3.1 Hz, 1H), 3.03–2.94 (m, 2H), 
2.86–2.77 (m, 2H); 13C NMR (100 MHz, CDCl3): δ = 128.8, 48.7, 44.9. 
 
(2R,3R)-1-(Cyclopent-3-en-1-yl)-3-methylocta-4,6-diyn-2-ol (201).  
A catalytic amount of 1,2-dibromoethane (20 µL) was added to a suspension of flame dried 
magnesium (145 mg, 5.96 mmol, 4.00 equiv) in anh. diethyl ether (3 mL). 
The mixture was briefly heated using a heat gun until the formation of 
gas was observed. Compound 199 (438 mg, 2.98 mmol, 2.00 equiv) was 
added dropwise to the suspension. After stirring for 2 h, the solution of the Grignard reagent was 
cannulated carefully into a −40 °C cold suspension of copper(I) iodide (56.8 mg, 0.30 mmol, 
20 mol%) in anh. diethyl ether (1 mL). Stirring was continued for 30 min −40 °C, before epoxide 
206 (200 mg, 1.49 mmol, 1 equiv) in anh. diethyl ether (0.5 mL) was added dropwise. After stirring 
for 4 h at −40 °C, the excess reagent was quenched by the addition of sat. aq. ammonium chloride 
solution (10 mL) and the layers were separated. The aq. layer was extracted with ethyl acetate (3 × 
10 mL) and the combined organic layers were dried over magnesium sulfate, filtered and 
concentrated. The crude product was purified by flash chromatography (hexane/ethyl acetate 
10:1 grading to 6:1) to afford title compound (260 mg, 1.29 mmol, 86%). 
[]
	
 = +9.20 (c = 0.40, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 5.73–5.63 (m, 2H), 3.59 (dd, J = 9.0, 
4.5 Hz, 1H), 2.64 (ddt, J = 6.7, 5.6, 1.4 Hz, 1H), 2.58–2.43 (m, 3H), 2.01 (tddd, J = 16.8, 8.3, 3.9, 2.4 
Hz, 2H), 1.92 (d, J = 1.1 Hz, 3H), 1.66–1.62 (m, 2H), 1.18 (d, J = 7.0 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ = 130.2, 129.7, 78.0, 74.5, 73.4, 67.6, 64.3, 40.4, 39.6, 38.5, 34.3, 34.0, 15.8, 4.3; IR (film): 
ν = 3393, 2931, 2842, 1451, 1070, 1038, 971 cm−1; MS: m/z calcd for C14H18ONa [M+Na+]: 
225.1248, found 225.1250. 
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2-((2R,4S)-2-((R)-Hepta-3,5-diyn-2-yl)-6-oxotetrahydro-2H-pyran-4-yl)acetaldehyde (165) 
Ozone was bubbled through a solution of cyclopentene 201 (150 mg, 0.742 mmol, 1 equiv) in anh. 
dichloromethane (10 mL) at −78 °C until a pale blue color persisted. The 
solution was flushed with argon, before triphenylphosphine (389 mg, 
1.48 mmol, 2.00 equiv) was added. After stirring for 1 h at −78 °C, the 
mixture was allowed to warm to 23 °C and was concentrated under 
reduced pressure. The crude product was purified by flash chromatography (hexane/ethyl acetate 
10:1 grading to 1:1) to give dialdehyde 207 (153 mg, 0.653 mmol, 88%). 
Ytterbium(III) trifluoromethanesulfonate hydrate (40.5 mg, 65.0 µmol, 10 mol%) was added at 0 °C 
to a solution of dialdehyde 207 (153 mg, 0.653 mmol, 1 equiv), 2,2,6,6-tetramethyl-1-
piperidinyloxy (20.4 mg, 0.131 mmol, 20 mol%) and (diacetoxyiodo)benzene (442 mg, 1.37 mmol, 
2.10 equiv) in anh. dichloromethane (6 mL). After stirring for 1 h at 23 °C, the mixture was diluted 
with dichloromethane (10 mL) and sat. aq. sodium thiosulfate solution (10 mL). The layers were 
separated and the aq. layer was extracted with methyl tert-butyl ether (3 × 10 mL). The combined 
organic layers were dried over magnesium sulfate, filtered and concentrated. The crude product 
was purified by flash chromatography to give the title compound (139 mg, 0.598 mmol, 92%). 
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 = −18.6 (c = 0.35, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 9.79 (s, 1H), 4.16 (ddd, J = 11.5, 6.9, 
3.3 Hz, 1H), 2.85–2.75 (m, 2H), 2.60–2.53 (m, 3H), 2.26 (dtd, J = 13.7, 3.1, 1.7 Hz, 1H), 2.14 (dd, J = 
17.5, 10.5 Hz, 1H), 1.92 (d, J = 1.1 Hz, 3H), 1.39 (dt, J = 13.7, 11.5 Hz, 1H), 1.28 (d, J = 7.0 Hz, 3H); 
13C NMR (100 MHz, CDCl3): δ = 199.5, 169.7, 81.9, 75.2, 75.2, 68.6, 64.1, 49.8, 35.9, 32.9, 32.0, 
25.8, 17.0, 4.3; IR (film): ν = 2918, 1724, 1385, 1235, 1082 cm−1; MS: m/z calcd. for C14H16O3Na 
[M+Na+]: 255.0990 found 255.0992.  
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6.3.3. Combination of Fragments 
(5S,7S,8S,9R,E)-9-Methoxy-2,2,3,3,8,10,14,14,15,15-decamethyl-5-(penta-1,3-diyn-1-yl)-4,13-
dioxa-3,14-disilahexadec-10-en-7-yl 2-(diethoxyphosphoryl)acetate (194) 
Molecular sieves (3Å, 15 pellets) and EDC (224 mg, 1.17 mmol, 1.80 equiv) were added at 0 °C to a 
solution of diethylphosphonoacetic acid (313 µL, 1.95 mmol, 
3.00 equiv) in anh. dichloromethane (16 mL). After stirring for 
15 min, a solution of alcohol 219 (330 mg, 0.649 mmol, 1 equiv) in 
anh. dichloromethane (12 mL) and 4-dimethylaminopyridine 
(23.8 mg, 0.195 mmol, 30 mol%) were successively added. The 
mixture was allowed to warm to 23 °C and stirring was continued for 2 h, before the mixture was 
filtered through a pad of cotton which was carefully rinsed with dichloromethane (50 mL). The 
filtrate was diluted with sat. aq. sodium chloride solution (50 mL) and extracted with 
dichloromethane (3 × 60 mL). The combined organic layers were dried over sodium sulfate, 
filtered and concentrated. The crude product was purified by flash chromatography (hexane/ethyl 
acetate 3:1 grading to 2:1) to afford 194 (400 mg, 0.649 mmol, 90%) as a pale yellow oil. 
[]
	
   = −10.0 (c = 0.20, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 5.53–5.48 (m, 1H), 4.98–4.89 (m, 
1H), 4.42–4.35 (m, 1H), 4.31 (dd, J = 13.2, 7.1 Hz, 1H), 4.22–4.09 (m, 5H), 3.19 (d, J = 7.0 Hz, 1H), 
3.17 (s, 3H), 2.93 (dq, J = 21.8, 14.3 Hz, 2H), 2.10–2.01 (m, 1H), 1.93 (d, J = 1.0 Hz, 3H), 1.89 (td, J = 
9.2, 8.3, 3.3 Hz, 2H), 1.61–1.58 (m, 3H), 1.34 (t, J = 7.1 Hz, 6H), 0.94 (d, J = 6.9 Hz, 3H), 0.90 (s, 9H), 
0.87 (s, 9H), 0.12 (s, 3H), 0.07 (s, 6H), 0.05 (s, 3H) 13C NMR (100 MHz, CDCl3): δ = 164.9, 133.2, 
129.3, 87.5, 76.5, 73.3, 63.8, 62.8, 62.6, 59.9, 59.9, 56.5, 38.5, 38.3, 35.3, 34.0, 26.1 (3C), 25.9 (3C), 
18.5, 18.3, 16.4, 16.3, 16.3, 11.9, 9.8, 4.5, −4.5, −5.1 (2C), −5.2; IR (film): ν = 2955, 2929, 2856, 
1735, 1471, 1463, 1255, 1090, 1048, 1024, 834, 777 cm−1; MS: m/z calcd for C34H63O8PSi2Na 
[M+Na+]: 709.3689, found 709.3691. 
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(5S,7S,8S,9R,E)-9-Methoxy-2,2,3,3,8,10,14,14,15,15-decamethyl-5-(penta-1,3-diyn-1-yl)-4,13-
dioxa-3,14-disilahexadec-10-en-7-yl (E)-4-((2R,4R)-2-((R)-hepta-3,5-diyn-2-yl)-6-oxotetrahydro-
2H-pyran-4-yl)but-2-enoate (193) 
Phosphonate 194 (161 mg, 0.235 mmol, 1 equiv) was added to a suspension of anh. lithium 
chloride (24.9 mg, 0.588 mmol, 2.50 equiv) in anh. acetonitrile 
(6 mL). After stirring for 20 min, 1,8-diazabicyclo[5.4.0]undec-7-
ene (38.8 µL, 0.259 mmol, 1.10 equiv) was added and the mixture 
was stirred for 30 min at 23 °C, before it was cooled to 0 °C. A 
solution of the aldehyde 165 (109 mg, 0.470 mmol, 2.00 equiv) in 
anh. acetonitrile (3 mL) was slowly added. After stirring 12 h at 
23 °C, aq. phosphate buffer solution (pH 7, 10 mL) was added and the aq. layer was extracted with 
methyl tert-butyl ether (3 × 20 mL). The combined organic layers were dried over magnesium 
sulfate, filtered and concentrated. The crude product was purified by flash chromatography 
(hexane/ethyl acetate 4:1 grading to 1:1) to afford 193 (138 mg, 0.180 mmol, 77%) and recovered 
starting material 194 (26 mg, 38.0 µmol, 16%). 
[]
	
   = −10.0 (c = 0.20, CHCl3).;1H NMR (400 MHz, CDCl3): δ = 6.83 (dt, J = 15.4, 7.3 Hz, 1H), 5.87 
(dt, J = 15.5, 1.5 Hz, 1H), 5.51 (ddd, J = 8.2, 5.0, 1.4 Hz, 1H), 4.91 (ddd, J = 10.7, 4.3, 2.4 Hz, 1H), 
4.39–4.28 (m, 2H), 4.17 (ddd, J = 13.2, 4.7, 1.2 Hz, 1H), 4.10 (ddd, J = 11.7, 7.0, 3.0 Hz, 1H), 3.16 (s, 
3H), 3.14–3.18 (m, 1H), 2.81 (ddt, J = 8.0, 6.9, 1.1 Hz, 1H), 2.68 (td, J = 11.0, 10.4, 1.9 Hz, 1H), 2.28–
2.18 (m, 3H), 2.16–2.08 (m, 3H), 1.93 (d, J = 1.0 Hz, 3H), 1.91 (d, J = 1.1 Hz, 3H), 1.94–1.80 (m, 2H), 
1.64–1.61 (s, 3H), 1.41–1.31 (m, 1H), 1.28 (d, J = 7.0 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 
0.86 (s, 9H), 0.09 (s, 3H), 0.07 (s, 6H), 0.00 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 169.9, 165.3, 
144.4, 133.3, 129.7, 124.4, 88.1, 81.8, 76.9, 76.7, 75.2, 75.2, 71.8, 69.5, 68. 6.64.1, 63.9, 59.9, 59.7, 
56.4, 38.7, 38.3, 37.9, 36.0, 32.9, 32.0, 30.8, 26.1 (3C), 25.8 (3C), 18.5, 18.1, 17.0, 11.6, 10.1, 4.5, 
4.3, −4.5, −5.0(2C), −5.2; IR (film): ν = 2929, 2856, 1718, 1250, 1089, 1048, 835, 778 cm−1; MS: m/z 
calcd for C44H68O7Si2Na [M+Na+]: 787.4396, found 787.4396. 
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Macrocyle 223 
Molecular sieves (4 Å, 100 mg and 5 Å, 200 mg) were added to a solution of 193 (15.4 mg, 
20.1 µmol, 1 equiv) in anh. toluene (20 mL). After stirring for 1 h, a 
solution of alkyne metathesis catalyst 8 (4.19 mg, 4.02 mmol, 
20 mol%)[31] in anh. toluene (1 mL) was added. The suspension was 
stirred for 45 min at 23 °C, before a second batch of the catalyst 8 
(4.19 mg, 4.02 mmol, 20 mol%) in anh. toluene (1 mL) was added. 
After stirring for additional 1 h, the mixture was filtered through a 
plug of silica which was rinsed with methyl tert-butyl ether (30 mL). The filtrate was concentrated 
and the residue was purified by flash chromatography (hexane/ethyl acetate 4:1 grading to 1:1) to 
afford title compound (7.3 mg, 11.0 µmol, 53%). 
[]
	
 = +4.00 (c = 0.10, CHCl3); 1H NMR (400 MHz, CDCl3): δ = 6.84 (ddd, J = 15.7, 10.0, 5.7 Hz, 1H), 
5.92 (d, J = 15.8 Hz, 1H), 5.45 (t, J = 5.4 Hz, 1H), 4.74 (dd, J = 9.0, 3.7 Hz, 1H), 4.35–4.28 (m, 2H), 
4.20 (dd, J = 13.3, 4.4 Hz, 1H), 4.02 (ddd, J = 11.2, 7.4, 4.0 Hz, 1H), 3.17 (s, 3H), 3.16–3.14 (m, 1H), 
2.79–2.67 (m, 2H), 2.53–2.39 (m, 2H), 2.24 (dd, J = 17.3, 10.8 Hz, 1H), 2.16–2.01 (m, 3H), 2.00–1.89 
(m, 1H), 1.82 (dd, J = 14.2, 4.0 Hz, 1H), 1.66 (s, 3H), 1.38–1.28 (m, 1H), 1.25 (d, J = 7.0 Hz, 3H), 0.96 
(d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 0.89 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H), 0.07 (s, 6H); 13C NMR 
(100 MHz, CDCl3): δ = 170.3, 165.6, 144.4, 134.6, 129.8, 126.3, 88.7, 82.4, 80.6, 78.8, 72.6, 69.6, 
68.8, 63.2, 59.9, 56.4, 39.3, 38.0, 37.6, 36.4, 34.1, 30.7, 29.7, 26.1 (3C), 25.9 (3C), 18.5, 18.2, 16.6, 
11.4, 10.0, −4.3, −4.8, −4.99, −5.01; IR (film): ν = 2927, 2855, 1718, 1463, 1258, 1083, 837, 779 
cm−1; HRMS (ESI): m/z: calcd. for C38H62O7Si2Na [M+Na+]: 709.3926, found: 709.3924. 
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7.2. List of Abbreviations 
Å Ångström, 1 Å = 10-10 m 
Ac Acetyl  
Acac Acetylacetonate 
ACN Acetonitrile 
AIBN Azobisisobutyronitrile 
approx approximately 
Ar  Aromatic group  
ARC Anion Relay Chemistry 
aq. Aqueous 
BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl 
BINOL 1,1'-bi-2- Naphthol 
Bn  Benzyl  
Biphep 2,2'-Bis(diphenylphosphino)-1,1'-biphenyl 
br  Broad  
brsm Based on recovered starting material 
Bu  Butyl  
calcd. Calculated  
cat.  Catalytic  
CBS Corey-Bakshi-Shibata 
CI  Chemical ionization  
conc. Concentrated 
conv. Conversion 
cp Cyclopentadienyl 
CSA Camphorsulfonic acid 
δ Chemical shift 
d Day 
d  Doublet  
DBU 1,8-Diazabicycloundec-7-ene 
DCC  N,N´-Dicyclohexylcarbodiimide  
DCE Dichloroethane 
DCM Dichloromethane 
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DDQ 2,3-Dichlor-5,6-dicyano-1,4-benzochinon 
decomp. Decomposition 
deg. Degassed (freeze-pump-thaw method) 
Dibal-H Diisobutylaluminium hydride 
DIPT Diisopropyl tartrate 
DMAP  4-(Dimethylamino)-pyridine  
DMP Dess–Martin periodinane 
DMSO Dimethyl sulfoxide 
d.r.  Diastereomeric ratio  
DTB Di-tert-butyl 
DTBM Di-tert-butyl methoxy 
e.e.  Enantiomeric excess  
EI  Electron ionization  
epi  Epimer  
ESI  Electronspray ionization  
Et  Ethyl  
equiv  Equivalents  
eV Electronvolt 
Fm Fluorenylmethyloxycarbonyl 
GC  Gas chromatography  
h Hour 
HMDS Bis(trimethylsilyl)amine 
HPLC  High pressure liquid chromatography  
HRMS  High resolution mass spectroscopy  
HSAB Hard and soft acids and bases 
HWE Horner–Wadsworth–Emmons 
Hz Hertz, 1 Hz = 1 s−1 
i iso 
IC50 Half maximal inhibitory concentration 
IG50 Half inhibition of growth 
Ipc Diisopinocampheyl 
IPr 1,3-Bis(2,6-diisopropylphenyl)-imidazolium 
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IR  Infrared spectroscopy  
J Coupling constant 
LA Lewis acid 
LB Lewis base 
LC Liquid chromatography 
LDA Lithiumdiisopropylamid 
Lit. Literature 
LLS Longest linear sequence 
m Meta 
m  Multiplet  
M Molar: mol·l-1 
m/z Mass per charge 
Me  Methyl  
min Minute 
Ms Methanesulfonyl 
MS  Mass spectrometry  
MS  Molecular sieves  
MW Microwave 
n Normal 
n.d. Not determined 
NBS  N-Bromosuccinimide  
n-BuLi n-Butyllithium 
NCI National Cancer Institute 
NHC N-heterocyclic carbene 
NIS N-Iodosuccinimide 
NMI  1-Methylimidazole  
NMO  N-Methylmorpholine-N-oxide  
NMR  Nuclear magnetic resonance  
NOE Nuclear Overhauser effect  
p  Para  
p-Ts p-Toluenesulfonic  
pd Product 
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PG Protecting group 
Ph  Phenyl  
phen 1,10-Phenanthroline 
PIDA Diacetoxyiodo)benzene 
PMB p-Methoxybenzyl 
ppm  Parts per million  
PPT Palmitoyl-protein thioesterase 
PPTS Pyridinium p-toluenesulfonate 
py Pyridine 
quart  Quartet  
quant.  Quantitative  
R  Organic substituent  
RCAM  Ring closing alkyne metathesis  
RCDM Ring closing diyne metathesis 
RCM  Ring closing olefin metathesis  
rec. Recovered 
rt Ambient temperature  
s Singlet  
SAR Structure-activity relationship 
sat. Saturated 
sm Starting material 
sp Side product 
sp. Species 
t Tertiary 
t  Triplet  
TASF Tris(dimethylamino)sulfonium difluorotrimethylsilicate 
TBA Tetrabutylammonium 
TBAF  Tetra-n-butylammoniumfluoride  
TBDPS tert-Butyldiphenylsilyl 
TBHP tert-Butyl hydroperoxide 
TBS  tert-Butyldimethylsilyl  
t-BuLi tert-Butyllithium 
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TC Thiophene-2-carboxylate 
TEA Triethanolamine/Triethylammonium 
TEAA Triethylammonium acetate 
TEMPO  2,2,6,6-Tetramethyl-1-piperidinyloxy 
tert Tertiary 
TES  Triethylsilyl  
TfO Trifluoromethanesulfonate 
THF  Tetrahydrofuran  
TIPS Triisopropylsilyl 
TLC  Thin layer chromatography  
TMEDA  Tetramethylethylenediamine  
TMS  Trimethylsilyl  
Tos Tosyl 
TPAP Tetrapropylammonium perruthenate 
Troc 2,2,2-Trichlorethoxycarbonyl 
XPhos 2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl 
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[157] B. Martıń-Matute, E. Buñuel, M. a. Méndez, C. Nieto-Oberhuber, D. J. Cárdenas, A. M. 
Echavarren, J. Organomet. Chem. 2003, 687, 410-419. 
[158] G. E. Keck, D. Krishnamurthy, Org. Synth. 1998, 75, 12. 
[159] F. Iwasaki, T. Maki, O. Onomura, W. Nakashima, Y. Matsumura, J. Org. Chem. 2000, 65, 
996-1002. 
[160] J. J. W. Duan, P. A. Sprengeler, A. B. Smith Iii, Tetrahedron Lett. 1992, 33, 6439-6442. 
[161] A. S. Khartulyari, M. Kapur, M. E. Maier, Org. Lett. 2006, 8, 5833-5836. 
[162] A. Krasovskiy, P. Knochel, Synthesis 2006, 2006, 0890-0891. 
[163] J. Inanaga, K. Hirata, H. Saeki, T. Katsuki, M. Yamaguchi, Bull. Chem. Soc. Jpn. 1979, 52, 
1989-1993. 
[164] V. Pawlowski, H. Kunkely, A. Vogler, Inorg. Chim. Acta 2004, 357, 1309-1312. 
[165] A. S. K. Hashmi, M. Hamzić, F. Rominger, J. W. Bats, Chem. Eur. J. 2009, 15, 13318-13322. 
[166] J. Caron, E. Lepeltier, L. H. Reddy, S. Lepêtre-Mouelhi, S. Wack, C. Bourgaux, P. Couvreur, 
D. Desmaële, Eur. J. Org. Chem. 2011, 2011, 2615-2628. 
[167] A. G. Davies, D. Griller, K. U. Ingold, D. A. Lindsay, J. C. Walton, J. Chem. Soc., Perkin Trans. 
2 1981, 633-641. 
 
 
   

